feel well live long grow deliver simplify annual report find gsk online wwwgskcom website glaxosmithkline website wwwgskcom give additional information group information available website constitute annual report notice limitation director liability english law uk company act safe harbour limit liability director respect statement omission report director contain page english law director liable company party report director contain error result recklessness know misstatement dishonest concealment material fact liable report director page inclusive consist report director draw present accordance reliance english company law liability director connection report shall subject limitation restriction provide law cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event shareholder identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result group undertake obligation update forwardlooke statement result new information future event forwardlooke statement involve inherent risk uncertainty group caution investor number important factor include document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor page annual reportgsk annual report grow content diversify global business chairman ceo summary strategy deliver product value report director business review corporate governance remuneration report simplify financial statement operating model director statement responsibilitie independent auditor report consolidated income statement consolidate balance sheet consolidate cash flow statement consolidate statement recognise income expense note financial statement financial statement glaxosmithkline plc set new strategic shareholder information financial record priority aim improve longterm product development pipeline financial performance shareholder information taxation information shareholder glossary term believe priority enable index navigate come year successfully retain leadingedge company able meet patient payer need future find priority follow page gsk annual report mission challenge inspire mission improve quality human life enable people feel well live long focus business strategic priority confident fulfil promise sir christopher gent andrew witty chairman chief executive officergsk annual report chairman ceo summary mark turning point gsk pivotal strategic priority period change redefine business model increase establish strategic priority grow sale growth reduce risk deliver longterm sustainable financial diversified global business deliver product value performance shareholder simplify operating model financial performance priority design radically transform business pleased response business reduce relative dependence small molecule pharmaceutical know challenging month adverse impact develop western market expect increase significant patent expiry decline avandia sale relative importance emerge market japanese anticipate factor lead decline earning share business increasingly great contribution business ep year compound unexpected legal vaccine consumer product anticipate charge fourth quarter grow capability deliver product value rd deliver benefit patient total sale year billion constant readily meet payer needs enable achieve exchange rate cer term ep exclude major restructure rapid reimburse product approval expand restructure p decrease cer term cash programme expect deliver annual saving generation remain strong net cash inflow operate billion vital catalyst change activitie billion sterling term prioritie progress implement board declare dividend year p p explain follow page find year complete share repurchase billion information include regular update progress expect significant repurchase visit website wwwgskcom financial strategy remain maintain efficient balance sheet cash resource invest strategic priority increase change board return shareholder progressive dividend policy sir ian prosser dr ronaldo schmitz retire board annual general meeting thank performance core pharmaceutical business dedicate service board gsk heritage company increase diversification sale base important indicator valuable contribution business gsk progress pharmaceutical turnover decline cer term reflect adverse impact generic competition welcome james murdoch board non patent product low avandia pandemic product sale executive director chairman chief executive news exclude genericise product avandia pandemic product corporation europe asia james bring great experience significant sale volatility remain pharmaceutical expertise boardroom particularly evident business deliver billion sale grow cer role member gsk corporate responsibility committee term vaccine sale rise billion outlook sale emerge market grow billion sale asia enter confidence expect good pacific japan total billion moving phase progress implement strategic priority enable convert extensive pipeline japan approve medicine meet longterm objective reduce risk deliver sustainable growth shareholder continue good work previous year launch pharmaceutical product include vaccine finally especially like recognise enormous start good traction new pharmaceutical contribution employee wide network partner product launch year contribute sale willingness energy enthusiasm change strong billion year foundation build new business model improve productivity discipline allocation capital key element rd strategy currently asset latestage pipeline level aim sustain augmentation pipeline past year accomplish substantial increase total rd expenditure sir christopher gent andrew witty sale consumer healthcare billion chairman chief executive officer make good progress strategy investment innovation acquisition marketing excellence area business find visit constant exchange rate cer explain wwwgskcom gsk annual report strategy pharmaceutical industry experience time unprecedented corporate responsibility challenge patent expiry regulatory issue increase pressure run business responsible way fundamental healthcare provider combine create environment success inseparable strategic priority sector associate low growth high risk operate way reflect value seeks understand addressing challenge key strategic respond stakeholder view connect business decision priority believe transform gsk company ethical social environmental concern way aim deliver growth risk improve financial performance minimise negative impact maximise positive benefit business key challenge patent medicine drive sale growth responsibility vital part business understand industry decade come end medicine need open operating understand replace product equivalent financial size transparency key factor build trust stakeholder implement number initiative improve addition increase pressure pharmaceutical transparency activity company deliver product demonstrable benefit current treatment long merely discover comprehensive information approach responsibility develop product help people feel well live issue find annual corporate responsibility report long justify product represent wwwgskcomresponsibility greatest value healthcare provider time pharmaceutical sector expose controversy ethical patient safety issue industry danger erode trust actually need build strong relationship government regulator general public factor combine industry expect deliver high growth low risk opposite strategic priority establish follow strategic priority grow diversified global business deliver product value simplify operating model believe priority enable navigate come year successfully retain leadingedge company able meet patient healthcare provider need future update progress publish website wwwgskcom feature regular financial resultsgsk annual report grow diversified global business reduce risk broaden balance portfolio diversify new product area potential fully capture opportunity product geographic boundary plan underpin strategic priority drive growth pharmaceutical business core market deliver ambitious vaccine forecast fulfil potential emerge market expand business japan grow consumer healthcare business find deliver product value strive build strong pipeline industry transform rd ensure deliver current pipeline able sustain flow new product year come plan underpin strategic priority focus good science diversify externalisation repersonalise rd focus return investment find simplify operating model manufacturing pharma rd vaccine consumer healthcare gsk complex organisation recognise need simplify operating model change way work remove unnecessary process structure slow distract mission plan underpin strategic priority evolve commercial model reshape manufacturing streamline process reduce work capital find gsk annual report reduce risk broaden balance portfolio diversify new product area potential fully capture opportunity product geographic boundary specifically expect generate future sale growth strengthen core pharmaceutical business supplement increase investment growth area vaccine biopharmaceutical consumer healthcare seek unlock geographic potential business particularly emerge market japan good progress priority believe remain opportunity gsk diversify grow diversified global business plan target sustained growth vaccine portfolio launch new vaccine work expand franchise drive growth pharmaceutical business japan emerge market core market establish strength small molecule pharmaceutical cervarix new cervical cancer vaccine sector large market usa uk france germany successful approximately tender achieve italy spain remain central business notable success include europe large vaccination programme receive european approval tyverb advanced breast cancer cervical cancer take place uk year volibris treatment pulmonary arterial hypertension see rotarix boostrix adult indication kinrix receive approval avamys new allergic rhinitis treatment approval fda promacta treatment thrombocytopenia entereg postoperative ileus pharmaceutical business fulfil potential emerge market initiate major change programme refocus marketing emerge market feature lessdefine distinction demonstrate value introduce new product offering pharmaceutical overthecounter retail market structure focus volume opportunity ability operate spectrum clear competitive advantage opportunity improve capability deliver ambitious vaccine forecast energise business fastgrowe emerge market increasingly healthcare provider recognise important role vaccine play preventative healthcare prove capability strong pipeline plus high barrier entry face competitor mean expect source future growth gskgsk annual report enter alliance aspen holding grow consumer healthcare business south africa new relationship give priority access consumer healthcare business continue commercialise product portfolio drive growth portfolio powerful potential product brand key segment overthecounter otc medicine oral healthcare nutritional healthcare year end acquire bms portfolio egypt reach agreement acquire bms portfolio pakistan brand portfolio include alli weight loss panadol early agree ucb acquire current range analgesic sensodyne toothpaste lucozade market product portfolio range territory support strategy focus innovation marketing excellence geographic expansion acquisition expand business japan japan key market gsk investment growth september launch sensodyne chinese extensive product pipeline expect launch market major consumer launch country decade product market year prepare launch alli otc weight loss product approve european commission europe major approval market recently lamictal epilepsy adoair copd find visit wwwgskcom gsk annual report strive build strong pipeline diversify externalisation industry transform rd ensure recognise monopoly good science deliver current pipeline new pharmaceutical proactively expand collaboration vaccine consumer healthcare product external partner academia access innovation able sustain flow new product year come strengthen early pipeline diversified business recent alliance organisation cellzome concentrate develop high volume midsize harvard stem cell institute acquisition sirtris product clearlydefine patient population genelab provide competitive advantage important help develop low risk portfolio area research dependent performance large product year complete expand new drug discovery positive step take latestage alliance add significant breadth scale rd activity asset currently pharmaceutical vaccine pipeline currently discovery unit work inside objective sustain throughput product company externally longterm biopharmaceutical play increasingly important role future portfolio offer worldwide market approximately plan billion project compound annual growth year biopharmaceutical compound capable focus good science manufacture living organism usually cultured cell asset pipeline entirely new compound vaccine demonstrate strong drive currently pipeline comprise biopharmaceutical innovation industry average significantly expand biopharmaceutical pipeline inhouse discovery year rebalance drug discovery organisation acquisition domantis inlicense latestage product improve efficiency focus area new science currently clinical research programme underway believe likely lead new medicine include asset latestage development vaccine gsk rd focus therapy area biopharmaceutical immunoinflammation infectious disease metabolic pathway neuroscience oncology ophthalmology respiratory deliver product valuegsk annual report repersonalise rd focus return investment want create environment impediment adopt disciplined approach good scientist make kind discovery allocate resource rd discovery project transform company future delivering value patient terminate follow therapy area rebalancing exercise healthcare provider shareholder review new drug discovery investment board see creation discovery performance unit dpus process discovery performance unit centre excellence drug discovery cedd dpu year funding place develop project compact fullyempowered focus integrate team responsibility small pipeline realise reimbursement key longterm financial performance work hard bring health outcome create new integrate rd unit focus rd turn deliver great value healthcare biopharmaceutical oncology rd centre establish provider example europe direct dialogue exist china people strong recruit payer organisation rd team improve experienced scientist dedicate solely gsk understand perceive benefit value new product neurodegenerative research find visit wwwgskcom v ti c u r p p e p l e c udorp gsk annual report gsk complex organisation recognise need simplify operating model change way work remove unnecessary process structure manufacture slow distract mission global restructuring programme vital catalyst strategy believe radically change business model give capability support diverse rd pharma grow business expect profitable longterm vaccine consumer healthcare simplify operating model plan continue improve efficiency site apply benchmarke study seize opportunity evolve commercial model addition simplify operating model clarify role reorganise single commercial responsibility improve prioritisation decision make support structure europe emerge market asia introduce simple efficient way work pacificjapan usa radically restructure pharmaceutical business include transformation streamline process sale force decision designate single headquarters simplify organisation speed decisionmake pharmaceutical locate research triangle park north improve alignment business priority carolina reduce complexity streamline operation different programme initiative gsk include comprehensive programme simplify reduce cost reshape manufacturing innovative partnership microsoft online manufacturing key capability gsk take produce financial saving improve productivity enhance ambitious approach reshape operation move collaboration internally external partner match network capacity closely volume leverage network site contractor ensure flexibility sustain growth adapt change business modelsgsk annual report manufacture rd pharma vaccine consumer healthcare simplify operating model strive ensure crossbusiness process structure simple efficient example number review currently underway simplify support function infrastructure create lean corporate centre reduce work capital current working capital requirement billion september start programme successfully deliver cash flow benefit million invest strategic priority find visit wwwgskcom gsk annual report report director financial trend ratio growth growth total result cer cer turnover cost sale sell general administration research development operating income operate profit profit taxation profit taxation year profit attributable minority interest profit attributable shareholder basic earning share penny p p p dilute earning share penny p p p result major restructuring turnover cost sale sell general administration research development operating income operate profit profit taxation profit taxation year profit attributable minority interest profit attributable shareholder basic earning share penny p p p dilute earning share penny p p p research development total pharmaceutical consumer healthcare total net finance cost cover total net finance cost cover time time net finance cost cover profit tax plus net finance cost divide net finance cost tax rate total tax rate major restructuring borrowing net debt gearing gearing ratio calculate net debt percentage total equity c er represent growth constant exchange rate sterling represent growth actual exchange rate calculation result major restructuring describe note financial statement presentation financial statementsgsk annual report report director report director report director provide user financial director remuneration statement complete picture gsk supplement set remuneration policy operate information financial statement discussion director corporate executive team cet member aspect activity future environment disclosure director remuneration include operate require director remuneration report regulation regulation section cover report divide number section letter chairman remuneration committee business review remuneration policy discuss financial nonfinancial activity executive director term condition remuneration resource development performance nonexecutive director term condition fee outline factor include trend principal risk director senior management remuneration uncertainty likely affect future development annual remuneration sub divide nonexecutive director remuneration financial trend ratio director interest performance overview share option product intellectual property competition incentive plan global manufacturing supply pension research development director senior management employee director interest contract responsibility accounting presentation regulation report prepare accordance international financial economy world market outlook reporting standard ifrs adopt european union financial review ifrs issue international accounting financial position resource standard board risk factor financial review datum market share market growth rate gsk estimate base corporate governance recent datum independent external source appropriate value sterle relevant exchange rate figure discuss management structure governance quote product market share reflect sale gsk licensee procedure include disclosure compliance combine code corporate governance financial reporting council exchange rate combine code law regulation group operate country earn revenue biography board incur cost currency result group biography corporate executive team report sterling affect movement exchange rate governance policy sterling currency average exchange rate dialogue shareholder prevail period translate result share capital control cash flow overseas subsidiary associate joint venture donation eu political organisation eu sterling period end rate translate net asset political expenditure entity annual general meeting currencie internal control framework currency influence group result remain committee report dollar euro yen pound combine code law regulation pound weaken dollar yearend addition pound weaken euro yen new record low set december gsk annual report report director performance overview key performance indicator strategie turnover bn cer growth set new strategic priority detail give page grow diversified global business broaden balance portfolio diversify new product area fully capture opportunity product earning share major restructuring geographic boundary pence cer growth total shareholder return deliver product value transform rd ensure deliver current pipeline able sustain flow product year come glaxosmithkline total return index glaxosmithkline pharma peer return index ftse total return index free cash flow simplify operating model simplify operating model ensure fit purpose able support business efficient effective way calculation result major restructuring describe note financial statement presentation financial statement free cash flow describe gsk annual report report director measure progress develop number measure track good progress year progress strategic priority number notable success medium long term include follow performance core pharmaceutical business exclude genericise product avandia prepandemic include growth vaccine preparation core pharmaceutical business turnover billion grow growth consumer healthcare market share consumer healthcare sale grow nearly billion continued market share growth oral healthcare nutritional healthcare sale fall otc low sale smoking cessation product contribution emerge market overall sale emerge market grow billion sale growth transaction aspen bm execute build broad geographically diverse portfolio expansion japanese business major recent approval japan lamictal epilepsy adoair copd new product opportunity development sale japan fall result price cut mandate government contribution sale new product new product launch year contribute sale billion number reimbursable product approval filing key product launch include tyverb volibris avamys europe treximet entereg promacta kinrix rotarix usa secure fda approval new chemical entity vaccine sustain latestage pipeline asset late stage pipeline maintain asset new asset move phase iii development include darapladib atherosclerosis syncria type diabete enhance productivity increase externalisation create discovery performance unit small team drug discovery threeyear funding place enter expand new drug discovery alliance delivery major restructure programme annual cost saving million achieve programme expand deliver annual saving billion evolution commercial model rescale redeploy pharmaceutical sale force sale force expand emerge market reshape global manufacturing supply manufacture network rationalisation continue multiple site exit ongoing reduction working capital deliver million cash flow benefit work capital reduction programme start september gsk annual report report director history development company business segment glaxosmithkline plc public limited company incorporate gsk operate industry segment th december english law share list pharmaceutical prescription pharmaceutical vaccine london stock exchange new york stock exchange consumer healthcare otc medicine oral healthcare th december company acquire glaxo wellcome plc nutritional healthcare smithkline beecham plc english public limited company way scheme arrange ment merger result major restructuring company gsk subsidiary associate undertakings october board approve implementation constitute major global healthcare group engage creation detail formal plan gsk announce significant new discovery development manufacture marketing pharma operational excellence restructuring programme second formal ceutical consumer healthrelate product plan represent significant expansion operational gsk corporate head office london excellence programme approve board announce headquarters research triangle park operation february estimate total cost approximately country product sell country billion expand programme expect deliver annual pretax saving approximately billion time substantially annual report summary complete gsk present restructuring cost incur report annual report glaxosmithkline plc solely direct result operational excellence programme year end st december prepare accordance separate column income statement title major restructuring united kingdom requirement approve board addition restructuring cost operational excellence director rd march publish th march programme major restructuring column income statement summary year intend shareholder need include restructuring cost incur solely direct result detail annual report produce separate restructuring programme follow relate material document issue shareholder summary acquisition operation acquire business overlap constitute set summary financial statement define extensively gsk exist operation billion section company act annual report million acquisition reliant pharmaceutical december issue shareholder elect receive acquisition october meet criteria document available gsk website group result cost operational excellence report glaxosmithkline group gsk mean programme acquisitionrelate restructuring programmes glaxosmithkline plc subsidiary undertaking company meeting criterion describe describe result mean glaxo smithkline plc glaxosmithkline share mean major restructuring presentation gsk intend ordinary share glaxosmithkline plc p american depositary apply consistently future major restructuring programme share ad represent glaxosmithkline share material impact gsk operating result manner gsk business conduct brand name adopt clearly group result brand name appear italic report trademark cost restructure programme management own andor license glaxosmithkline associate believe presentation assist shareholder gain company exception baycol levitra trademark clear understanding group financial performance bayer bonivabonviva trademark roche citrucel trademark make projection future financial performance result merrell pharmaceuticals entereg trademark adolor include cost virtue size nature limited corporation usa volibris trademark gilead nicoderm comparative value presentation consistent trademark sanofiaventis pfizer canada elan novartis merrell way management assess group financial performance glaxosmithkline vesicare trademark astellas pharmaceutical cer growth country yamanouchi pharmaceutical certain order illustrate underlying performance group country certain country licence practice discuss result term constant exchange rate group cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged previous year cer represent growth constant exchange rate represent growth actual exchange rate commentary report present term cer statedgsk annual report report director product intellectual property competition pharmaceutical product pharmaceutical industry introduction new product process competitor affect pricing gsk principal pharmaceutical product currently direct result change pattern product use assurance main therapeutic area description product page product outmoded notwithstanding patent analysis sale therapeutic area trademark protection addition increase government competition pressure physician patient use generic pharmaceutical brandname medicine increase principal pharmaceutical competitor range small competition product long protect patent large pharmaceutical company substantial resource company intellectual property abbott laboratorie intellectual property key business asset company amgen effective legal protection intellectual property astrazeneca patent trademark register design copyright domain registration critical ensure reasonable return bristolmyer squibb investment rd eli lilly patent johnson johnson merck policy try obtain patent commercially important protectable invention discover develop rd novartis activity patent protection new active ingredient available pfizer major market patent obtain new drug roche holding formulation manufacturing process medical use device sanofiaventis administer product obtain patent product prevent challenge scheringplough expire grant patent provide wyeth assurance issue patent hold valid enforceable pharmaceutical subject competition court significant litigation concern challenge product period patent protection summarise note financial statement legal patent generic version manufacturer proceeding court determine patent hold invalid generic product typically bear significant research non infringe unenforceable protect market development education marketing development cost party entry prior patent expiry consequently able offer product considerably life patent country year file date low price brand competitor research patent protect new active ingredient generally apply development base company normally seek achieve early development process long development time sufficiently high profit margin sale volume period pharmaceutical product result substantial patent protection repay original investment patent life launch market include generally substantial generate profit fund research usa europe possible lose time future competition generic product generally occur restore lead variation patent life patent major market expire increasingly patent challenge actually available product market certain prior patent expiry claim innovator patent country provide period datum market exclusivity prevent valid andor infringe generic product party company rely clinical trial datum enter detail challenge product legal market copy period exclusivity proceeding page follow loss patent protection generic product rapidly capture large share patent expiry date significant product market particularly usa follow table date provide expiry patent usa major european market active ingredient believe remain competitive dependent indicate include extension patent term include discovery development new product paediatric use usa available effective marketing exist product gsk annual report report director product intellectual property competition continue product compound indication major patent expiry date competitor brands usa eu respiratory seretideadvair salmeterol xinafoate asthmacopd singulair symbicort fluticasone propionate spiriva asmanex pulmicort combination combination flixotideflovent fluticasone propionate asthmacopd qvar singulair expire expire serevent salmeterol xinafoate asthmacopd foradil spiriva expire expired veramyst fluticasone furoate rhinitis nasacort flixonaseflonase fluticasone propionate rhinitis nasonex rhinocort expire expire antiviral epzicomkivexa lamivudine abacavir hivaids truvada atripla combination combination combivir lamivudine zidovudine hivaids truvada atripla combination combination trizivir lamivudine zidovudine hivaids truvada atripla abacavir combination combination agenerase amprenavir hivaids prezista kaletra reyataz lexiva fosamprenavir hivaids prezista kaletra reyataz epivir lamivudine hivaids truvada atripla ziagen abacavir hivaids truvada atripla valtrex valaciclovir genital herpe coldsore famvir shingle zeffix lamivudine chronic hepatitis b hepsera relenza zanamivir influenza tamiflu central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expire expire imigranimitrex sumatriptan migraine zomig maxalt relpax expire expire seroxatpaxil paroxetine depression effexor cymbalta expire expire anxiety disorder lexapro wellbutrin sr bupropion depression effexor cymbalta expire lexapro requip ropinirole parkinson disease mirapex expire restless leg syndrome use treat parkinson disease treximet sumatriptan naproxen migraine zomig maxalt relpax na combination use cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride lovaza formulation omega acid high triglyceride tricor ethyl ester formulation coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension leave ventricular dysfunction post mi fraxiparine nadroparin deep vein thrombosis lovenox expire expire pulmonary embolism arixtra fondaparinux deep vein thrombosis lovenox fragmin expire expire pulmonary embolism innohep vesicare solifenacin overactive bladder detrol detrol la enablex na sanctura generic competition possible result patent settlement uk patent revoke uk courtsgsk annual report report director product intellectual property competition continue product compound indication major patent expiry date competitor brands usa eu metabolic avandia rosiglitazone maleate type diabetes actos januvia avandamet rosiglitazone maleate type diabete competact janumet metformin hci actoplus meet bonvivaboniva ibandronate osteoporosis actonel fosamax antibacterials augmentin amoxicillinclavulanate common infection expire expire potassium altabax retapamulin skin infection oncology emesis hycamtin topotecan ovarian cancer small cell doxil gemzar lung cancer zofran ondansetron nausea vomit kytril emend aloxi expire expire cancer tykerb lapatanib advance metastatic herceptin breast cancer positive patient vaccine infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentavac pentaxim polio hepatitis b hepb polio hepatitis b hepb pediacel pentacel inactivated antigen fluarix split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone subtype type b antigen influvac aggripal fluad flulaval split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone subtype type b antigen influvac aggripal fluad cervarix hpv virus like particle human papilloma virus gardasil silgard vlp adjuvant mpl type aluminium hydroxide rotarix live attenuate rotavirus rotavirus gastroenteritis rotateq strain gip trademark gsk commercial product protect register trademark major market local variation example usa trademark advair cover product sell eu seretide trademark protection generally extend long trademark renew necessary gsk trademark important maintain brand identity product gsk enforce trademark right prevent infringement consumer healthcare product portfolio comprise main category otc medicine oral healthcare nutritional healthcare sale key consumer healthcare product show lead consumer healthcare product include follow otc medicine alli licence weight loss medicine available prescription launch usa approval launch europe panadol global paracetamolacetaminophen analgesic smoking control product nicoderm niquitin cq nicabate usa nicorette brand include breathe right nasal strip tum citrucel contac fiberchoice gsk annual report report director product intellectual property competition continue oral healthcare global manufacturing supply gms aquafresh range toothpaste toothbrushe people work gms network mouthwash site country gms support commercial ambition sensodyne range toothpaste toothbrush include gsk deliver quality medicine consumer product pronamel protect acid erosion patient customer world biotene acquire late lead treatment scale manufacturing gsk stagger dry mouth manufacture billion pack year different presentation include tablet creamsointment inhaler polident poligrip corega denture care cleanser injection liquid sterile supply adhesive market billion spend production year brand include odol macleans dr good gms operate procurement operation behalf group nutritional healthcare spend billion annually external supplier purchase active ingredient chemical intermediate package lucozade range energy sport drink component partfinishe finished product horlick range milkbase malt food chocolate drink commercial customer seek ribena blackcurrant juicebase drink opportunity grow business focus cost competitive supply quality product meet ambition consumer healthcare competition begin adapt emerge commercial model leverage gsk hold lead global position key consumer product network site contractor builtin flexibility area worldwide large oral healthcare sustain future growth adapt emerge commercial otc medicine nutritional healthcare hold lead business model increasingly rigorous external regulatory position uk india ireland environment continue leverage technology environment consumer healthcare business support process understand control capability operate challenge primary supply site supply high quality competitively price consumer demand well quality well value bulk actives focus improvement primary technology improve performance process new product global supply site work closely rd development team ensure right technical retailer consolidate globalise competency place support rapid successful new product strengthen negotiation power introduction site serve focal point develop cycle time innovation reduce introduce new secondary manufacturing technology site regional pharma supply division focus reduce cost allow gsk main competitor include major international company compete effectively market consumer healthcare colgatepalmolive johnson johnson procter gamble unilever site deliver highquality competitively price product support wyeth addition small company rapid new product introduction highly innovative competitive compete gsk certain market business new technology fundamental platform major competitor product otc medicine drive innovation lower cost provide flexibility operation usa metamucil laxative pepcid indigestion private embed new way work simplify label smoking control product business achieve great efficiency focus customer service include support new product launch uk lemsip cold remedy nurofen anadin strong compliance culture commitment health safety analgesic nicorette nicotinell smoking control environment commitment develop people treatment deliver strong result gsk external oral healthcare major competitor colgatepalmolive environment demand colgate procter gamble crest vaccine manufacture particularly complex requires use nutritional healthcare major competitor horlick innovative technology living microorganism sophisticated ovaltine milo malt food chocolate drink quality assurance quality control procedure place competitor ribena primarily local fruit juice product ensure vaccine quality safety include animal use lucozade compete energy drink accord health authority requirement biological nature individual health authority subject vaccine second control guarantee high quality standardsgsk annual report report director research development research development pharmaceutical continue identify compound company enhance portfolio create innovative gsk rd strive build strong pipeline collaboration ensure see partner choice potential new medicine industry pharmaceutical large small company internal rd expertise allow rd actively manage project human clinical strong position business development make trial globe deliver pipeline patient safely able complement internal pipeline acquisition efficiently number goal inlicense comarketingcopromotion deal future discover potential medicine option collaboration late stage early research identifie biological target interfere project team mdc development particular disease create small molecule biopharmaceutical interact disease target drug discovery dd form centres excellence drug discovery cedd group focus define therapy area therapy area review exercise conduct early help rd refocus discovery effort identify promising area science likely deliver product rd unit value rd invest growth area ophthalmology cease promising area science urology focus drug discovery gsk summarise table f ollowe therapy area review major transformation drug discovery conduct company create nimble creative entrepreneurial environment building discovery cedd drug success exist cedd model cedd create performance discovery discovery performance unit dpu gather small integrate unit empower group scientist size range people deliver medicine patient focus particular disease pathway take cedd model step number dpus cedd vary accord progression latestage development consist optimise science standalone dpus create explore physical product property medicine new therapy area ophthalmology new way work chemical step formulation require manufacture deliver large scale study human cedds standalone dpus submit year business confirm efficacy safety combination result plan overall budget clearly define objective cedd step regulatory file submission regulatory accountable production quality proof concept agency approval patient use responsibility tackle challenge internal discovery regulatory team extensive collaboration academia biotech companies medicine development collection therapeutically centre excellence drug discovery cedd align medicine development centre mdcs cardiovascular metabolic cvm infectious disease d neuroscience include discovery performance unit dpu respiratory mdc ultimate accountability immunoinflammation develop experimental drug regulatoryapprove infectious disease medicine patient mdcs responsible create metabolic pathway value execution product development plan neuroscience ensure strong partnership rest rd gsk respiratory particular cedd preclinical development regulatory centre excellence external drug discovery ceedd commercial group manufacture additional standalone discovery performance unit dpu emphasis creation strongly macrolide empower project team creation medicine opthiris focus ophthalmology development leader role key late stage asset virtual poc centre clinical study excellence create sirtris professional organisation provide study operation capabilitie academic dpu partnership mdc cedd deliver gsk clinical trial gsk annual report report director research development continue major opportunity oncology creation rd employee oncology rd unit rd employ staff wide variety educational background create integrate oncology unit span biologist chemist clinical scientist physicians drug target identification late stage development prominent qualification give number strong pipeline cancer medicine unique aspect structural change ensure staff retention oncology medicine development creation priority personal development programme staff oncology rd unit oncology important investment area engagement strategy active talent management gsk see late stage pipeline flourish disease develop world future growth biopharmaceutical creation continue investment research disease develop biopharm rd unit world essential longterm improvement goal leader biopharmaceutical health people live region create biopharm rd unit biopharmaceutical response challenge operate drug discovery unit base large molecule antibodie protein peptide tre canto spain focus malaria tuberculosis manufacture live cell different additional rd site usa uk focus small molecule chemical synthesis development new medicine treat hivaids drug rd process require specific treatment discovery resistant bacteria vaccine research conduct development manufacturing perspective biopharm rd rixensart belgium unit bring function single cohesive rd effort address prevention group discovery biopharmaceutical process development treatment world health organization late stage development form organisation priority infectious disease investment global rd growth rd china publicprivate partnership ppps remain essential fund research line aim access good science ensure gsk commercially viable market potential truly global company announce creation product remain leader working ppp continue rd china group grow employee focus collaborate closely government academic centre neurodegeneration create dpus year united nations agency global funding body rd china currently focus discovery unit grow area maximise expertise knowledge pipeline mature expand capability fully integrate rd centre governance key project reach significant milestone review month product management board pmb responsible determine medicine meet criterion pass phase development gsk chief medical officer work global safety board ultimately accountable oversight major decision patient safety global safety board responsible internally approve pivotal study investigate issue relate patient safety arise development programme information gsk clinical trial widely easily available clinical trial register gsk website oversight strategic issue organisation choice budget management rd own radex rd executive teamgsk annual report report director research development continue vaccine rd animal research gsk active field vaccine research development ethical regulatory scientific reason research production portfolio vaccine approve animal remain small vital research development marketing scientist devote new medicine vaccine use animal discover innovative vaccine contribute health alternative number require test wellbee people generation world strive exceed regulatory standard care use discovery development new vaccine complex process animal undertake internal external review assure require longterm investment vaccine standard clinical development strong vaccine vast majority experimental method use animal pipeline industry vaccine traditionally actively engage research develop validate ward illness gsk vaccine division develop test avoid use animal research reduce therapeutic immunotherapeutic aim educate patient number need animal research unnecessary immune system identify attack cancer cell highly pain suffering scrupulously avoid specific manner decide initiate funding study great ape vaccine discovery involve collaboration academia th october voluntary decision provide biotech industry identify new vaccine antigen tangible demonstration commitment rs express yeast bacteria mammalian cell animal research advocate replacement reduction purify high level follow formulation animal research refining experiment improve clinical lot vaccine involve mix antigen animal welfare select gsk novel proprietary adjuvant system combination select adjuvant design elicit understand use animal research purpose appropriate immune response specific antigen right command high level public interest public policy position combination antigen adjuvant system help body care ethical use animal research mobilise effective immunological pathway information report available website design provide maximum protection specific disease research development target population consumer healthcare formulate candidate vaccine evaluate safety continuous creation development innovative efficacy perspective different phase preclinical product keep brand relevant vibrant valuable testing clinical trial involve healthy individual portfolio span major category overthecounter otc range safety analysis small group volunteer medicine oral healthcare nutritional healthcare phase dose adjustment proof concept phase ii major brand dedicate rd team partner work largescale safety efficacy analysis phase iii result alongside commercial brand team colleague officefree obtain clinical trial datum development hub environment foster collaboration fast decision quality largescale production process facility make hub quickly preferred way work combine regulatory file submit innovation centre weybridge uk parsippany usa authority country vaccine available launch post marketing study considerable size set assess vaccination programme monitor vaccine safety gsk annual report report director research development continue therapeutic area compound diverse product development pipeline biopharmaceutical belimumab systematic lupus erythematosus key late stage project highlight comprise otelixizumab type diabete new chemical entity new combination formulation syncria type diabete exist asset advanced status show include ofatumumab follicular lymphoma approval major market rheumatoid arthritis refractory chronic lymphocytic leukaemia key bosatria mepolizumab hypereosinophilic syndrome phase iii large comparative study compound versus placebo andor cardiovascular metabolic avandamet xr type diabetes extend release establish treatment patient establish clinical benefit avandia simvastatin type diabete safety darapladib atherosclerosis arixtra treatment acute coronary syndrome file f follow successful phase iii trial file product approval neuroscience almorexant insomnia regulatory authority retigabine epilepsy partial seizure approval rosiglitazone xr alzheimer disease approval grant begin market lamictal xr epilepsy partial seizure oncedaily medicine vaccine lunivia insomnia solzira restless leg syndrome pipeline page website wwwgskcom oncology avodart reduction risk prostate cancer elesclomol metastatic melanoma pazopanib tyverbtykerb inflammatory breast cancer tyverbtykerb breast cancer adjuvant therapy breast cancer line therapy gastric cancer head neck squamous cell carcinoma resectable disease pazopanib sarcoma renal cell cancer duodart avodart alpha blocker benign prostatic hyperplasia fix dose combination zunrisarezonic chemotherapyinduce postoperative nausea vomit revoladepromacta chronic liver disease induce thrombocytopaenia hepatitis c induce thrombocytopaenia idiopathic thrombocytopaenic purpura vaccine hibmencytt neisseria meningitis group c disease haemophilus influenzae type b disease prophylaxis magea asci treatment nonsmall cell lung cancer treatment melanoma menacwytt neisseria meningitis groups c w disease prophylaxis new generation flu vaccine seasonal influenza prophylaxis elderly simplirix genital herpe prophylaxis synflorix streptococcus pneumoniae disease prophylaxis infant child cervarix human papilloma virus infection prophylaxis prepandrix flu prepandemic prepandemic influenza prophylaxis inlicence alliance relationship party note financial statement post balance sheet eventsgsk annual report report director research development continue indication phase fila edpproved biopharmaceutical belimumab systematic lupus erythematosus otelixizumab type diabete syncria type diabete ofatumumab follicular lymphoma rheumatoid arthritis refractory chronic lymphocytic leukaemia f bosatria mepolizumab hypereosinophilic syndrome f cardiovascular metabolic avandamet xr type diabetes extend release avandia simvastatin type diabetes darapladib atherosclerosis arixtra treatment acute coronary syndrome neuroscience almorexant insomnia retigabine epilepsy partial seizure rosiglitazone xr alzheimer disease lamictal xr epilepsy partial seizure oncedaily f lunivia insomnia f solzira restless legs syndrome f oncology avodart reduction risk prostate cancer elesclomol metastatic melanoma pazopanib tyverbtykerb inflammatory breast cancer tyverbtykerb breast cancer adjuvant therapy breast cancer line therapy gastric cancer head neck squamous cell carcinoma resectable disease pazopanib sarcoma renal cell cancer f duodart avodart alpha blocker benign prostatic hyperplasia fix dose combination f zunrisarezonic chemotherapyinduce postoperative nausea vomit f revoladepromacta chronic liver disease induce thrombocytopaenia hepatitis c induce thrombocytopaenia idiopathic thrombocytopaenic purpura vaccine hibmencytt neisseria meningitis group c disease haemophilus influenzae type b disease prophylaxis magea asci treatment nonsmall cell lung cancer treatment melanoma menacwytt neisseria meningitis groups c w disease prophylaxis new generation flu vaccine seasonal influenza prophylaxis elderly simplirix genital herpe prophylaxis synflorix streptococcus pneumoniae disease prophylaxis infant child f cervarix human papilloma virus infection prophylaxis prepandrix flu prepandemic prepandemic influenza prophylaxis gsk annual report report director employee recruitment talent management face face communication activity town hall presentation leadership development lead senior executive lunch cet senior executive year recruit retain develop ensure communication activity effective employee critical enhancing sustain enable continue improve number performance reputation area focus evaluation process feedback monitoring mechanism major communication event qa feedback recruiter proactively identify engage attract external facility core feature web communication channel talent assess potential fit organisation broad process include global leadership survey take place function business geographical year survey ask manager area assessment process align core set worldwide comment critical issue culture competency ethic integrity central confidence gsk future streamline annual performance development planning business evolve change affect pdp process mean employee businessaligne objective employee remain committed consult behavioural goal regular review progress change number internal consultation forum ongoing culminate endofyear review discussion european employee consultation forum annual talent management cycle identify similar body country national practice high perform people business follow tailor management leadership programme key talent employee number region performance reward usa europe reward system support high performance help attract emerge market retain good people performancebase pay bonus asia pacific share reward share option align employee interest japan business target canada communication employee involvement new fulltime employee join organisation diversity opportunity gsk experience interactive commit employment policy free discrimination induction programme offer location uk exist potential employee ground age usa programme module provide support race ethnic national origin gender sexual orientation faith local induction awareness seminar world disability gsk commit offer people disability experience give employee flavour communication access range recruitment career opportunity engagement activity offer gsk effort retain support employee communication channel design employee disabled work gsk detail diversity inform engage involved activity area measure corporate responsibility report organisation encourage twoway open honest communication employee web technology healthy high performance increasingly engage employee immediate able meet mission strategy employee health way new update communication channel include performance initiative focus health factor enable employee perform high level sustain myceo area gsk intranet allow employee energy engagement programme develop engage directly ceo discussion qa deliver health strategy range traditional ambassador community provide slide statement immunisation smoke control weight management film employee company information cuttingedge programme area team personal uptodate issue affect gsk resilience ergonomic energy performance pharmaceutical industry programme available language design address gsktv webbase library gsk video asset include root cause excessive work pressure low energy presentation strategy employee broadcast engagement work home compliment commitment flexible working enable employee interactive multimedia event web broadcast multisite good work environment help integrate qa session regular update globally ceo business work personal live detail scope impact function leader programme corporate responsibility reportgsk annual report report director responsibility improve access medicine programme country introduce orange card provide discount access healthcare develop world certain gsk prescription medicine eligible patient easy solution challenge provide number country nature discount sustainable access healthcare develop country poverty varie country way healthcare single big barrier country people system operate food access clean water supply hospital clinic receive treatment healthcare professional care patient advocacy patient advocacy initiative demonstrate significant committed play address progress inception initially launch healthcare challenge develop world take programme critical initiative gsk patient innovative responsible sustainable approach gsk advocacy team usa europe share good practice make vital contribution develop country healthcare establish process optimise interaction patient group action number area include preferential typically relationship provide mutual opportunity pricing antiretroviral antimalarial tiere pricing learn patient need priority patient group vaccine invest rd target disease particularly develop understand drug development challenge affect develop world community continue partner patient group investment activity partnership foster effective common issue advocate access medicine treatment healthcare seek innovative partnership increase funding health program improve health solution cover contribution improve access care delivery consider trustworthy partner medicine extensively corporate responsibility report patient group work patient group clear leader access medicine trade association increase transparency index produce atm foundation continue build interaction product pricing partnership commitment help improve healthcare develop world february work community announce new approach pricing un define list work partner underserve community develop country significant increase develop develop world support programme fund global community need support innovative sustainable bring real benefit rd provide access resultant medicine community global community investment vaccine million compare million like like basis increase comprise product achieve sustainable progress donation value million cash give million occur significant barrier stand way well inkind donation million plus cost million access healthcare tackle share responsibility manage deliver community programme sector global society government international agency country product donation include million gsk charity academic institution pharmaceutical industry patient assistance program million worth albendazole lymphatic filariasis lf programme million access medicine develop world humanitarian product donation product donation programmes usa time value cost average cost good work provide access medicine people wholesale price wac new approach value donation limit financial resource prescription accurate reflection cost gsk drug insurance transparent believe pharmaceutical company adopt practice comparative purpose uninsure americans qualify medicare total value donation wac product medicaid gsk pharmaceutical company create million compare million rx access programme qualified individual offer reduction pharmacy cost medicine operate single charitable foundation rx access cardholder save community investment programme number million country base foundation grant include investment total gsk annual report report director responsibility continue cash giving target primarily health education phase initiative follow phase programme personal hygiene sanitation education initiate provide education thousand school child country improve health hygiene health fight infectious disease commit year fund education extend programme india art culture humanitarian product donation environment donate essential product antibiotic nonprofit partner include americare direct relief international map international project hope support humanitarian relief effort community healthcare total value international humanitarian product donation global health programme million average cost eliminate lymphatic filariasis community initiative effort eliminate disable disease lf world dedicated strengthen fabric community continue close partnership government country provide health education initiative support disease endemic partner local civic cultural institution improve quality organisation commit donate life uk contribute million antiparasitic drug albendazole require treat continue programme charitable activity support billion people risk country million organisation health medical research science education albendazole treatment donate country art environment donate billion albendazole treatment global elimination programme start programme north america national local level focus improve public education increase access healthcare positive action hivaid child healthcare prevention access breast positive action pioneer global programme working gynaecologic cancer fund million community affect aid start support communitybased organisation deliver effective hiv aid gsk company manufacture education prevention healthcare service company award new communitymark follow positive action work partner support programme independent assessment mark create business country positive action large programme operate community bitc give work local national mexico kenya india china cambodia vietnam level uk large international programme glaxosmithkline african malaria partnership malaria advocacy programme mobilising malaria launch country coalition malaria uk belgium france ethiopia cameroon increase awareness malaria mobilise resource gsk cosponsor guardian international development journalism award recognise work ngo address un millennium development goal include focus malariagsk annual report report director responsibility continue health initiative contribution improve healthcare include follow grant non profit partner purpose grant children health fund extend referral management initiative rmi ensure usa continuity specialist medical care highrisk child homeless pittsburgh mercy foundation provide access healthcare homeless man women usa pittsburgh usa gsk impact award recognise excellence nonprofit community health uk philadelphia organisation charity receive unrestricted grant work deal diverse difficult social issue medical research charity support medical research programme uk education initiative non profit partner purpose grant institute competitive workforce improve education create skilled workforce future usa working partnership broad business coalition staff chamber commerce science summer teach basic scientific concept inspire school child philadelphia pittsburgh north carolina librarybase science education programme project enthuse support continue professional development cpd science uk teacher ultimately encourage child engage science pursue career science technology crest star investigator provide science activity award school club uk uk primary school work partnership british association advancement science information gsk grant programme available gskcom employee involvement employee encourage contribute local community employee volunteer scheme support include employee time cash donation charity employee volunteer match gift programme gsk match gift program match employee retiree gift value million plus million united way campaign gsk programme provide grant organisation employee volunteer ukbased nonprofit organisation gsk make difference programme gsk annual report report director responsibility continue responsibility environment health ehs sustainability strategy plan safety year strategic plan ehs extend align caring environment health safety eh strategic priority include management objective employee key drive sustainable company performance measure target gsk progress evaluate target set traditional environmental control programme address risk impact waste generate manufacturing focus embed ehs business activity meet responsibility treatment waste fundamental making gsk sustainable business involve disposal system comply law regulation care present thinking future make standard performance standard practice decision support aspiration company beginning plan embed ehs business environmental sustainability continue improve handle waste recognise open transparent stakeholder relation change incremental transformative review ehs sustainability priority external internal stakeholder review identify follow early concept sustainability emerge key issue sustainability mean need concerned short term impact pollution long term manufacture efficiency mass efficiency process impact resource consumption type material development continues improve progress persistence waste environment journey achieve target double mass efficiency halve sustainability start look holistically continue waste unit product manufacturing process treat waste find way prevent waste phase iii compound late stage product produce require call sustainable evaluate efficiency make technology efficient chemistry efficient progress goal process recognise sustainability principle apply climate change comprehensive strategy climate change aspect operation apply minimise waste energy efficiency approve available gsk consumption natural resource possibly website climate change energy reduction team renewable material discover manufacturing packaging form manage special fund support sell product impact consumer climate change project team identify use product project reduce energy consumption traditional environmental programme see increase use renewable energy cost financial return sustainable approach pharmaceutical environment apply product resource concern social impact stewardship principle issue pharmaceutical operation financial benefit resource environment principally unmetabolised drug excrete spend money operation patient need continue address traditional environmental issue process safety process safety management system time integrate sustainability aspect enhance new engineering standard training business discover develop manufacturing programme development standard sell pharmaceutical consumer healthcare product design new process plant upgrade exist plant use energy resource produce emission waste need training programme increase process safety awareness competency engineer chemist managersgsk annual report report director responsibility continue ehs management gsk remain track eliminate use cfc meet target water consumption progress responsibility ehs high level corporate meet target wastewater pollution disposal responsibility committee board director provide waste emission volatile organic compound air oversight sustainability council form combination conservation programme reduce representative area company corporate production product rate injury illnesse department report chief staff overall improve line target continue emphasis responsibility provide governance leadership ehs employee safety behaviour sustainability issue head department make regular report corporate executive team cet audit progress energy relate corporate responsibility committee board greenhouse gas emission target carbon business executive manager responsible ehs footprint remain unchanged energy efficiency project support sitebased ehs occupational medical staff continue project complete identify gain project fully realise governance responsibility conduct ehs audits gain experience part site operate entity key supplier assess business offset continue expansion management key risk impact performance vaccine business global ehs standard include provide audit site supplier quantitative performance information final ehs performance data explanation highlight area risk reduction improvement trend publish corporate responsibility report ehs target sustainability ehs plan target set year work sustainability address economic baseline year target environmental social issue research manufacturing sale distribution medicine consumer healthcare select measure performance improvement base product sustainability start healthcare solution find potential adverse impact people environment rd continue innovation improve efficiency business continuity business reputation manufacturing process new product reduce resource measure select similar report use turn lower waste cost low cost company recommend global product available wide population world report initiative longterm multistakeholder international future ehs plan excellence propose investigate undertaking develop disseminate globally applicable use renewable resource manufacture sustainability report guideline seek dialogue external stakeholder consider target set eliminate chlorofluorocarbon cfc view develop approach sustainable development use year reduce nonhazardous waste information ehs programme performance dispose reduce water use volatile organic compound find gsk website voc release air reduce pollution wastewater measure chemical oxygen demand reduce energy usage relate greenhouse gas emission target normalise sale base constant exchange rate gsk annual report report director regulation regulation pharmaceutical generally national regulatory authorisation require approve switch product prescription otc gsk operate highly regulate environment regional historymake otc industry countryspecific law regulation define datum require weight loss medicine alli receive centralised european positive safety efficacy pharmaceutical product opinion committee medicinal product human govern testing approval manufacturing labelling marketing use chmp october result approval market alli drug regulatory requirement major factor eu member country license weight loss determine marketable product successfully treatment available prescription develop time expense associate development price control drug safety remain primary focus fda country price pharmaceutical product congressional oversight committees europe evaluation control law government influence price benefit risk continue paramount consideration control national healthcare organisation bear approval new drug fda amendment act legislation large cost supply medicine consumer pass renew user fee system drug review recent government healthcare reform country france mandate rigorous fda review safety approval spain germany restrict pricing reimbursement postmarketing phase product legislation provide fda authority convene advisory usa recent legislative proposal healthcare reform committee review new drug prior approval decision crossborder trade acceleration generic market fda require sponsor complete postmarketing study comparative effectiveness increase focus direct company product labelling change fda pricing currently government price control routinely exercise new authority private sector purchase federal law require pharmaceutical manufacturer pay prescribe rebate certain drug regulation require development prescription drug eligible reimbursement medicaid state biologic paediatric population place federal healthcare programme healthcare remain lead eu gsk fully support objective ensure development domestic issue presidential election well medicine child candidate focus health reform address chronic disease europe proposal legislative change announce primary healthcare cost driver focus drug european commission aim price strengthen eu system safety monitor medicine improve citizen access reliable information medicine medicare strengthen eu law protect citizen well threat medicare program federally funded pose fake medicine healthcare insurance programme benefit senior citizen certain disabled americans include coverage prescription regulatory environment emerge market asiapacific medicine coverage voluntary include brandname continue evolve number country continue generic drug open million americans develop regulatory review system gsk actively participate medicare coverage number specific regional national regulatory initiative provide opportunity meaningful scientific regulatory value money dialogue industry agency stakeholder gsk payer world concern cost continue include broad set patient population healthcare pricing medicine requirement number country medicine development programme satisfy healthcare purchaser value money order increase global patient access new innovative medicine additional hurdle product acceptance optimise regulatory approval regulatory test safety efficacy quality regulation consumer healthcare consumer healthcare industry subject national regulation comparable prescription medicine testing approval manufacturing labelling marketing product high standard technical appraisal frequently involve lengthy approval process new product launchedgsk annual report report director economy world market outlook world economy world market pharmaceutical world economy deteriorate sharply financial global pharmaceutical sale billion compare crisis deepen particularly follow bankruptcy lehman billion brother september despite aggressive cut official interest rate fiscal stimulus measure national initiative support world market value growth international banking system international monetary fund geographic region bn total forecast global growth slow estimate usa mere low rate world war ii europe advanced economy expect contract france annual contraction postwar period germany italy slump global demand lead collapse equity price uk ftse index fall dow jones industrial rest world average collapse commodity emerge market price weak economic activity low commodity price asia pacific dampen inflationary pressure advanced economy japan headline inflation rate forecast imf decline canada estimate record low total order engender economic recovery federal open market market increase represent committee fomc decide december cut target global prescription pharmaceutical market compare federal fund rate decision signal decade ago fomc effectively target supply credit price credit nonetheless imf forecast real th september gsk hold second position world gdp usa contract housing market pharmaceutical market market share pfizer remain particular concern market share gsk world pharmaceutical product lamictal seretideadvair like fomc monetary policy committee bank england valtrex aggressively ease monetary stance cut bank rate bank rate cut world market value growth reinforce impact cut bank rate therapeutic class bn total government empower bank england purchase central nervous system high quality asset like corporate bond commercial paper cardiovascular commercial bank imf forecast real gdp uk alimentary tract metabolic contract advanced economy antineoplasticimmunomodulatory antiinfective bacterial european central bank maintain cautious approach viral fungal exclude monetary relaxation cut refinance rate vaccine refinancing rate cut percentage respiratory point january additional monetary easing anticipate imf forecast real gdp eurozone contract note datum base month th september real gdp germany plunge outlook like major industrialise economy japan fall recession mark turning point factor impact prime factor downturn external demand performance particular decline avandia sales bank japan cut overnight money rate start reduce see step real gdp forecast imf contract radical transformation business model enter confidence expect good progress china india remain path economic expansion implement strategic priority enable meet pace expansion decelerate longterm objective reduce risk deliver sustainable deceleration expect economic activity brazil growth shareholder remain buoyant expect slow markedly uncertainty surround economic outlook unusually large downside risk continue dominate gsk annual report report director financial review pharmaceutical turnover cns growth rate include review turnover constant cns sale decrease billion exchange rate cer state sterling growth majority gsk cns franchise impact generic rate find table pharmaceutical turnover competition usa generic competition lamictal imigran therapeutic area geographic region remain presentation wellbutrin start course positive news total pharmaceutical turnover decline year treximet approve migraine fda april billion drive largely performance cardiovascular urogenital billion impact expect generic competition cardiovascular urogenital sale increase billion mature brand decline avandia sale sale asia pacific japan fall billion reflect strong growth portfolio product partly low government order relenza impact offset generic competition coreg ir lovaza high pharmaceutical price cut japan decline partly triglyceride acquire reliant pharmaceutical offset growth europe billion emerge grow proforma basis million market billion sterling term pharmaceutical grow market share avodart benign prostatic turnover grow reflect weakness sterling hyperplasia enlarge prostate grow million take major currency percentage point market share arixtra deep vein thrombosis pulmonary embolism grow million pharmaceutical turnover therapeutic area coreg cr grow million gsk turnover decline impact low metabolic avandia sale generic competition range gsk metabolic sale decrease billion product low flu prepandemic sale partly offset strong growth key product advair valtrex epzicom strong growth bonvivaboniva postmenopausal osteoporosis avodart lovaza vaccines franchise million offset year impact avandia sale start fall financial respiratory review avandia product sale decline respiratory sale increase billion year million sale fall million european sale million sale seretideadvair asthma copd rise emerge market avandia product sale return growth billion usa advair sale rise billion second half year q sale return volume growth second half year fda grant advair indication copd prevention oncology emesis exacerbation helped grow copd segment oncology emesis sale decrease billion advair business europe sale increase billion advair performance particularly strong tykerb breast cancer continue grow follow approval emerge market million japan usa year approval country achieve sale product double million follow european approval achieve launch june antiviral vaccine antiviral decrease billion vaccine sale increase billion gsk hiv business continue experience strong competition vaccine portfolio strong performance epzicomkivexa grow million hepatitis vaccine million combination offset decline rest portfolio sale paediatric vaccine infanrixpediarix million valtrex herpe rise billion sale rotarix rotavirus gastroenteritis rise million fuel growth sale flu antiviral relenza fall largely drive government tender order latin america million reflect few government order launch product usa august new cervical prepandemic stockpile cancer vaccine cervarix record sale million year follow tender win include national government order uk netherlandsgsk annual report report director financial review continue pharmaceutical turnover therapeutic area total usa europe rest world therapeutic area growth growth growth growth major product total cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antiviral hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip requip xl treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin altabax oncology emesis hycamtin zofran tykerb vaccine hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix cer represent growth constant exchange rate represent growth actual exchange rate turnover quarter give financial record page gsk annual report report director financial review continue regional analysis follow table give adjustment order restate turnover market europe turnover pharmaceutical turnover geographic region create basis invoice basis turnover report table represent sale invoice region invoice adjustment create invoice adjustment create gsk local entity customer local market plus major market copromotion income market europe france region growth uk major market total cer italy usa germany europe spain france europe uk italy adjustment gsk estimate base recent germany datum independent external source value sterle spain relevant exchange rate management believe turnover europe create basis report turnover market provide well rest world reflection performance business market emerge market europe japan total turnover europe region unaffected asia pacific adjustment canada parallel trade occur occasionally world sufficiently material affect significantly turnover datum market present invoice basis cer represent growth constant exchange rate represent growth pharmaceutical turnover geographic region actual exchange rate turnover create basis individual government determine pricing medicine country europe result wide price variation turnover market europe adjust product parallel trade occur party effect parallel trade turnover basis exploit price differential purchasing product market country product finally consume low price enforce sell government product sell gsk purchaser market high price agree parallel trade permit single region growth major market total cer market rule european union gsk derive usa benefit profit resale high price europe result management believe european region france turnover market invoice basis present uk properly represent consumption product italy market gsk employee base market germany instrumental promotion group product spain market create product sale final consumption europe market rest world emerge market japan asia pacific canada cer represent growth constant exchange rate represent growth actual exchange rate turnover quarter give financial record page gsk annual report report director financial review continue usa otc medicine sales usa decline billion principally reflect otc product sale decline billion sale year impact avandia generic competition smoke cessation product million panadol sale significant product lamictal imigran grow million twice global average wellbutrin xl requip coreg ir decline partly offset advair oral healthcare valtrex lovaza proforma basis sale oral healthcare product rise billion market grow strong performance sensodyne europe million aquafresh million sale europe increase billion continued growth sensodyne growth represent world toothpaste growth seretide particularly strong vaccine growth offset market gsk compete impact generic competition number product continue price cut government region nutritional healthcare nutritional horlick sale rise million lucozade emerge market sale rise million ribena sale flat million sale emerge market increase billion strong sale lucozade ribena second half year growth russia china latin america decline slightly largely result poor weather uk growth fuel primarily vaccine billion respiratory franchise billion result major restructure total result asia pacificjapan october board approve implementation increase sale seretideadvair million detailed formal plan gsk announce significant offset low government order relenza japan new operational excellence restructure programme price cut second formal plan represent significant expansion consumer healthcare turnover operational excellence programme approve board announce february restructure growth programme comprise detailed formal plan cover total cer area gsk business include manufacturing sell rd overthecounter medicine infrastructure estimate total cost approximately panadol franchise billion expand programme expect deliver smoking cessation product annual pretax saving approximately billion time tum substantially complete approximately cold sore franchise cost incur st december approximately breathe right expect incurred alli balance total approximately oral healthcare cost expect cash expenditure expect aquafresh franchise accounting writedown uncertainty exist exact sensodyne franchise time cash outflow result potential dental care future exchange rate fluctuation element restructure programme subject employee consultation nutritional healthcare lucozade procedure make difficult predict precision horlick procedure complete majority ribena remain cash payment expect give extent cost operational excellence programme management believe material cer represent growth constant exchange rate represent growth impact gsk operating result manner actual exchange rate turnover quarter give financial record gsk business conduct gsk present restructure cost page incur solely direct result operational excellence total consumer healthcare sale year rise billion programme amount million compare growth benefit tax million separate column income launch stock new antiobesity treatment alli sales alli statement title major restructuring million exclude alli consumer healthcare sale rise gsk annual report report director financial review continue addition restructuring cost operational excellence remain cost million arise programme major restructuring column income miscellaneous expenditure incur solely direct result statement include restructuring cost incur solely direct restructuring programme include consultancy project result restructure programme follow relate management fee termination lease site closure cost material acquisition operation acquire respect recognition foreign exchange loss business overlap extensively gsk exist operation follow liquidation subsidiary puerto rico cost arise gsk ongoing operating activity report restructuring activity follow relate major restructuring column acquisition nature undertake operational excellence programme carry restructuring cost arise solely direct result follow detailed formal plan management consider operational excellence programme restructure appropriate present cost restructuring activity programme follow relate acquisition meeting manner billion million acquisition criterion describe continue report operate reliant pharmaceuticals inc december expense result major restructuring cost acquisition october meet criterion set include restructuring cost relate minor acquisition acquisition cost incur million cost million relate direct result related restructure programme restructuring activity initiate commencement include major restructure column total operational excellence programme restructure restructuring cost incur direct result acquisition activity material impact gsk operate result million charge pay manner business conduct anticipate duration operational excellence group result cost operational excellence programme gsk currently expect incur material programme acquisitionrelate restructuring programme restructure cost related programme meeting criterion describe present acquisition meeting criterion describe separate column income statement describe unanticipated material restructuring cost arise result major restructuring presentation period gsk expect include major gsk intend apply consistently future major restructuring restructuring column programme material impact gsk operate gsk operate profit profit taxation taxation profit result manner gsk business conduct year discuss term total result adopt clearly group result include major restructuring cost result major cost restructure programme restructure management believe presentation assist shareholder gain clear understanding group financial operating profit total result performance make projection future financial total result include restructure cost relate new performance result include cost virtue operational excellence programme commence size nature limited comparative value presentation october reliant restructuring programme consistent way management assess group financial performance growth cer restructuring cost incur solely direct result turnover operational excellence programme restructuring programme follow reliant acquisition report cost sale major restructuring column income statement sell general restructuring cost principally arise impairment administration research property plant equipment termination development employment contract staff redundant operate restructuring activity set note financial income statement major restructuring programme asset impairment staff redundancy account million operating profit million restructuring cost incur report major restructure column milliongsk annual report report director financial review continue cost sale profit taxation total result cost sale increase turnover constant exchange rate cost sale percentage turnover net finance cost increase percentage point reflect charge relate major restructuring programme million finance income million unfavourable product regional interest finance income mix compare partly offset saving fair value adjustment hedge restructure programme sell general administration finance cost sga cost include legal charge turnover interest cost increase percentage point constant unwind discount liability exchange rate increase percentage point legal fair value adjustment hedge cost million million include million charge announce january relate investigation gsk market promotional practice share tax profit associate joint venture originate colorado sga cost include charge share tax profit associate million million million relate major million arise principally group hold restructuring programme exclude legal cost sga decrease quest diagnostic inc profit taxation total result research development take account net finance cost share profit rd expenditure increase include charge relate associate total profit taxation million compare major restructuring programme million million cer decline million exclude charge rd expenditure sterling decline increase cer term investment late stage pipeline partly offset restructure saving operating profit result major restructuring operating income operate income million million result major restructuring set include strong growth royalty income million million product intellectual property equity growth cer investment disposal realise million compare turnover million roche litigation settlement include cost sale sell general operating profit total result administration research total operating profit million decrease sterling development term cer term compare pharmaceutical operate operate profit million consumer income healthcare operating profit fall million operating profit year gain asset disposal settlement million million cost legal matter cost sale million million fair value movement financial cost sale increase percentage point instrument result charge million income turnover constant exchange rate increase percentage million charge relate previous restructuring point turnover principally reflect impact generic programme million million charge competition high margin product usa low avandia relate major restructuring programme million sale high proportion sale generate low margin million impact item total vaccine brand sell emerge market consumer operating profit million charge compare healthcare product partly offset saving million charge restructuring programme gsk annual report report director financial review continue sell general administration profit taxation result sga cost include legal charge turnover major restructure constant exchange rate sga cost increase percentage point turnover legal cost net finance cost million million include million charge announce january relate investigation finance income gsk market promotional practice originate interest income colorado exclude legal cost sga percentage turnover fair value adjustment hedge fall percentage point growth sterling term reduction constant exchange rate reflect benefit restructure finance cost programme sell distribution fall advertising interest cost promotion general administration expenditure unwind discount liability exclude legal charge fair value adjustment hedge research development rd expenditure increase turnover take account net finance cost share profit investment late stage pipeline partly associate profit tax major restructuring offset restructure saving million compare million cer decline flat sterling term operate income operate income million million taxation include strong growth royalty income million million product intellectual property equity investment disposal realise million compare uk corporation tax million roche litigation settlement overseas taxation include current taxation operate profit result major restructuring defer taxation operate profit major restructuring million taxation total profit year increase sterling term decrease cer term compare pharmaceutical charge taxation profit major restructuring operating profit million consumer charge amount million million healthcare operating profit flat cer term million represent effective tax rate exclude legal cost operating profit decrease charge taxation total profit amount great turnover decline primarily million million represent high cost sale percentage turnover effective tax rate group balance sheet st december include tax payable liability year gain asset disposal settlement million tax recoverable asset million million million cost legal matter million million fair value movement group main open tax issue usa canada japan financial instrument result charge million july follow discussion hmrc group settle income million charge relate previous substantially outstanding uk tax issue period restructure programme million million include st december impact item operate profit major follow audit period irs issue restructure million charge statutory notice deficiency gsk assert income million withholding tax deficiency associate penalty arise reclassification intercompany financing arrangement year debt equity consequent recharacterisation amount pay dividend subject withholding tax uk treaty amount financing arrangement timely pay final payment april gsk annual report report director financial review continue irs commence audit period june total result include restructuring cost produce basic eps examine issue year gsk disagree p compare p decline irss position august initiate action cer decline sterling term exclude major united states tax court contest statutory notice restructure cost ep p compare p deficiency gsk estimate irs claim tax penalty decline cer increase sterling term interest st december net federal tax relief percentage point currency benefit arise weakness million gsk believe claim sterle major currency merit adjustment warrant contrary gsk view irs prevail argument court respect dividend year gsk expect additional board declare fourth interim dividend penny liability year period share result dividend year penny penny million tax penalty interest st december increase dividend penny share net federal tax relief year event equivalent fourth interim dividend receivable adr holder company able resolve issue irs court cent ad base exchange rate decision expect exdividend date th february record date th february payment date th april low court japan uphold claim tax authority yen billion million relate japanese cfc critical accounting policy legislation company pay fully provide tax pursuing claim refund japanese supreme consolidated financial statement prepare accordance court canada court decision respect transfer pricing ifrs adopt use european union early complete gsk file ifrs issue iasb follow accounting policy appeal june court date await approve board describe note financial statement accounting principle policy management gsk continue believe adequate provision require estimate assumption affect liability likely arise open assessment amount asset liability revenue expense report ultimate liability matter vary amount financial statement actual amount result differ provide dependent outcome litigation estimate critical accounting policy adopt relate proceeding negotiation relevant tax authority follow area profit year turnover taxation growth legal dispute cer property plant equipment total profit taxation year goodwill total profit attributable intangible asset shareholder pension postemployment benefit basic earning share penny p p basic earning ad information judgement estimate area give note financial statement key accounting result major restructure profit taxation year judgement estimate result major restructuring respect turnover accounting policy group large profit attributable shareholder business pharmaceutical market adjust earning share penny p p complex arrangement rebate discount allowance adjust earning ad follow briefly describe nature arrangement weight average number existence group pharmaceutical business share million gsk arrangement certain indirect customer diluted total earning share penny p p customer able buy product wholesaler dilute total earning ad reduce price chargeback represent difference dilute weight average number share million invoice price wholesaler indirect customer contractual discount price accrual estimate chargeback calculate base term agreement historical experience product growth rate gsk annual report report director financial review continue customer rebate offer key manage care group chargeback decrease result sale purchasing organisation gpo direct indirect product government stockpile customer arrangement require customer achieve arise manage care medicare gpo rebate certain performance target relate value product purchase flat dollar term despite additional tricare prescription formulary status predetermine market share relative rebate january national defense authorisation act competitor rebate give medicare include approve authorise department defense category medicare programme introduce access discount federal pricing drug dispense tricare replace government medicaid subsidy individual network retail pharmacy member armed force subsidise coverage provide private prescription plan dependant military retiree rebate give accrual rebate estimate base specific term government state programme rise mainly agreement historical experience product growth rate pricing adjustment imitrex lamictal follow introduction generic competition inclusion medicaid programme stateadministere programme new product reliant pharmaceutical acquisition provide assistance certain poor vulnerable patient medicaid drug rebate program establish total accrual rebate discount allowance return reduce state federal expenditure prescription drug pharmaceuticals business follow gsk participate provide rebate state accrual st st medicaid rebate calculate base specific term december december individual state agreement combination historical experience product population growth anticipate price chargeback increase impact contracting strategy manage care medicare cash discount offer customer encourage prompt gpo rebate payment accrue time invoice government state programme adjust subsequently reflect actual experience cash discount customer return historical experience customer return gsk record accrual estimate sale return apply total historical experience customer return amount invoice market relate information stock level sterling value increase largely result exchange wholesaler anticipate price increase competitor activity rate movement dollar term provision largely unchanged monthly process operate monitor reconciliation gross turnover net turnover inventory level wholesaler abnormal movement pharmaceutical business follow process use gross sale volume prescription volume base party datum source information receive key wholesaler aim maintain inventory gross turnover consistent level year year base pattern consumption basis pharmaceutical inventory level chargeback wholesaler distribution channel st december manage care medicare estimate approximately month gpo turnover calculation use party information accuracy rebate totally verify believe sufficiently government state programme reliable purpose cash discount customer return prior year adjustment item total deduction net turnover sterling value increase approximately compare result exchange rate movementsgsk annual report report director financial position resource financial position property plant equipment gsk business sciencebase technologyintensive highly regulate governmental authority group allocate significant asset financial resource renewal maintenance property noncurrent asset plant equipment minimise risk interruption production property plant equipment achieve compliance regulatory standard number goodwill process use chemical hazardous material intangible asset investment associate joint venture total cost group property plant equipment investment st december million net book defer tax asset value million land building represent derivative financial instrument million plant equipment million asset noncurrent asset construction million gsk invest million new renewal property plant equipment mainly total noncurrent asset relate large number project renewal improvement current asset expansion facility worldwide site property inventory mainly hold freehold new investment finance group liquid current tax recoverable resource st december gsk capital contractual trade receivables commitment future expenditure million operate derivative financial instrument lease commitment million gsk believe facility liquid investment cash cash equivalent adequate current need asset hold sale group observe stringent procedure use specialist skill total current asset manage environmental risk activity environmental total asset issue date operation modify discontinue report responsibility environment liabilitie health safety note financial current liability statement legal proceeding shortterm borrowing trade payable goodwill derivative financial instrument goodwill increase year million current tax payable st december million increase primarily reflect shortterm provision goodwill arise acquisition sirtris pharmaceuticals total current liabilities inc million arise acquisition bms noncurrent liability egypt business million significant strengthen longterm borrowing overseas currency translation exist foreign currency defer tax provision goodwill balance pension postemployment benefit provision intangible asset derivative financial instrument intangible asset include cost intangible acquire noncurrent liability party computer software net book value intangible asset st december million total noncurrent liability million increase reflect addition total liability million currency movement partly offset amortisation net asset impairment exist intangible large element equity addition million relate acquisition sirtris share capital pharmaceuticals inc reflect existence technology share premium account large patent application portfolio cover area sirtuin biology retain earning reserve shareholder equity minority interest total equity gsk annual report report director financial position resource continue investment pension postemployment benefit gsk hold investment include associate joint venture group account pension postemployment carrying value st december million arrangement accordance ias net deficit million market value st december allow deferred taxation million million million large million pension arrangement million investment associate quest diagnostic inc million unfunded postemployment liability book value st december million pension liability increase follow decline asset value million investment include equity stake negative impact exchange movement partially offset company group research collaboration special funding contribution uk pension fund provide access biotechnology development potential interest million million uk pension scheme interest company arise business divestment strengthen longterm interest rate include increase rate discount uk pension liability derivative financial instrument asset decrease estimate long term inflation rate uk gsk noncurrent current derivative financial instrument hold fair value million million increase net debt primarily reflect fluctuation far forward valuation foreign exchange contract hedge intercompany loan deposit exchange movement largely change euro cash cash equivalent dollar yen market rate liquid investment borrowing repayable year inventory borrowing repayable year inventory million increase million net debt year majority increase arise strengthen overseas currency remainder cause partly net debt increase million primarily share strategic stock building support growth specific product repurchase acquisition business significant strengthen foreign currency group debt trade receivable denominated partly offset increase cash inflow trade receivables million increase operating activity reflect impact strengthen overseas currency translation foreign currency receivables partly offset total equity completion nonrecourse factoring arrangement japan summary movement equity set reduction overdue receivables certain european market derivative financial instrument liability gsk hold noncurrent current derivative financial total equity beginning year instrument hold fair value million total recognise income expense million relate primarily hedge exchange translation year currency asset consolidation increase reflect dividend shareholder impact euro dollar yen currency fluctuation ordinary share issue ordinary share purchase hold trade payable treasury share trade payable amount million ordinary share purchase cancel consideration receive share transfer increase primarily reflect strengthen esop trust overseas currency ordinary share acquire esop trust provision sharebase incentive plan tax sharebase incentive plan group carry defer tax provision shortterm distribution minority interest noncurrent provision million st december million respect estimate future liability total equity end year million relate legal dispute provision st december total equity decrease legal dispute indemnify disposal million st december million decrease liability cost restructure programme extent arise principally actuarial loss define benefit pension balance sheet date actual constructive obligation plan year share repurchase partially offset exist reasonably estimate recognised income expense yeargsk annual report report director financial position resource continue share purchase contractual obligation commitment employee share ownership plan esop trust acquire follow table set group contractual obligation million share gsk plc million share hold commitment st december fall payment trust satisfy future exercise option award group share option award scheme proportion total yr yrs yrs yrs share hold trust respect award rule loan scheme require gsk satisfy exercise market purchase interest loan issue new share share hold trust finance lease obligation match option award grant finance lease charge st december esop trust hold million gsk share operating lease future exercise share option share award commitment carry value million million intangible asset deduct reserve market value share property plant equipment investment million million purchase commitment gsk repurchase million share cancellation business combination million nil share hold treasury share pension million order ensure gsk sufficient commitment flexibility deliver strategic priority company expect total significant repurchase exist share buyback programme exact time future commitment respect loan future interest payable loan purchase extent repurchase share hold disclose take account effect derivative treasury share cancel determine group enter number research collaboration develop company dependent market condition factor new compound pharmaceutical company term st december gsk hold million share treasury arrangement include upfront fee equity investment loan share million share cost million commitment fund specify level research addition million deduct group agree payment future milestone retain earning achieve agreement relate compound early stage development milestone payment continue purchase december number year compound successfully exist programme development process generally close product marketing approval great possibility success payment show commitment contingent liability intangible asset represent maximum pay financial commitment summarise note financial milestone achieve statement commitment contingent liability obligation respect short longterm debt set note number new commitment financial statement contingent liability note financial licensing agreement include arrangement statement net debt actelion pharmaceutical limited archemix corporation dynavax technologies corporation mpex pharmaceuticals inc amount provide pension postretirement benefit set commitment relate business combination reflect agreement note financial statement pension post acquire issue share capital genelabs technologies inc bristol employment benefit amount provide restructure programme myers squibb pakistan private limited az tika snc legal environmental dispute set note subject clearance swedish competition authority financial statement provision gsk formalise agreement trustee uk pension scheme additional contribution addition normal contribution year period end st december order eliminate fund pension deficit ias basis point table show commitment net million additional contribution exclude normal ongoing annual funding requirement approximately million gsk commit eliminate future deficit arise rolling fiveyear period agreement review information pension obligation note financial statement pension postemployment benefit gsk annual report report director financial position resource continue contingent liability net cash outflow investing activity million follow table set contingent liability comprise discount decrease million reflect marginally low capital bill performance guarantee letter credit item arise expenditure repayment liquid investment reduce cost normal course business expect expire business purchase include sirtris pharmaceutical million net cash acquire million egyptian total yr yrs yrs yrs business bms million net defer consideration million comparable acquisition comprise reliant guarantee pharmaceutical million domantis million net contingent liability cash acquire total free cash flow normal course business gsk provide free cash flow indemnification guarantee respect business disposal legal dispute subsequently arise provision reasonable estimate likely outcome dispute include note financial statement provision group policy provide settlement cost assert claim environmental dispute reasonable estimate prior point liability record legal environmental cost discuss risk factor page note financial statement legal proceeding gsk continue believe adequate provision free cash flow cash generate business liability likely arise open taxation assessment ultimate meeting obligation interest tax dividend pay minority liability matter vary significantly amount provide interest capital expenditure noncurrent tangible dependent outcome litigation proceeding intangible asset million increase negotiation relevant tax authority discuss principally reflect high operating profit noncash charge note financial statement taxation primarily major restructuring programme work capital improvement partly offset high level interest pay result cash flow significant debt issuance year billion summary consolidate cash flow set shelf registration billion emtn programme free cash flow gsk management planning reporting purpose discussion presentation investment analyst net cash inflow operating activity rating agency gsk free cash flow measure define ifrs net cash outflow investing activity measure directly comparable similarly describe net cash outflow financing activity measure company reconciliation net cash inflow increasedecrease cash bank overdraft operating activity close equivalent ifrs measure free cash flow show exchange adjustment cash bank overdraft begin year reconciliation free cash flow cash bank overdraft end year cash bank overdraft end year comprise net cash inflow operating activity purchase noncurrent tangible asset cash cash equivalent purchase noncurrent intangible asset overdraft disposal noncurrent tangible fix asset interest pay net cash inflow operating activity taxation pay interest receive million increase million reflect dividend receive joint venture associate undertake unchanged profit tax exclude impact significant dividend pay minority interest increase noncash charge year primarily major restructuring programme improve work capital free cash flow managementgsk annual report report director financial position resource continue movement net debt payment policy group company responsible monitoring manage work capital term sale collection supplier net debt begin year payment reflect local commercial practice increase cash bank overdraft cash inflowoutflow liquid investment uk company uk subsidiarie net increase longterm loan policy ensure supplier pay time particular net repayment ofincrease shortterm loan uk company seek exchange movement settle term payment supplier agree movement term transaction net debt end year ensure supplier aware agree term investment appraisal payment gsk formal process assess potential investment abide term payment proposal order ensure decision align group overall strategy process include analysis policy permit arrangement accelerate payment impact project earning return invest small supplier capital assessment return base discount payment performance cash flow discount rate perform financial analysis st december average number day payable decide internally allow determination extent outstanding represent trade payable parent company investment cover group cost capital specific nil nil respect company uk investment discount rate adjust subsidiary aggregate day day account country risk weighting treasury policy capital expenditure financial investment cash payment tangible intangible fix asset gsk report sterling pay dividend sterling profit amount million million role corporate treasury manage monitor million disposal realise million external internal funding requirement financial risk million million cash payment support corporate objective treasury activity acquire equity investment million million govern policy procedure approve board million year sale equity director recently th september investment realise million million treasury management group tmg chair chief million financial officer meet monthly basis review treasury future cash flow activity member receive management information relate group expect future operating cash flow sufficient treasury activity fund operate debt service cost satisfy normal level capital management capital expenditure meet obligation exist licensing operation global primarily subsidiary company agreement meet expenditure arise major establish market trade significant restructuring programme precise time uncertain level patent protection product compete largely outlined note financial statement major restructuring product efficacy price selling margin sufficient programme meet routine outflow include tax cover normal operating cost operating subsidiary dividend subject risk factor discuss page generally cash generative gsk time time additional demand finance acquisition access source liquidity operate cash flow fund investment research short longterm capital market bank development new product routine financial institution addition cash flow operation outflow capital expenditure tax dividend repayment need mature debt extent determine board share repurchase policy borrow centrally variety capital market issue borrow facility meet anticipated funding requirement gsk annual report report director financial position resource continue borrowing cash generate operation st december centrally available cash reserve onlent contribute equity certain subsidiary billion commit undrawn bank facility pay dividend acquisition fund share buyback billion date shortterm debt bank overdraft loan repayable year billion detail gsk share buyback programme note share capital share premium account manage net borrowing requirement portfolio longterm borrowing include bond short liquidity term finance billion commercial paper programme st december cash liquid investment year commit undrawn bank facility reduce hold follow billion billion consequence royal bank scotlands acquisition abn amro collapse lehman brothers facilities renew october consider level commit facility adequate give bank balance deposit treasury treasuryrepo money current cash holding information facility market fund refer note financial statement net debt corporate debt instrument benefit strong positive cash flow operating unit government security european medium term note programme billion st december billion note issue programme shelf billion manage centrally available registration statement st december month net debt st december billion billion note issue programme billion table summarise cash gross debt tmg monitor cash flow forecast monthly basis longterm borrowing mature date longterm debt rating remain stable cash liquid investment february currently rate stable outlook gross debt fix float standard poor negative outlook moodys shortterm debt rating p standard poor net debt moodys respectively maturity profile gross debt show table maturity profile gross debt equivalent usd eur gbp othergsk annual report report director financial position resource continue treasury operation use interest rate swap redenominate external borrowing interest rate coupon require gsk objective treasury activity manage posttax net duration swap match duration principal cost income financial operation benefit earning instrument interest rate derivative instrument account corporate treasury operate profit centre use fair value cash flow hedge relevant asset liability variety financial instrument include derivative finance operation manage market risk operation counterparty risk management policy counterparty risk management work derivative principally comprise forward foreign currency select group relationship bank global counterparty limit contract interest rate currency swap swap assign gsk banking investment counterpartie borrowing liquid asset require currency base longterm credit rating moodys standard manage exposure funding risk change foreign poor corporate treasury usage limit monitor exchange interest rate daily corporate compliance officer cco independent hold issue derivative financial instrument corporate treasury breach limit report speculative purpose treasury policy specifically prohibit cfo immediately cco monitor credit rating activity transaction financial instrument counterpartie change rating occur notifie undertake manage risk arise underlie business corporate treasury appropriate amendment activity speculation limit counterparty analysis present tmg annually approval foreign exchange management foreign currency transaction exposure arise internal july tighten criterion hold cash external trade flow hedge exposure overseas equivalent liquid investment response credit crisis operating subsidiary transaction risk minimised match th september lehman brother file chapter local currency income local currency cost proceeding usa appoint administrator purpose internal trading transaction match uk lehman gsk relationship bank centrally manage intercompany payment term reduce exposure lehman time collapse limited risk exceptional foreign currency cash flow hedge selectively immaterial cost foreign exchange contract management corporate treasury termination quest collar refer detail note financial statement investment associate manage shortterm cash surplus borrow joint venture requirement subsidiary company centrally forward financial asset liability contract hedge future repayment originate currency analysis net debt give note financial seek denominate borrowing currency statement net debt analysis financial asset liability principal asset cash flow primarily denominate carrying value fair value give note financial dollar euro sterle certain borrowing swap statement financial instrument relate disclosure currency require continue benefit strong positive cash flow borrowing denominate swap foreign currency operating activity net debt decrease match investment overseas asset treat hedge year st december purchase relevant asset forward contract major share market billion acquisition currency reduce exposure investment overseas approximately billion group asset net investment hedge section note financial asset liability st december details tmg review ratio borrowing asset representative treasury policy strategy apply major currency july gsk raise billion capital market december billion raise interest rate risk management expect significant share repurchase policy interest rate risk management require minimum net borrowing fix rate increase ratio forecast interest payable trading profit fix float ratio review monthly tmg gsk annual report report director risk factor risk factor generic drug manufacturer seek market generic version group important product prior risk uncertaintie relevant group business expiration group patent exhibit readiness financial condition result operation affect future product future launch generic performance include rd anticipate sale growth product compete lamictal imitrex paxil cr requip expect earning factor wellbutrin xl significant impact group overall group think cause actual result differ materially turnover earning expect historical result risk potential change intellectual property law regulation uncertainty currently know group proposal change exist patent datum exclusivity law deem immaterial management mitigation risk regulation major market group sell discuss corporate governance product continue feature political process major risk affect gsk business country include proposal effect make prosecution patent new product difficult risk rd deliver commercially successful timeconsume adversely affect exclusivity period new product group product include biological product continue development commercially viable new product proposal enact adverse impact development additional use exist product critical group future sale result operation group ability replace sale old product decline expiration exclusive right increase overall sale weakness intellectual property protection develop new product costly lengthy uncertain process certain country country group operate patent new product candidate fail stage process protection significantly weak usa latestage product candidate fail receive european union effort control public health crisis regulatory approval develop country south africa thailand brazil new product candidate appear promise development consider plan substantial reduction scope significant investment fail reach market limit patent protection pharmaceutical product particular commercial success example result efficacy country facilitate competition market safety concern inability obtain necessary regulatory approval generic manufacturer unable difficulty excessive cost manufacture erosion patent term introduce compete product number year result lengthy development period infringement patent loss patent protection include abrogation patent intellectual property right inability differentiate right compulsory licensing likely affect adversely product adequately compete group operate result national market health authority fda european medicine expect material group overall absence adequate agency japan pharmaceuticals medicine device patent protection limit opportunity look agency increase focus safety assess market future sale growth benefitrisk balance drug payer increasingly risk substantial adverse outcome litigation demand regard incremental benefit require government investigation gain reimbursement secure appropriate pricing note financial statement legal proceeding risk unplanne loss patent discussion proceeding governmental investigation patent infringement litigation involve matter prove rise civil group patent common patent challenge criminal liability group currently involve time effort generic manufacturer involve challenge unfavourable resolution similar future proceeding validity enforceability patent assertion investigation material adverse effect group generic product infringe group patent financial condition result operation group gsk successful defend attack patent material provision relate legal maintain exclusive right market major proceeding investigation reduce earning product particularly usa group high group additional significant provision relate turnover margin group turnover margin legal proceeding investigation future adversely affect note financial statement reduce earning case practice plaintiff bar legal proceeding discussion patentrelate proceeding claim damage amount bear relationship underlie group involve description harm accordingly potentially mislead quantify potential resolution prior proceeding affect date exposure claim proceeding investigation type generic version group product introduced describe note financial statement legal proceedingsgsk annual report report director risk factor continue recent insurance loss experience include pharmaceutical usa example group respond federal product liability exposure increase cost state governmental investigation pricing marketing narrow coverage afford insurance pharmaceutical reimbursement prescription drug product company generally include group investigation result related restitution civil false claim act litigation behalf federal state government order contain insurance cost recent year group relate proceeding initiate group behalf continue adjust coverage profile accept great degree consumer private payer proceeding result uninsured exposure addition claim trebling damage award fine respect violation insurance policy insurer reserve right deny coverage law criminal proceeding initiate group ground denial coverage ultimately uphold claim result material additional charge risk competition price control limitation product liability litigation sale preclinical clinical trial conduct party competition development potential product determine safety group operate highly competitive market efficacy product use human follow approval pharmaceutical business face competition proprietary regulatory body notwithstanding effort drug product large international manufacturer producer vaccine introduce marketplace unanticipated generic pharmaceutical significant product innovation technical effect evident advance intensification price competition competitor adversely affect group operating result group instance party perform analysis publish predict timing impact competitive product clinical trial result necessarily accurate potential impact sale group product continue meaningful raise question safety pharmaceutical consolidation pharmaceutical industry adversely affect product publicise medium result group competitive position continue consolidation product liability claim group currently defendant group customer increase pricing pressure number product liability lawsuit include class action involve substantial claim damage relate group group product million annual pharmaceutical product litigation particularly usa global sale product augmentin ir imitrex inherently unpredictable excessive verdict justify lamictal generic competition avandia evidence occur class action sweep person valtrex respect group intellectual property prescribe group product inflate potential right usa currently subject litigation settlement liability force number claim pain suffer agreement relate litigation punitive damage frequently assert product liability action group major product subject allow represent potentially openende exposure problem unplanne loss patent protection unexpected antitrust litigation effect regulatory proceeding publicity affect doctor usa increasingly common follow patient confidence pressure competitive product publicity government investigation adverse outcome new effective treatment introduce adverse prosecution patent infringement action defendant impact group revenue operating result direct indirect purchaser payer initiate antitrust significant particular group face intense competition action claim direct indirect purchaser manufacturer generic pharmaceutical product payer typically file class action relief seek major market generic product enter market include treble damage restitution claim damage adverse expiration patent datum exclusivity period antitrust verdict subject automatic trebling usa group product introduction generic product typically lead similarly antitrust claim bring follow settlement dramatic loss sale reduce group revenue patent litigation allege settlement anti margin proprietary product expiration date competitive violation antitrust law patent group major product description litigation settlement affect date generic sale marketing regulation version group product introduce set group operate globally complex legal regulatory legal proceeding involve patent challenge set environment vary jurisdiction failure note financial statement legal proceeding comply applicable law rule regulation jurisdiction result civil criminal legal proceeding governmental payer control rule regulation change governmental pharmaceutical product subject price control pressure interpretation rule regulation evolve prior conduct restriction market include japan germany call question spain france italy government intervene directly set price gsk annual report report director risk factor continue addition market major purchaser pharmaceutical risk interruption product supply product governmental agency private health care manufacture pharmaceutical product constituent provider economic power exert substantial pressure material require compliance good manufacturing practice price term access formulary regulation group manufacture site subject review approval fda regulatory agency compliance group predict exist control pressure failure supplier key service material group restriction increase new control pressure restriction manufacture facility lead product recall seizure introduce reduce group margin affect interruption production delay approval new product adversely ability introduce new product profitably pende resolution manufacturing issue noncompliance example usa group high margin result fine disgorgement profit sale country pricing pressure interruption supply fine disgorgement remedy significantly increase experience develop outpatient materially adversely affect group financial result pharmaceutical programme cover medicare beneficiary example resolution fda observation deficiency begin private insurer coverage manufacturing practice group cidra puerto rico facility offer enormous purchasing power refer note financial statement legal proceeding programme demand discount implicitly create supply certain product manufacture site curtail price control prescription drug constrict adverse impact sale change enable legislation afford government group undertake business continuity plan direct role negotiate price medicare programme single source certain component bulk active material additionally number state propose implement finished product create risk failure supply scheme control price senior citizen event regulatory noncompliance physical disruption programme include importation country bulk manufacturing site purchase drug growth number patient cover large manage care institution usa risk concentration sale wholesaler increase implementation medicare benefit increase usa line pharmaceutical company group pricing pressure group product trend adversely sell product small number wholesaler addition affect group revenue margin sales usa hospital pharmacie physician group sale regulatory control large wholesaler amount approximately group comply broad range regulatory control group pharmaceutical sale st december testing approval manufacturing marketing group trade receivable wholesaler pharmaceutical consumer healthcare product particularly total million st december million usa countries european union affect group expose concentration credit risk respect cost product development time require reach wholesaler affect financial market uncertainty successfully health authority difficulty materially adversely affect group increase focus safety assess benefit risk financial result balance drug context initial product approval context approval additional indication review reliance information technology information market product strict regulatory control group increasingly dependent information technology heighten risk change product profile withdrawal system include internetbased system internal regulator basis postapproval concern product communication communication customer safety reduce revenue result product recall supplier significant disruption system product liability lawsuit great regulatory scrutiny computer virus outside incursion materially especially usa advertising promotion particular adversely affect group operation directtoconsumer advertise global political economic condition addition case group voluntarily cease describe world large economy market product face decline sale base concern include major market group operate efficacy safety example decline sale avandia financial institution currently face extreme financial difficulty follow publicity question risk associate include decline asset price liquidity problem limit product scientifically justify availability credit uncertain long crisis absence regulatory action development postapproval country concern economy enter adverse event profile product product class deep prolong recession major impact marketing sale productgsk annual report report director risk factor continue decline economic activity material adverse failure manage properly environmental risk result effect group sale result operation financial additional remedial cost materially adversely affect condition ability raise capital group group operation note financial statement legal business include consumer healthcare particularly proceeding discussion environmentalrelate proceeding sensitive decline consumer spending addition group involve financial crisis result low return group financial accounting standard investment cause value group investment new revise accounting standard rule interpretation pension plan decrease require group increase circulate time time international standard setting board funding pension plan result change recognition income expense group conduct substantial portion operation outside adversely impact group report financial result uk group management foreign exchange rate international standard change market valuation certain discuss business review foreign exchange management financial instrument reflect group report result fluctuation exchange rate sterling gain loss actually realise currency especially dollar euro significant impact income statement give period japanese yen materially affect group financial result account defer taxation intercompany inventory group control change inflation interest rise volatility depend ownership rate foreign currency exchange rate control inventory regulator regularly review financial statement economic factor affect business possibility list company compliance account regulatory political unrest legal regulatory change nationalisation requirement jurisdiction group operate group believe complie appropriate regulatory requirement concern financial statement disclosure taxation company experience investigation effective tax rate group earning benefit fact potential noncompliance accounting disclosure portion earning tax favourable rate requirement result restatement previously jurisdiction outside uk change tax law application report result significant penalty respect matter transfer pricing foreign dividend control company restriction tax relief allow human resource interest intragroup debt increase group effective tax group approximately employee globally rate adversely affect financial result group open issue subject law regulation concern employee range revenue authority usa japan canada discrimination harassment personal privacy labour matter discuss note financial statement taxation relation vary significantly jurisdiction jurisdiction group face intense competition qualified individual disruption pandemic influenza pharmaceutical biotechnology company university event pandemic influenza group subject governmental entity research institution failure disruption range factor national government continue recruit retain right people maintain willing abrogate intellectual property right medicine culture compliance significant adverse effect short supply failure party provider country afflict pandemic flu risk employee family affect consequence unaffiliated thirdparty supplier provide number good sale distribution manufacturing activity service group operation service shut supply continuity active ingredient example service provide clinical research organization support finish good affect development key product important operation group business material provide thirdparty supplier environmental liability necessary commercial production product include environmental law jurisdiction impose actual speciality chemical commodity component necessary potential obligation group remediate contaminate site manufacture fillfinish package group group identify potentially responsible party pharmaceutical consumer health product group comprehensive environmental response compensation believe thirdparty relationship individually liability act number site remediation cost relate significant context overall group failure group use ownership site party supplier fulfil contractual obligation timely manner result delay service interruption constrain sale group product gsk annual report report director financial review accordance sec disclosure requirement follow sterling term total pharmaceutical turnover decrease discussion compare result year st december percentage point cer principally strength result year st december sterling dollar group realign regional reporting structure pharmaceutical turnover therapeutic area pharmaceutical business reallocate entity expense pharmaceuticals consumer healthcare turnover line highvalue growth business comparative information product offset low avandia sale generic restate consistent basis note financial competition coreg ir flonase wellbutrin xl zofran statement accounting principle policy highvalue growth product include seretideadvair vaccine lamictal valtrex requip avodart boniva exchange respiratory currency influence group result continue global leader respiratory pharmaceutical dollar euro japanese yen sale key product seretideadvair flixotide dollar fall pound flovent serevent amount billion yearend yearend rate euro strengthen total sale seretideadvair asthma copd rise billion usa sale grow billion europe japanese yen sterling sale grow billion rest world market sale world market pharmaceutical grow million enhanced launch japan june global pharmaceutical sale billion compare billion cns cns sale decrease billion sale decrease world market value growth usa europe reflect generic competition seroxatpaxil geographic region bn total region rest world sale grew include usa growth paxil japan total seroxatpaxil sale decline europe million total wellbutrin sale decline rest world million owe generic competition wellbutrin srir total wellbutrin xl mg tablet market decrease represent sale lamictal treatment epilepsy bipolar disorder global prescription pharmaceutical market compare grow billion drive sale usa decade ago million benefit new indication th september gsk hold second position world sale requip parkinson disease restless leg pharmaceutical market market share pfizer syndrome rls grow million market share gsk world antiviral pharmaceutical product avandia lamictal seretide total sale hiv product billion advair valtrex competition old product combivir world market value growth million epivir million largely offset therapeutic class bn total strong sale growth new product epzicomkivexa central nervous system grow million lexivaagenerase cardiovascular million alimentary tract metabolic sale valtrex herpe rise million antineoplasticimmunomodulatory sale million drive increase use antiinfective bacterial product prevention disease transmission sale europe viral fungal exclude grow million rest world grow vaccine million sale relenza antiviral treatment flu respiratory million million drive primarily oneoff government order stockpile possible flu pandemic note datum base month th september pharmaceutical turnover metabolic total pharmaceutical turnover million sale avandia product group type diabete compare million line decline billion usa sale fall turnover cer million fourth quarter sale milliongsk annual report report director financial review continue pharmaceutical turnover therapeutic area restate total usa europe rest world therapeutic area growth growth growth growth major product total cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antiviral hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip cardiovascular urogenital avodart lovaza coreg fraxiparine arixtra vesicare levitra metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin altabax oncology emesis hycamtin zofran tykerb vaccine hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report report director financial review continued follow publication article new england consumer healthcare turnover restate journal medicine article suggest cardiovascular risk associate avandia despite gsk effort growth doctor reluctant start new patient avandia total cer guidance fda follow clarification overthecounter medicine fda october new approve label avandia panadol franchise outside usa sales europe grow million smoking cessation product tum rest world market sale decline million cold sore franchise record turnover million share copromotion breathe right income bonivabonviva oncemonthly oral bisphosphonate alli treatment postmenopausal osteoporosis oral healthcare aquafresh franchise vaccine sensodyne franchise vaccine sale increase billion good dental care performance region sale rise million european sale grow million sale rest nutritional healthcare world million sale hepatitis vaccine lucozade grow million drive growth horlick ribena infanrixpediarix grow million drive growth sale new twodose vaccine rotarix prevent rotavirus gastroenteritis double million cer represent growth constant exchange rate represent growth strong growth europe rest world sale cervarix actual exchange rate gsk vaccine prevent cervical cancer million oral healthcare oral healthcare sale grow billion sale cardiovascular urogenital aquafresh million help success sale coreg heart disease fall million new aquafresh white tray sensodyne grow strongly follow introduction generic competition coreg ir year million drive successful launch september sale coreg cr launch march sensodyne pronamel million avodart benign prostatic hyperplasia enlarge prostate continue perform strongly sale nutritional healthcare million nutritional healthcare product sale grow million lucozade grow million horlick grow antibacterial million ribena sale million antibacterial sale decline million reflect generic competition region operate profit total result oncology emesis total result include restructure cost relate new tykerb achieve sale million year million operational excellence programme commence arise usa follow launch march sale october zofran decline million reflect generic competition usa europe rest world sale growth cer decline respectively turnover consumer healthcare sale cost sale sell general otc medicines administration overthecounter medicine sale grow billion research panadol million alli sale million development operate launch usa june smoking control product income decline million strong competition market breathe right fiberchoice add portfolio operating profit acquisition cns december achieve combine sale milliongsk annual report report director financial review continue cost sale total operating profit impact item million cost sale percentage turnover increase charge million charge percentage point constant exchange rate cost sale percentage turnover increase percentage point profit taxation total result reflect charge relate new operational excellence programme million nil unfavourable net finance cost product regional mix compare finance income sell general administration interest income sell general administration sga cost percentage fair value adjustment hedge turnover reduce percentage point constant exchange rate decrease percentage point reflect flat expenditure compare prior year turnover growth finance cost sga cost include charge relate new operational interest cost excellence programme million nil advertising unwind discount liability promotion increase selling distribution increase fair value adjustment hedge general administration expenditure decline research development finance cost increase owe increase level debt rd expenditure decline include charge relate finance share buyback programme new operational excellence programme million nil benefit arise low impairment charge share tax profit associate windingdown previous restructuring activity exclude joint venture item rd expenditure decline year pharmaceutical share profit associate arise principally group rd expenditure represent hold quest diagnostic inc pharmaceutical turnover profit taxation total result operate income take account net finance cost contribution operating income include royalty income equity associates total profit taxation million investment disposal impairment product disposal compare million increase fair value adjustment financial instrument operate constant exchange rate sterling decline income million million increase primarily high royalty income million major restructuring programme compare million favourable fair october gsk announce significant new billion value movement financial instrument million operational excellence programme improve effectiveness compare million roche litigation productivity operation settlement relate carvedilol partially offset low asset disposal profit expansion programme announce february programme expect deliver annual pretax operating profit total result saving billion oneoff charge million overall operate profit margin decrease percentage tax relate programme record q point operating profit decrease sterle term significant acquisitionrelate restructuring cost million operating profit increase constant incur exchange rate cer margin increase percentage extent cost operational excellence point reflect flat sga expenditure high programme columnar presentation adopt operating income partially offset increase cost sale income statement analysis operate profit gain asset disposal million subsequent discussion exclude restructure cost relate million cost legal matter million new operational excellence programme management million fair value movement financial believe presentation assist shareholder gain instrument result income million income clear understanding group financial performance million charge relate old restructuring activity consistent way management assess group million million charge relate financial performance new operational excellence programme million nil gsk annual report report director financial review continue operate profit result operate profit result major restructure major restructuring overall operate profit margin increase percentage point operating profit increase sterling term growth million operating profit increase constant cer exchange rate margin increase percentage point turnover reflect decline sga rd expenditure turnover cost sale growth high operating income sell general gain asset disposal million administration million cost legal matter million research million fair value movement financial instrument development result income million million operating charge relate old restructure activity million income million operating profit impact item operate profit million charge million cost sale profit taxation result cost sale percentage turnover increase major restructure percentage point constant exchange rate cost sale percentage turnover increase percentage point net finance cost reflect unfavourable product regional mix finance income sell general administration interest income sell general administration sga cost percentage fair value adjustment hedge turnover reduce percentage point constant exchange rate decrease percentage point reflect decline expenditure compare prior year finance cost turnover growth sga cost low sell general administration expenditure partly offset interest cost high advertising promotion advertising promotion unwind discount liability increase account increase fair value adjustment hedge total sga selling distribution decline general administration expenditure decline collectively item account decline total sga profit taxation result major restructure percentage point low charge relate legal matter take account net finance cost contribution associate result major restructure profit taxation research development million compare million rd expenditure decrease partly result low increase cer flat sterling term impairment charge windingdown previous restructuring activity exclude item rd expenditure taxation flat pharmaceutical rd expenditure represent pharmaceutical turnover uk corporation tax operating income overseas taxation operate income million million increase primarily high royalty current taxation income million compare million defer taxation favourable fair value movement financial instrument taxation total profit million compare million roche litigation settlement relate carvedilol partially charge taxation total profit amounting offset low asset disposal profit million represent effective tax rate charge taxation result major restructuring profit amount million represent effective tax rate gsk annual report report director financial review continue group balance sheet st december include tax result major restructure profit year payable liability million tax recoverable asset million increase sterling term million profit attributable minority interest million profit attributable shareholder million increase integrate nature group worldwide operation sterling term interest cost share buyback involve significant investment research strategic programme adversely impact group profit benefit manufacture limited number location consequential eps result major restructuring eps increase crossborder supply route numerous endmarket give rise reflect high profit reduction weight complexity delay negotiation revenue authority average number share result group share profit individual group company liable buyback programme actual rate exchange earning tax disagreement revenue authority share increase unfavourable currency impact ep intragroup transaction particular price good percentage point reflect strengthen sterling transfer group company different dollar compare percentage point tax jurisdiction produce conflict claim revenue unfavourable currency impact turnover authority profit tax individual territory resolution issue continue fact life gsk dividend main open tax issue uk usa canada board declare fourth interim dividend penny japan share result dividend year penny penny increase dividend penny share late position taxation taxation financial review profit year growth cer total profit taxation year total profit attributable shareholder basic earning share penny p p basic earning ad result major restructure profit taxation year result major restructuring profit attributable shareholder adjust earning share penny p p adjust earning ad weight average number share millions diluted total earning share penny p p diluted total earning ad weight average number share million total result include restructuring cost relate new operational excellence programme produce basic eps p compare p increase cer term compare decline sterling term gsk annual report report director board sir christopher gent age dr stephanie burn age appoint st june chairman sir christopher appoint th february nonexecutive director chief executive officer vodafone group plc retirement dr burns chairman president chief executive officer july nonexecutive director lehman brothers dow corning corporation member american holdings inc nonexecutive director ferrari spa member chemical society sit executive committee kpmgs chairman advisory group senior adviser bain society chemical industry america section serve board co member advisory board reform director american chemistry council board director society womens health research dr burn andrew witty aged hold phd organic chemistry iowa state university appoint st january chief executive officer mr witty name chief executive officer designate gsk lawrence culp age october appoint chief executive officer ceo appoint st july nonexecutive director st join group hold senior mr culp president chief executive officer danaher positions asia africa usa immediately prior corporation prior join danaher hold position appoint ceo andrew president pharmaceuticals europe accenture previously andersen consulting position hold january member business sir crispin davis aged council britain board member phrma vicepresident appoint st july nonexecutive director efpia member singapore economic development sir crispin chief executive officer reed elsevi plc prior board international advisory council chief executive aegis group plc join professor sir roy anderson age guinness plc member main board appoint st october nonexecutive director group manage director united distiller spend early professor anderson professor infectious disease epidemiology career procter gamble faculty medicine imperial college london rector julian heslop age imperial college fellow royal society foreign appoint st april chief financial officer associate member institute medicine national mr heslop join glaxo wellcome financial controller april academy sciences september professor anderson january appoint senior vice president chief scientific adviser ministry defence uk operation controller prior join group hold senior finance role grand metropolitangsk annual report report director sir deryck maughan age dr moncef slaoui aged appoint st june nonexecutive director appoint th chairman research sir deryck partner kohlberg kravis roberts co development dr slaoui join gsk biological nonexecutive director thomson reuters blackrock engineer development robust vaccines pipeline inc chairman chief executive officer subsequently lead worldwide business development citigroup international salomon brothers inc pharmaceutical appointment lead rd member board agency science technology dr daniel podolsky aged research astar phd molecular biology appoint st july nonexecutive director immunology universit libre de bruxelles dr podolsky president university texas southwestern medical center dallas hold phillip obryan montgomery jr md tom de swaan aged distinguished presidential chair academic administration appoint st january nonexecutive director doris bryan wildenthal distinguish chair medical science mr de swaan member board director zurich financial member board southwest medical foundation service vice chairman supervisory board chairman chairman board scientific cofounder audit committee royal ahold member supervisory gi company board royal dsm chairman supervisory board vanlanschot bankiers january member sir ian prosser aged managing board chief financial officer abn amro appoint rd senior independent director sir ian nonexecutive director smithkline beecham sir robert wilson aged plc nonexecutive deputy chairman bp plc chairman appoint st november nonexecutive director navy army air force institute naafi nonexecutive sir robert nonexecutive chairman bg group plc director sara lee corporation member cbi economist group previously executive chairman rio tinto presidents committee james murdoch aged dr ronaldo schmitz aged join board th nonexecutive director appoint rd nonexecutive director mr murdoch chairman chief executive news corporation dr schmitz nonexecutive director glaxo wellcome europe asia nonexecutive chairman bskyb plc nonexecutive director legal general group plc member board news corporation serve member board director rohm haas company chief executive officer bskyb cabot corporation supervisory board sick ag previously chairman chief executive officer star tv serve leadership council climate group directors dr jeanpierre garnier chief executive officer retired board st mr christopher viehbacher detail membership board committee find president north american pharmaceuticals appoint board st january resign board effect th september gsk annual report report director corporate executive team cet andrew witty eddie gray chief executive officer andrew succeed jp garni chief president pharmaceuticals europe eddie responsible executive officer join glaxo uk group operation europe january join career company hold role manage beecham prior current appointment senior director south africa vice president general manager vice president general manager pharmaceutical uk market senior vice president asia pacific julian heslop appoint president pharmaceuticals europe chief financial officer julian chief financial officer glaxosmithkline january april head finance function responsible simon bicknell activity financial reporting control tax treasury senior vice president company secretary compliance finance system internal audit insurance join glaxo officer simon ensure compliance risk management wellcome financial controller april effectively embed business oversee corporate abbas hussain governance group simon join corporate secretariat president emerge market abbas join gsk june appoint deputy company secretary glaxo eli lilly company spend year oversee wellcome company secretary glaxosmithkline plc market europe africamiddle east australasia duncan learmouth john clarke senior vice president corporate communication president consumer healthcare john responsible community partnership duncan responsible group consumer healthcare business produce oral healthcare investor relation internal external communication image overthecounter nutritional healthcare product join partnership community join glaxo beecham president futures group vice president global investor relation appointment current appointment january current position july deirdre connelly bill louv president north american pharmaceutical deirdre join gsk chief information officer bill appoint chief information february work eli lilly company year officer january responsible information hold variety position include sale professional general technology gsk bill join glaxo vice president manager puerto rico executive director human resource medical data science prior current role bill senior vice recently president operations president rd information technology marc dunoyer president pharmaceuticals asia pacificjapan marc appoint president pharmaceutical asia pacificjapan join group president pharmaceuticals japan january current appointmentgsk annual report report directors dan phelan jean stphenne chief staff dan responsible corporate strategy president general manager biologicals jean lead development hr real estate facility environmental gsk global vaccine business previously vice health safety global security join smith kline president human vaccines research development french previously hold role senior vice production join company head bacterial president human resource appointment chief viral vaccine production jean name baron king albert ii staff belgian recognition lead contribution rd industry belgium david pulman president global manufacturing supply david claire thomas responsible global manufacturing supply organisation senior vice president human resource claire lead global global procurement join glaxo broad human resource hr function previously oversee hr experience manufacturing operation previously lead pharmaceutical international pharmaceuticals europe claire primary supply european manufacturing north american join company appoint director human manufacturing global logistic manufacturing strategy resource uk pharmaceuticals claire honour organisation outstanding european woman achievement david redfern dan troy chief strategy officer david responsible proactive senior vice president general counsel dan joined gsk exploration new business opportunity strategic plan senior vice president general counsel september begin career gsk corporate development previously partner washington law firm sidley appoint finance director europe pharmaceutical austin llp chief counsel fda serve appoint area director central europe primary liaison white house department northern europe health human service hhs moncef slaoui member chairman research development moncef lead group bob ingram continue act special consultant group drug discovery development activity join group attend cet meeting capacity key player building gsk vaccine pipeline change cet appoint senior vice president worldwide business jp garni chief executive officer retire gsk development current appointment june rupert bondy senior vice president general counsel left gsk march russell greig president pharmaceuticals international leave cet new role president gsk venture fund chris viehbacher president pharmaceuticals leave gsk december gsk annual report report director corporate governance continue governance policy chairman ceo sir christopher gent chair company st january section discuss gsk management structure governance chairman mr witty chief procedure include disclosure compliance combine executive officer ceo succeed dr garni retire code corporate governance financial reporting council board end agm st combined code law regulation mr wittys biographical detail find board corporate executive team chairman lead board represent board director list board ceo cet member necessary board meeting ceo manage group implement board responsible group system corporate strategy policy adopt board chairman governance ultimately accountable group activitie chairman board committee communicate regularly strategy financial performance ceo cet member division responsibilitie independence role chairman ceo set board consider nonexecutive director write agree board appear independent character judgement company website dr schmitz served board year ceo responsible executive management group appoint board glaxo wellcome plc assisted cet cet meet time year st january consideration annual review necessary member responsibilitie board effectiveness meeting january board list corporate executive team conclude dr schmitz remain independent notwithstanding senior independent director length service opinion board dr schmitz sir ian prosser appoint senior independent director sid continue demonstrate characteristic independence st january hold role sir objectively challenge management take rigorous robert wilson sid follow sir ians retirement debate time possess outstanding knowledge board company business affair experience gain chairman audit committee long cycle board process investment business gsk consider particularly board authority accountable shareholder important experienced member board ensure company appropriately manage achieve strategic objective set board discharge sir christopher gent appoint board deputy responsibility annual programme meeting chairman determined board independent include approval overall budgetary planning business take chairmanship board st january strategy board review company internal control accordance combine code exclude risk management policy approve governance structure determination half board code ethic independent nonexecutive director sir christopher gent member remuneration committee permit board appraise approve major financing investment combine code light independence appointment licensing decision excess define threshold addition chairman board evaluate monitor performance group include board consider professor sir roy anderson dr burns mr culp sir crispin davis sir deryck maughan dr podolsky sir ian prosser engage board meeting ceo executive dr schmitz mr de swaan sir robert wilson independent directors member cet appropriate accordance recommendation combine code financial operating performance gsk external issue material group prospect mr james murdoch join board effect th evaluate progress achievement group board determine independent non financial business objective annual plan executive director accordance combine code monitoring report receive directly sir ian prosser dr schmitz retire board follow committee significant risk face group agm date publication majority board member exclude chairman independent non executive directorsgsk annual report report director corporate governance continue board overall responsibility succession planning indemnification director ceo executive director board give ceo qualify party indemnity provision define section broad authority operate business group ceo company act force benefit accountable report board performance director director hold office business cet member regular presentation board director conflict interest area responsibility board meet cet directors duty avoid situation member annual basis discuss collectively group strategy direct indirect conflict interest possible conflict primary element induction process new nonexecutive interest company duty apply particular director undertake member cet non exploitation property information opportunity executive director encourage separate informal gsk advantage company article discussion discretion cet members association include general power board authorise conflict breach duty relevant matter board meet time member attending authorise advance follow board establish procedure handle situational number meeting hold whilst board number conflict interest line good practice member meeting attend guidance issue general counsel group sir christopher gent accordance company article authorise mr witty nominations committee grant review periodically mr j heslop event annually potential actual conflict authorisation dr slaoui director count quorum authorisation professor sir roy anderson actual potential conflict company secretary minute consideration conflict authorisation grant dr burns record company secretary register conflict mr l culp authorisation note board meeting sir crispin davis ongoing basis director responsible informing sir deryck maughan company secretary new actual potential conflict dr podolsky arise change circumstance sir ian prosser affect authorisation previously give provide dr r schmitz authorisation director absolve duty mr de swaan promote success company actual conflict arise sir robert wilson post authorisation board choose exclude director dr jp garnier relevant information debate suspend director mr c viehbacher board resort require director resign mr witty mr viehbacher appoint board st company secretary january dr garnier retired board st company secretary responsible board mr viehbacher resign board th september available individual director respect board procedure company secretary mr simon bicknell appoint addition schedule meeting board meet barrister joined group quorate basis occasion secretary board committee remuneration business environment development committee deputy company secretary mrs victoria whyte ensure board keep uptodate important matter appoint secretary remuneration committee include legal governance regulatory development presentation effect th january solicitor fellow regular basis external internal adviser institute charter secretary administrator independent advice board committee board recognise occasion board establish number committee provide director feel necessary independent legal sufficient resource enable undertake duty andor financial advice company expense executive director member audit remuneration agree procedure enable explain nomination corporate responsibility committee governance section company website invite attend meeting director member corporate administration transaction finance committee gsk annual report report director corporate governance continue corporate governance framework board chairman executive director independent nonexecutive director audit committee remuneration committee corporate responsibility chief executive independent independent nonexecutive independent nonexecutive officer nonexecutive director director chairman directors chairman nominations committee corporate administration finance committee independent nonexecutive transaction committee cet director director chairman director cet members key board committees management committee current membership committee show table corporate audit remuneration nomination responsibility sir christopher gent c c professor sir roy anderson dr burns mr l culp sir crispin davis sir deryck maughan dr podolsky sir ian prosser dr r schmitz mr de swaan c sir robert wilson c key c chairman membergsk annual report report director corporate governance continue committee write term reference approve board follow summary role term reference committee current term reference committee obtain company secretary governance section company website meeting committee report committee role term reference membership comprise year audit review financial internal reporting process independent non system internal control management executive director risk external internal audit process committee propose shareholder appointment external auditor directly responsible remuneration oversight work remuneration determine term service remuneration independent non executive director members cet executive director assistance external independent adviser chairman evaluate make recommendation board overall executive remuneration policy chairman ceo responsible evaluating make recommendation board remuneration nonexecutive director nomination review structure size composition independent non board appointment member board executive director cet make recommendation chairman board appropriate committee monitor plan succession board senior management corporate provide boardlevel forum regular review independent non responsibility external issue potential executive director impact group business reputation chairman committee responsible oversight gsk worldwide donation community support finance review approve behalf board executive non necessary annual report form f convene executive director agm preliminary quarterly statement trading result approve certain major licensing capital transaction change group investment instrument counterparty limit corporate review approve matter connection executive non necessary administration administration group business executive director transaction certain corporate transaction cet member company secretary gsk annual report report director corporate governance continue evaluation board board committee agm take place london formal notification send director shareholder month advance meeting previous year evaluation performance business presentation shareholder director able chairman board committee director attend available formally agm informally undertake sid collaboration committee question committee chairman ordinarily attend chairman board engage dr long boardroom agm respond shareholder question entire board review act independent facilitator board attendance company agm resolution evaluation process agm decide poll require company article association result poll announce london process include tailor questionnaire onetoone stock exchange post company website detail interview director company secretary agm set section annual general meeting observation board committee meeting hold notice agm publish december review associate paper question companys website cover variety aspect associate board effectiveness include board committee role responsibility culture ensure nonexecutive director aware dynamic process support individual effectiveness understand view major shareholder company feedback review provide form write board place process focus sectorspecific issue report presentation board discuss general shareholder preference finding ceo cfo maintain dialogue institutional review conclude chairman board shareholder performance plan objective committee operate effectively high level programme regular meeting follow appointment board agree follow action generate inclusive ceo andrew witty undertake extensive engagement executive management team series meeting gsk institutional shareholder improve collective decision make process group investor relation department office london identify utilise time spend board committee philadelphia act focal point contact investor meeting effectively facilitate contribution year nonexecutive director broad range issue chairman meet regularly institutional investor seek enhance nonexecutive director continue hear view discuss issue mutual importance education process initial induction communicate view investors board sid available shareholder provide great visibility board gsk executive talent management succession planning process chairman remuneration committee meet annually major shareholder discuss executive remuneration policy board member meet separately chairman present discuss chairman performance nonexecutive director include new appointee contribution agree meeting chairman available meet major shareholder request perform unanimous unequivocal company website provide access current financial support director executive nonexecutive business information group dialogue shareholder share capital control financial result announce quarterly detail company authorise issue share capital company report formally shareholder twice year number share hold treasury st december halfyear fullyear result announce fullyear find note financial statement share result include company annual report capital share premium account gsk share list publish shareholder company produce london stock exchange quote new york annual summary send shareholder advise stock exchange nyse form american depositary share availability annual report notice meeting ad ad represent ordinary share wwwgskcom ceo cfo presentation fullyear result institutional investor analyst medium normally webcast teleconference release second quarter result institutional investor analyst medium annual report summary quarterly result available company websitegsk annual report report director corporate governance continue holder ordinary share entitle receive dividend bank new york mellon depositary company declare company report account attend ad list new york stock exchange ordinary speak general meeting company appoint proxy share represent company adr program exercise voting right manage depositary register bny nominees limit detail number ordinary share hold restriction transfer limitation hold depositary find ordinary share requirement obtain prior approval transfer ordinary share carry special right company acquire disposed interest regard control company restriction share connection company share voting right major shareholder voting right buyback programme detail share purchase cancel share shareholder know arrangement hold treasury disclose note financial financial right hold person statement share capital share premium account holder share know agreement restriction director officer share transfer vote right interest director officer connect share acquire gsk share scheme plan rank person issue share capital company give equally share issue special right remuneration report page trustee companys employee share ownership plan rule appointment replacement director esop trust waive right dividend share hold contain company article association company esop trust article approve shareholder accordance change control essential contract legislation force time time company contract arrangement article provide director appoint individually essential business party ordinary resolution member resolution significant agreement effect alter director provide instance director appoint terminate change control follow takeover bid way retire agm follow appointment company agreement director article provide director subject officer provide compensation loss office reelection agm interval year employment result takeover provision hold office continuous period year company share plan cause option award grant company member remove director pass ordinary plan vest takeover resolution special notice give director interest voting right automatically cease director state far company aware bankrupt compound creditor generally person significant direct indirect holding company information provide company pursuant cease director virtue company act financial service authority fsa disclosure transparency article rule dtrs publish regulatory information service suffer mental ill health company website miss director meeting continuous period th february company receive notification month permission board resolve shall accordance fsa dtrs follow notifiable cease director interest voting right company issue share capital prohibit director law percentage issue share capital resign barclays plc offer resign board accept offer p ercentage ordinary share issue exclude treasury share th february director number require resign gsk annual report report director corporate governance continue memorandum article association definition political donation political expenditure power director determine uk legislation political organisation legislation wide company memorandum articles association particular definition eu political organisation extend available gsk website article amend body concern policy review law reform special resolution member director exercise representation business community special interest company power provide article applicable group concern environment legislation stipulate power exercise company subsidiary wish support result member director authorise issue definition cover legitimate business activity allot ordinary share article company ordinary sense consider political donation political authorise purchase share article expenditure activity design support power article subject shareholder political party independent election candidate authority authority seek annual basis agm board seek annually precautionary measure share purchase company cancel hold ensure company subsidiary inadvertently treasury share breach legislation share buyback programme effect st january ensure consistent billion programme share repurchase commence approach political contribution gsk group july share cost billion repurchased gsk introduce global policy stop voluntarily programme company expect political contribution significant repurchase programme cover purchase company share cancellation hold political donation treasury share accordance authority renew eu political organisation shareholder company agm noneu political organisation company authorise purchase comprise maximum million share detail share purchase usa hold treasury share cancel disclose canada note financial statement share capital share premium account total company purchase billion share st january prior introduction group new approach political contribution usa large recipient political exact time future purchase extent donation line law corporate donation repurchase share hold treasury share federal level candidate political cancel determine company party state local level gsk support dependent market condition factor candidate seek environment appropriately donation eu political organisation eu rewarded highrisk highinvestment industry political expenditure situation similar canada rest world agm shareholder authorise donation rare low value company donation eu political organisation incur eu political expenditure provision political notwithstanding new policy company continue party election referendum act support gsk political action committee pac employee year authority renew annually law usa give political donation pac employee require company continue obtain shareholder approval organisation allow employee contribute fund donation eu political organisation political donation employee decide recipient incur eu political expenditure company pac donation total intend donation political party donate political organisation gsk pac independent election candidate donation eu political organisation incur eu political expendituregsk annual report report director corporate governance continue annual general meeting shareholder entitle appoint proxy attend agm hold pm wednesday th agm speak vote behalf queen elizabeth ii conference centre broad sanctuary detail appoint appoint corporate westminster london swp ee business transact representative proxy find notice meeting include agm publish company website receive adopt glaxosmithkline internal control framework annual report board recognise responsibility present balanced approve remuneration report understandable assessment group position prospect remuneration report page set board accountability review approve remuneration policy operate glaxosmithkline adequacy effectiveness internal control operate disclosure director remuneration include require group include financial operational compliance control company act director remuneration risk management board delegate responsibility report regulation resolution propose review audit committee receive report approve remuneration report individual identify committee report page retirement election reelection director responsibility management mr larry culp sir crispin davis dr moncef slaoui mr tom cet implement board policy risk control cet de swaan retire offer reelection responsible identify approve monitoring enforce board article company article key policy heart group conduct association business internal control framework include central direction resource allocation risk management key activity sir ian prosser dr ronaldo schmitz retire research development manufacturing marketing sale rotation seek reappointment legal human resource information system financial practice retire board conclusion agm framework comprehensive planning mr james murdoch appoint director effect system annual budget approve board result th offer election operating unit report monthly compare board budget forecast prepare regularly year reappointment remuneration auditor extensive financial control procedure risk activity resolution propose reappoint review group internal auditor commercial pricewaterhousecooper llp auditor authorise financial responsibility clearly delegate local audit committee determine remuneration business unit support regional management structure special business principle design provide environment company seek authority central leadership couple local operating autonomy framework exercise accountability control donation eu political organisation incur eu group political expenditure cap group attach importance clear principle allot ordinary share company procedure design achieve appropriate accountability director authority disapply preemption right control group policy risk management legal compliance allot new share connection right issue mandate business unit establish process manage maximum current issue share monitoring risk significant business group capital purchase ordinary share maximum internal control framework rely follow current issue share capital oversee report risk compliance issue exempt auditor state senior statutory auditor company gsk annual report reduce notice require general meeting clear day adopt new performance share share option defer annual bonus plan gsk annual report report director corporate governance continue risk oversight compliance council rocc cec manage corporate compliance officer rocc council senior executive authorise board report directly ceo corporate compliance officer assist audit committee oversee risk management chair rocc provide summary report roccs internal control activity group membership comprise activity group significant risk cet audit cet member head departments committee regular basis corporate compliance officer internal control risk management assurance audit direct reporting line audit committee provide mechanism compliance responsibility bypass executive management need arise rocc meet regular basis review assess significant risk mitigation plan provide oversight internal area potentially significant risk control ensure compliance applicable law regulation detail risk affect group risk factor internal gsk policy rocc respond group page note financial statement policy refer provide business unit legal proceeding framework risk management upward reporting effectiveness control significant risk mitigation planning identification internal control framework operation manager overall responsibility management give year review continue operate risk requirement date approval report system internal control risk management compliance board rmcbs design manage eliminate risk achieve risk management compliance board rmcbs business objective provide reasonable establish major business unit membership absolute assurance material misstatement loss comprise member senior executive team respective audit committee receive report area significant business unit augment specialist appropriate risk group relate internal control follow rmcbs oversee management risk consider consideration report audit committee report important respective business unit include risk annually board effectiveness control designate significant glaxosmithkline control mitigate eliminate risk addition increase number risk actively manage area group business necessary group risk achieve satisfactory return shareholder rmcb regularly report status significant investment rd acquire new product business risk rocc case group objective apply expertise compliance function prudent management elimination risk number risk area specific standard meet director review relate company subsidiary exceed requirement applicable law establish extend material associate undertaking joint specialist audit compliance function example corporate venture investment environment health safety audit global manufacturing board audit committee review supply audit risk management research assessment risk internal control framework development global quality compliance assist operate glaxosmithkline consider effectiveness dissemination implementation audit standard system internal control operation group audit function coordinate corporate assurance group year cover report date approval report corporate compliance officer board process follow board review corporate ethic compliance cec system internal control accord guidance internal rocc support corporate ethic compliance control issue turnbull committee department responsible support development implementation practice facilitate employee compliance law group policy thrust group compliance effort diligence prevent detect misconduct noncompliance law regulation promote ethical behaviour compliance law regulation corporate responsibility level effective compliance systemsgsk annual report report director corporate governance continue committee report financial accounting experience board committee report regularly board mr tom de swaan chief financial officer abn amro performance activity assign st december audit committee report etermine board audit committee financial expert define attendance meeting sarbane oxley act sarbanesoxley quorate sir deryck maughan partner kohlberg kravis roberts co members committee member meeting meetings kkr chairman kkr japan mr tom de swaan st january f ormer chairman ceo citigroup chairman international vice chairman st september citigroup inc sir deryck maughan st january chairman cochief executive dr daniel podolsky st january officer salomon smith barney sir ian prosser th december chairman chief executive officer salomon brothers inc dr ronaldo schmitz th december sir robert wilson th december sir ian prosser cfo subsequently ceo bass plc charter accountant attendee committee meetings dr ronaldo schmitz member glaxo wellcome plcs ceo audit committee cfo member executive board chairman director deutsche bank ag general counsel head investment banking head global internal audit deutsche bank company secretary corporate compliance officer external auditor member executive board director basf cfo committees main responsibility include basf review corporate accounting financial reporting process chairman committee monitoring integrity financial statement april september evaluating system internal control management risk mba insead overseeing activity group compliance audit function oversee compliance law regulation sir robert wilson economist ethical code practice chairman bg group plc r etire rio tinto hold committee oversight role require address regularly senior management position culminate relationship management internal external appointment executive chairman auditor understand monitor report relationship tier accountability scientific expertise committee receive regular report member cet dr daniel podolsky world renowne researcher advanced senior manager cover key compliance activity knowledge underlie mechanism disease group include concern rd manufacturing sale new therapy gastrointestinal disorder marketing environment health safety president university texas qualifications audit committee member southwestern medical centre committee member exception dr podolsky f ormer mallinkrodt professor medicine bring considerable financial accounting experience chief gastroenterology committee work member past employment experience massachusetts general hospital harvard finance accounting role comparable experience medical school corporate activity dr podolskys background world renowned researcher enable bring scientific expertise committee deliberation gsk annual report report director corporate governance continue committee work structure programme audit committee management internal auditor activitie stand item committee require board work ensure quality company consider meet matter focus corporate accounting financial reporting committee coincide key event annual financial reporting cycle serve primary link board external internal auditor facilitate necessary independence external auditor r eporte critical accounting management encourage external internal auditor policy significant judgement communicate freely regularly committee practice group alternative committee meet collectively separately accounting treatment external auditor head global internal audit discuss management corporate compliance officer member management resultant conclusion material write present communication management committee primary responsibility make restriction access information recommendation shareholder appointment cfo report financial performance reappointment removal external auditor annually company technical financial assess qualification expertise resource independence accounting matter external auditor effectiveness audit process general counsel report material litigation make assessment committee consider paper detail relevant regulatory requirement relate external company secretary report corporate governance auditor evaluate report external auditor corporate activity undertake rocc compliance requirement external auditor compliance officer provide nonaudit services committee ensure auditor head majority head group objectivity independence safeguard policy require group compliance report audit scope annual preapproval committee service service audit group coverage audit resource include audit service auditrelated service tax service result audits conduct service preapproval detailed particular service year category service subject specific budget company secretary report matter affect external auditor management report regularly chairman quality timely disclosure financial committee extent service provide accordance disclosure material information preapproval fee services perform committee board public market committee preapprove additional service shareholder enable committee casebycase basis expenditure audit nonaudit services review clarity completeness set note financial statement operate profit disclosure publish guideline set company policy engage annual financial statement interim external auditor provide nonaudit service include ascertain report quarterly preliminary result skill experience external auditor announcement formal suitable supplier nonaudit service adequate safeguard announcement relate financial place objectivity independence audit performance prior release compromise fee level relative annual board audit fee limit set committee company wellestablishe policy include code ethic available website helpline facility report investigation unlawful conduct waiver code gsk annual report report director corporate governance continue nomination committee report appoint new executive director cet members committee consider skill knowledge experience attendance require particular executive position committee meeting consider potential external internal candidate recommend board approve new appointment member committee member meeting new director offer election company agm appointment announce publicly sir christopher gent th december chairman committee recommend appointment mr larry culp st january sir robert wilson nominations committee march mr larry culp th march committee recommend board appointment sir ian prosser th december mr james murdoch nonexecutive director member committee chairman corporate responsibility committee effect th februarydecember additionally committee recommendation board dr ronaldo schmitz th approve follow change effect sir ian prosser sir robert wilson th march dr schmitzs retirement board conclusion agm sir robert wilson replace sir ian attendee committee meeting sid sir crispin davis replace sir robert chairman remuneration committee professor sir roy anderson ceo member audit committee sir crispin sir deryck chief staff maughan member nomination committee head hr company secretary remuneration report remuneration report find page committee main responsibility include propose appointment board committee member corporate responsibility committee report committee main focus recruitment attendance new nonexecutive director refresh board meeting recruit nonexecutive director committee consider member committee member meeting particular skill knowledge experience benefit board significantly appointment sir christopher gent th december chairman broad selection criterion focus achieve st january balance representation european uk market individual ceo experience skill dr stephanie burn th december develop sector speciality dr daniel podolsky st july particular focus place recruiting replacement sir ian prosser th sir ian prosser dr ronaldo schmitz retire agm mr tom de swaan st july process continue committee place emphasis candidate current ceo follow appointment board effect government administration experience professional th mr james murdoch member search agency engage specialise recruitment committee high calibre nonexecutive director dossier potential nonexecutive appointee provide committee attendee committee meeting include candidate shortlist interview consider ceo relevant qualification general counsel customise induction process conduct new head corporate communication nonexecutive director focus particular experience communitypartnership take account different background process head corporate responsibility include meeting member cet senior executive chief staff visit particular operational facility group head hr company secretary gsk annual report report director corporate governance continue main responsibility corporate responsibility nyse rules committee set committee roll general nyse rule permit company follow uk corporate agenda receive report member cet governance practice instead apply usa provide senior manager ensure progress meeting gsk company explain significant variation explanation corporate responsibility principle review principle contain company form f filing access access medicine standard ethical conduct research security exchange commission sec edgar innovation employment practice global community database company website nyse rule come partnership review annually principle discuss effect require company file annual interim write year committee review affirmation concern audit committee company approve corporate responsibility report statement significant difference corporate governance year committee review follow area sarbanesoxley act follow number corporate accounting scandal usa access medicine develop country congress pass sarbanesoxley act sarbanesoxley community partnership investment wide range piece legislation concern largely financial report corporate governance humanitarian donation recommend sec gsk establish disclosure employee volunteer committee committee report ceo cfo sale marketing practice audit committee chair company secretary member consist senior manager finance legal disclosure fund medical education patient compliance corporate communication investor relation advocacy group external legal counsel external auditor invite attend product safety communication clinical trial result meeting periodically responsibility consider rd disease develop world materiality information timely basis determine disclosure information responsibility timely use animal research filing report sec formal review annual globalisation externalisation rd report form f committee meet time reduction employee number restructuring sarbanesoxley require annual report contain statement member company audit employee consultation requirement committee audit committee financial expert define employment litigation usa sarbanesoxley summary board judgement gsk corporate responsibility report available matter refer additional disclosure requirement companys website arise section section sarbanesoxley respect disclosure control procedure internal control combined code financial reporting company comply provision combine code follow b design scheme performancerelate remuneration remuneration committee follow provision schedule code item schedule state general basic salary pensionable company position explain remuneration report page law regulation number provision law regulation apply gsk company share quote nyse form adsgsk annual report report director corporate governance continue section corporate responsibility ceo cfo expect complete certification report financial report conclusion effectiveness disclosure control sarbanesoxley introduce requirement ceo procedure th march follow certificate cfo complete formal certification confirm file sec group form f review annual report form f section management annual report internal control financial reporting base knowledge contain material misstatement accordance requirement section sarbane omission oxley follow report provide management respect base knowledge financial statement companys internal control financial report financial information fairly present material respect financial define rule af df security condition result operation cash flow date exchange act period present annual report form f management responsible establish maintain responsible establish maintain disclosure adequate internal control financial reporting group control procedure ensure material information internal control financial reporting design provide known evaluated effectiveness reasonable assurance reliability financial control procedure yearend result report preparation financial statement external evaluation contain annual report form f purpose accordance ifrs responsible establish maintain internal management conduct evaluation effectiveness control financial reporting provide reasonable internal control financial reporting base assurance reliability financial reporting framework internal control integrate framework preparation financial statement external purpose issue committee sponsor organisation accordance generally accept accounting principle treadway commission disclose annual report form f change group internal control change internal control financial report financial reporting materially affect period cover annual report form f reasonably likely affect materially group internal materially affect reasonably likely affect materially control financial reporting company internal control financial reporting management assess effectiveness internal control disclose base recent evaluation financial report st december internal control financial report external auditor conclusion file group form f audit committee significant deficiency material pricewaterhousecooper llp audit consolidated weakness design operation internal control financial statement group year end st financial reporting reasonably likely affect adversely december assess effectiveness company ability record process summarise report group internal control financial reporting audit financial information fraud regardless materiality standard public company accounting oversight involve person significant role company board united states audit report file internal control financial reporting group form f group carry evaluation supervision participation group management include ceo cfo effectiveness design operation group disclosure control procedure st december inherent limitation effectiveness system disclosure control procedure include possibility human error circumvention override control procedure accordingly effective disclosure control procedure provide reasonable assurance achieve control objective gsk annual report report director remuneration report dear shareholder manage balance quantum versus risk behalf board please present committee current economic crisis emphasise need ensure report remuneration seek potential quantum stretch performance approval shareholder agm target implicitly encourage inappropriate behaviour background principle propose change satisfied propose structure follow appointment new chief executive officer improves alignment uk investor expectation remuneration committee decide review cap longterm incentive plan senior executive arrangement ensure remuneration reflect problem banking sector policy support future direction business shareholder raise question current longterm incentive plan expire clawback mechanism problem arise year review year early necessary award effort address current economic climate change propose continuity executive usbase ukbased chief executive officer provide responsibility initiation adverse event opportunity fundamental change gsk emergence problem adverse event take remuneration policy propose change design account assess annual bonus year problem strengthen alignment gsk remuneration arrangement identify mean course intend view express investor particularly uk penalise executive misjudgement predecessor reflect well gsk uk home base far annual bonus concern consequence fundamental change apply largely company adverse event share price inevitably reduce ukbased executive include chief executive officer potential value longterm incentive chief financial officer rebalancing longterm incentive follow set key principle review new policy executive include chief highlight main change propose executive officer chief financial officer remuneration benchmarke primarily uk crossindustry comparator align pay relevant market group receive share option grant foreseeable remuneration ukbased member cet future instead longterm incentive focus include chief executive officer chief financial performance share order remain competitive officer benchmarke primarily uk cross global pharmaceutical market certain executive include industry comparator group obvious reason chairman research development continue receive ignore intraindustry comparison remuneration share option weight overall package chairman research development certain keep review role continue benchmarke global pharmaceutical company reflect market gsk annual bonus plan compete talent operate additional bonus flagged remuneration report integrate exist far benchmarke chief executive officer role annual bonus structure maximum annual bonus opportunity concern shift global pharmaceutical uk cross remain salary reduce industry company represent major change performance threshold annual plan reflect significant impact structure quantum stretch annual bonus plan target remuneration time propose remuneration package chief executive officer addition chief executive officer chief financial officer median pharmaceutical industry peer executive participate share option plan opportunity invest half annual bonus gsk share match subject relative total shareholder return performance yearsgsk annual report report director remuneration report continue align performance measure strategy performance condition performance share plan broaden cet incentivise range measure intend broadly half award continue base relative total shareholder return global pharmaceutical company remain half base additional measure measure support gsk strategy come year award award remain relative total shareholder return global pharmaceutical company remain targeted generate cash investment andor return shareholder accordingly award subject achievement adjust free cash flow target committee adjustment acquisition divestment currency movement distortion arise subject shareholder approval performance share award follow agm satisfy concern transparency disclose adjust free cash flow target performance share award announcement london stock exchange time award reflect longterm nature pharmaceutical industry reflect well longterm nature pharmaceutical industry performance period performance share grant member cet extend half total shareholder return element award measure year half year performance period share option grant cet member similarly extend addition support emphasis longterm decision make timeframe vest award retirement redundancy extend maturity vest year departure time committee like range long term performance measure fully reflect company strategic direction eg turnover growth rd productivity introduce metric committee want satisfied measure robust capable create unintended behaviour committee believe new policy represent significant step forward support future direction business good interest shareholder sir robert wilson chairman remuneration committee rd march gsk annual report report director remuneration report continue director remuneration report prepare course committee principal focus accordance director remuneration report review appropriateness gsk current remuneration regulation regulation meet relevant policy light appointment new ceo change requirement fsa list rule accordance management team gsk new strategy lead regulation follow section remuneration development policy appropriately support report subject audit annual remuneration non business go forward include design new longterm executive director remuneration share option incentive incentive lti plan replace exist plan expire plan performance criterion vest performance share plan award share option pension benefit quorate meeting hold year approve opinion thereon express remain formal grant share option performance share award section subject audit page refer accordance gsk remuneration policy audit section exception mr bicknell company secretary remuneration committee mrs whyte deputy company secretary employee sir robert wilson chairman committee company involve conduct committee meeting th sir crispin davis mr culp sir christopher gent dr garnier ceo mr witty ceo mr phelan chief dr schmitz members committee staff ms thomas senior vice president human resource board deem members committee invite attend meeting committee independent nonexecutive director accordance require combine code exception chairman deloitte llp appoint committee provide company sir christopher gent independent independent advice executive remuneration appointment company provide tax service gsk year committee meet time member provide advice executive remuneration matter attend follow committee tower perrin provide additional market datum committee attendance meeting commitment shareholder member committee member committee engage regular dialogue shareholder sir robert wilson st january hold annual meeting gsk large investor committee chairman discuss feedback remuneration policy key development year particular mr l culp st january committee discuss significant change policy sir crispin davis st july measure assess performance line sir christopher gent st january commitment gsk large investor consult propose change set report dr r schmitz th summary proposal sir robert step chairman committee gsk remuneration policy base follow conclusion agm principle achieve competitiveness global succeed sir crispin davis sir robert remain member pharmaceutical industry primary pay committee comparator essential policy change underlie new role committee set company remuneration proposal committee decide individual policy executive director cet member executive basis primary pay comparator executive ensure consistent company global pharmaceutical sector ukbase large cross scale scope operation support business strategy industry multinational comparator group growth plan help drive creation shareholder example executive director committee value set remuneration policy level propose primary comparator group ceo senior executive committee give consideration cfo time ukbase large crossindustry remuneration policy level wide employee multinational chairman research development population committee term reference chairman rd comparator group continue available company website global pharmaceutical companiesgsk annual report report director remuneration report continue follow chart summarise propose change gsk remuneration policy particularly gsk individual remuneration element summary propose change gsk remuneration policy current propose policy executive director ceo cfo chairman rd remuneration global pharmaceutical ukbase large crossindustry global pharmaceutical comparator benchmarke comparator group comparator group group annual bonus bonus base financial change calculation bonus target range reflect personal performance change target set line new strategy operational bonus na operational target include overall annual bonus framework standalone operational bonus lti share mix ltis provide mix eligible performance share eligible performance share c performance share defer annual bonus share option c share option value performance base match eligible defer annual receive share option bonus performance base foreseeable future match plan limit levels lti award set annually annual individual limit introduce benchmarke project value expect value methodology key term remuneration element current propose policy salary benchmarke global benchmarke uk crossindustry comparator pharmaceutical comparator group group global pharmaceutical comparator group comparator group appropriate annual bonus bonus base achievement addition current target achievement financial target base group profit operational efficiency take account interest tax business unit operate determine annual bonus respect profit rd specific key performance indicator rd employee individual performance take account determine individual bonus payment performance base relative total shareholder return tsr base relative tsr comparator group share comparator group pharmaceutical currently comprise pharmaceutical company plan psp company base adjust free cash flow measure year tsr component measure half year twoyear hold period half year vest median vest adjust free cash flow measure year performance line second company twoyear hold period remove threemonth averaging period tsr tsr element vest median dividend equivalent vest upper quartile performance cash flow element vest threshold rise stretching performance exceed set threshold specify margin twelvemonth averaging period tsr dividend equivalent share option base ep growth relative rpi intend certain executive plan measure year base ep growth relative rpi vest threshold performance measure andor year vest threshold performance defer annual na individual eligible share option bonus plan bonus defer oneforone match subject relative tsr performance year vest psp dividend equivalent gsk annual report report director remuneration report continue total remuneration benchmarking ceo committee review gsk total remuneration comparable company regular basis ensure salary remuneration arrangement competitive structured cash bonus appropriately deliver value money shareholder defer bonus include match new remuneration policy relevant comparator group performance share determine individual executive benchmarking purpose total remuneration incorporate base salary annual bonus include defer element ltis cfo set pay committee take account pension arrangement salary cash bonus uk crossindustry comparator group global pharmaceutical comparator group defer bonus include match angloamerican france sanofiaventis performance share astrazeneca switzerland novartis barclay roche holdings bg group uk astrazeneca bhp billiton usa abbott laboratories chairman rd bp amgen british american tobacco bristolmyers squibb salary diageo eli lilly cash bonus hsbc johnson johnson share option reckitt benckiser merck performance share royal dutch shell pfizer rio tinto scheringplough standard charter wyeth tesco unilever base salary vodafone base salary set reference relevant comparator group secure talent need deliver gsk strategic priority mgen include benchmarke tsr comparator group salary level review annually influence gsk project value methodology executive role experience table set current benchmark remuneration principal reason base salary propose recognise difference lti arrangement particular common use performance target global mr witty mr heslops salary increase form pharmaceutical company wide change propose remuneration package particular reflect benchmark remuneration give increase emphasis benchmarke uk uk crossindustry comparator group mr wittys propose company increase introduction performance target salary increase reflect committee assessment ltis pharmaceutical comparator committee performance role appointment dr slaouis increase decide expect value benchmarking reflect progression role intend bring methodology approach provide benchmark take line market salary increase typically possible outcome account base probability effect april integral wider achieve different performance level remuneration policy mr witty mr heslops salary increase implement agm individual element remuneration balance fix base salary variable annual base effective date base effective date bonus lti element remuneration vary depend salary salary salary salary performance chart opposite anticipate mix mr witty nd st april fix variable pay expect value basis mr heslop st april st april new remuneration policy actual mix high dr slaoui st april st april lower depend performance gsk individual reflect mr wittys base salary take effect succession ceo typically significant portion approximately executive director package variablegsk annual report report director remuneration report continue annual bonus strategic objective set focused particular annual bonus design drive achievement gsk continue development launch latestage pipeline asset annual financial target personal objective delivery commercial target execution restructuring programme simplify operating model maximum annual bonus ceo remain salary maximum bonus executive bonus measure rd employee include dr slaoui ceo range salary link pipeline robust governance structure increase maximum bonus opportunity establish ensure bonus payable fairly reflect rd productivity performance performance profit wide remuneration review committee revise target plan relatively new committee review annual bonus plan strengthen alignment new operation year decide continue business strategy budgeting process annual bonus rd committee continue majority annual bonus opportunity operation review future consider extend base formal review performance stretch executive include ceo financial target base group profit interest tax committee take account gsk success achieve business unit operating profit target remainder objective individual performance base achievement individual objective annual determine bonus award actual bonus payment bonus calibrate reflect stretch target show range base establish drive significant change gsk salary st december business model bonus threshold target maximum payable achievement target ltis reduction bonus threshold reflect currently lti award provide mix performance stretch bonus target share share option gsk exist lti plan performance remuneration report reference share share option plan expire light possible introduction additional bonus encourage delivery change company committee decide operational target review appropriate review term lti plan committee determine increase overall bonus wide remuneration review new longterm opportunity measure incorporate incentive plan submit shareholder exist overall bonus approval agm bonus target ceo set board set line new remuneration policy base individual objective ceo board focus strategy market focus provide well alignment market practice develop company set intend ceo cfo receive share annual report reason commercial sensitivity option grant foreseeable future instead ltis specific objective keep confidential follow end form performance share financial year board review ceo performance opportunity defer bonus earn share generally set objective committee receive matching share subject achievement additional determine bonus payable performance condition change base establish practice uk crossindustry comparator group executive ceo make recommendation committee performance objective chairman rd certain executive continue recommendation consider committee determining receive share option grant performance share level bonus payable committee consider remain competitive global pharmaceutical market reduce individual executive bonus award use share option keep review reflect revise provision relate prior year activity relative importance reduce future share determine current executive materially involve option continue incentivise employee management relevant issue cet reduction bonus payment appropriate propose new lti plan committee future bonus year committee continue review reduce grant vest level determine participant ongoing financial impact prior year activity role engage conduct contrary legitimate individual executive activity committee expectation company employee appropriate adjustment future individual bonus award participant position reflect circumstance gsk annual report report director remuneration report continue typically performance share share option deliver provide focus sustain longerterm performance resident executive form ad award deliver performance period extend half tsr form ordinary share executive resident uk element award measure year half country award plan incorporate year element base adjust free cash flow dilution limit consistent guideline provide measure year reteste association british insurers current estimate dilution performance exist award gsk employee share scheme tsr element percentage vest median merger approximately company share capital reduce align well remuneration policy st december shareholder expectation vest place upper new plan summarise relevant section quartile performance adjust free cash flow element basis award vest threshold performance rise stretch executive performance exceed set threshold specify margin graph show tsr vest schedule award performance share grant gsk performance fall performance share plan ensure focus gsk longterm company vest calculated straightline basis shareholder return relative pharmaceutical company delivery gsk strategic priority proportion vest plan measurement performance broaden senior team incentivise operational measure align gsk business strategy tsr tsr consider remain appropriate comparative measure focus return shareholder wellunderstood test mechanism measure performance allow comparison company operate different country typically award executive continue subject relative tsr balance base strategic operational measure support business strategy award performance share award executive follow approval new performance share plan tsr rank position agm individual annual limit maximum value performance award award base share grant individual year relative tsr group currently comprise global introduce exceptional circumstance pharmaceutical company maximum face value performance share grant order recognise importance effective work capital individual year time salary management generate cash remain vest intend value performance share grant ceo subject achievement adjust free cash flow target time salary cfo receive award adjust free cash flow target adjust material factor time salary chairman rd receive award distort free cash flow performance measure ad typically include exchange rate movement provide stable assessment performance reflect include legal major taxation settlement special pension well longterm nature pharmaceutical industry contribution materially distort calculation tsr averaging period month award direction impact acquisition divestment onwards quantify adjust time event major adjustment calculation disclose shareholder awards threshold free cash flow target billion maximum vest billiongsk annual report report director remuneration report continue provide close link shareholder return payment vest schedule award show executive notional dividend reinveste pay proportion vest proportion vest award value reinveste dividend incorporate benchmarking award level performance share plan award grant executive director exclude dr slaoui february performance period start st january end st december vest gsk tsr performance median award senior executive include dr slaoui cet time award dependent tsr performance ep performance tsr element vest eps element vest vest table recent performance share award show rpi rpi rpi rpi b share option eps target gsk share option plan design ensure gsk remain individual annual limit maximum value share competitive global pharmaceutical peer option grant individual year incentivise sustain delivery earning growth shareholder introduce individual receive award value creation performance share share option expect value share option grant year typically exceed note early chairman rd certain expect value aggregate ltis individual executive continue grant share option grant performance share annual award limit share participate new defer annual bonus option calculate equivalent basis ceo cfo receive share option apply performance share plan foreseeable future committee set basis decision consider wide review committee review appropriate significant adjustment calculation performance measure share option conclude ep performance measurement purpose eps remain important measure success vest share option grant executive continue significant adjustment respect share link achievement compound annual eps growth option grant february vest performance period target review set annually c defer annual bonus take account company market expectation new defer annual bonus plan introduce award executive long receive share option grant target award remain unchanged include ceo cfo plan design encourage longterm shareholding help drive longterm shareholder reflect well longterm nature pharmaceutical return relative global pharmaceutical company industry performance period extend half share option grant measure year annual bonus earn invest share half measure year reteste defer year company match performance share oneforone depend company relative tsr period performance measure vest schedule percentage vest threshold performance threeyear tsr component reduced award reflect well performance share plan describe shareholder expectation threshold vest place compound ep growth rpi plus pa vest dividend equivalent accrue deliver respect compound ep growth rpi plus pa eps measure cer invest share matching share vest line gsk practice measure performance cer basis gsk annual report report director remuneration report continue gsk lti performance condition continue challenge executive participate define contribution plan demonstrate table tsr important benefit company contribution base salary lti measure year maintain depend grade opportunity receive propose policy reason set match contribution line policy remain primary measure psp despite tsr member pension plan element pay legacy final salary plan provide twothird final follow table show vest level gsk performance salary age employee subject cap benefit share share option award executive total excess cap currently provide unfunded vest percentage indicate gsk tsr performance arrangement legacy final salary plan actuarial median comparator group reduction factor apply participant leave employment performance period hisher accord age employment terminate company cause reduction share factor apply way member performance share plan option plan legacy final salary plan vest vest vest performance tsr ep total eps b pension arrangement period measure measure vest measure usa gsk operate cash balance plan provide annual contribution interest sum accumulate cash balance plan contractual promise provide specific level retirement income plan incorporate executive pension credit senior executive contribution rate plan range base salary performance measure psp award executive change exclude eps depend grade current senior executive eligible follow remuneration review award new executive pension credit change award cycle cap employee usa benefit cap pension provide unfunded nonqualified plan executive participate gsk senior executive pension plan pension arrangement structure accordance plan operate executive country likely retire detail individual arrangement executive director set new executive gsk eligible define contribution scheme cash balance plan exist obligation define benefit scheme uk continue honour year committee review competitiveness pension policy new employee ensure remain competitive enable company attract talent require run business successfully review highlight define contribution pension policy uncompetitive uk executive committee change align well evolve practice wide market uk pension arrangement company currently operate define contribution plan legacy final salary plan close new entrant newly hire executive uk participate define contribution plangsk annual report report director remuneration report continue share ownership requirement executive director term condition remuneration align interest executive shareholder executive director contract executive require build maintain significant policy set provide framework contract holding share gsk time ceo require build executive director shareholde value time base salary executive director require build value time base salary notice period calendar month member cet value time base salary termination shareholding purpose share ownership requirement employ company executive sor st december termination payment x annual salary hold sor purpose x annual ontarget bonus mitigation require mr witty ordinary share mr heslop ordinary share vest ltis rule relevant incentive plan dr slaoui ordinary share pension base exist arrangement executive require continue satisfy shareholde term relevant pension plan requirement minimum month follow retirement noncompete clause month termination company support longterm nature business notice date st december dr garnier hold excess share ownership requirement r wittys target bonus salary dr slaouis mr heslops salary review policy level severance payment remuneration element committee consider shareholder department business enterprise executive participate allemployee share plan regulatory reform guidance determine line competitive practice appropriate provide payment salary uk usa target bonus termination sharesave plan sharereward plan uk hm revenue imposition month noncompete period nonsolicitation customs approve plan open uk employee restriction executive consider vitally important company order protect group intellectual property staff light non term mr witty mr heslop member sharesave plan compete clause competitor practice committee believe mr witty contribute month plan appropriate provide mitigation contract maturity saving contract december mr heslop approve shareholder glaxosmithkline glaxo wellcome contribute month plan provide smithkline beecham appropriate option buy share end threeyear saving period follow table set detail executive director line opportunity available uk employee service contract mr witty mr heslop contribute month buy share sharereward plan company match current director date contract effective date expiry date number share buy month mr witty executive receive benefit include healthcare mr j heslop medical dental personal financial advice life assurance dr slaoui cash value benefit receive executive director r wittys contract renew june follow appointment show ceo th february company conditional award termination payment respect ad mr viehbacher vest subject continue notice period extend contract expiry date employment gsk committee assessment performance vest period follow mr viehbacher resignation th september award lapse gsk annual report report director remuneration report continue entitlement nonexecutive director term condition fee addition contractual provision outline event nonexecutive director glaxosmithkline executive director service agreement terminate service contract instead letter appointment employ company follow apply agree serve company non executive director conclusion agm follow case outstanding awards glaxosmithkline anniversary appointment case annual investment plan provide agreement extend term year mutual terminate cause defer agreement director serve term long year income gain automatically distribute soon offer reelection shareholder administratively practicable termination resign retire termination cause defer follow table show date initial letter distribute end minimum threeyear deferral period appointment nonexecutive director line policy applicable senior executive nonexecutive director date letter appointment dr garnier entitle receive continue medical dental insurance retirement dr slaoui member plan professor sir roy anderson eligible future date receive continue dr burns medical dental cover retirement mr l culp sir crispin davis follow merger participant legacy share option sir deryck maughan scheme elect exchange legacy option option mr james murdoch glaxosmithkline share receive additional cash benefit dr podolsky equal grant price original option additional sir ian prosser benefit trigger new option exercise lapse dr r schmitz qualify additional cash benefit participant retain mr de swaan option second anniversary effective date sir robert wilson merger fee structure nonexecutive director chairman outside appointment executive director review year change outside appointment approve chairman board ensure remain competitive company aim behalf board company policy remuneration provide nonexecutive director fee competitive earn appointment keep individual company equivalent size complexity fee executive director applying follow annum standard annual cash retainer fee supplemental fee senior independent director audit committee chairman scientificmedical expert chairman remuneration corporate responsibility committee nonexecutive director undertake intercontinental travel meeting meetinggsk annual report report director remuneration report continue exchange rate tsr performance graph fee pay dollar convert rate follow graph set performance company period st january st march relative ftse index company exchange rate apply th july constituent pharmaceutical performance comparator fee arrangement initially approve group st january st december graph board follow approval new fee arrangement prepare accordance regulation exchange rate applicable set board indication likely vest award grant rate apply st april companys incentive plan st december tsr performance nonexecutive director share allocation plan enhance link director shareholder glaxosmithkline require nonexecutive director receive significant fee form share nonexecutive director total fee exclude chairman pay form share ad allocate share account nonexecutive director opportunity invest balance fee share account share ad notionally award non executive director allocate interest account include director interest table accumulate balance share ad notional dividend subsequently reinveste pay nonexecutive director retirement board retirement nonexecutive director receive share ad cash equal value glaxosmithkline total return index share ad date retirement nonexecutive glaxosmithkline pharma peer return index director entitle compensation appointment ftse total return index terminate chairman director senior management remuneration sir christopher gents letter appointment board follow table set director glaxosmithkline date th agree plc remuneration earn interest share serve company deputy chairman glaxosmithkline plc interest share option incentive st december st january chairman plan pension benefit member cet conclusion agm follow anniversary participate remuneration plan executive appointment extend term director aggregate remuneration interest year mutual agreement director senior management provide chairman fee increase annum plus allocation share value annum previously effect st april line gsk policy ensure non executive director fee remain competitive gsk annual report report director remuneration report continue annual remuneration total total fee annual annual fee annual annual salary benefit bonus remuneration salary benefit bonus remuneration footnote executive director mr witty ab mr j heslop b dr slaoui c nonexecutive director professor sir roy anderson sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson dr burns mr l culp sir deryck maughan dr podolsky director mr j coombe dr barzach sir richard syke dr jp garni bc mr c viehbacher f dr yamada b dr l shapiro e total remuneration analyse executive director nonexecutive director director total remuneration remuneration director payroll report dollar dollar amount include total base conversion sterling average exchange rate year r witty joined board st january remuneration disclose date b f ollowe merger order encourage employee convert nonsaving relate option hold glaxo wellcome smithkline beecham share ad option glaxosmithkline share ad employee grant additional cash benefit equal grant price original option additional benefit know exchange offer incentive eoi payable new option exercise lapse qualify additional cash benefit participant retain option second anniversary effective date merger year mr witty receive eoi payment result option grant march lapse mr heslop receive result option grant july lapse dr garnier receive mr viehbacher receive dr yamada receive c r garnier retire director st retire company st nonexecutive director united technologies corporation respect receive end form defer stock unit include dr slaoui nonexecutive director agency science technology research astar respect receive include r barzach receive fee glaxosmithkline france healthcare consultancy provide include fee salary e dr shapiro retired board th step member glaxosmithkline scientific advisory board st july receive fee form ad include fee salary f r viehbacher appoint board st january remuneration disclose date resign board th september director receive reimbursement expense year require separate disclosure require regulationsgsk annual report report director remuneration report continue nonexecutive director remuneration total cash sharesad total cash sharesad fee current nonexecutive director professor sir roy anderson sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson dr burns mr l culp sir deryck maughan dr podolsky total remuneration table set remuneration receive nonexecutive director glaxosmithkline nonexecutive director require total fee form share allocate share account pay retirement board detail total value share ad date award cash payment form total fee include annual remuneration table fee salary table set value fee receive form cash share ad table set accumulate number share ad hold nonexecutive director relation fee receive board member st december movement account year number share ad dividend nonexecutive director share arrangement elect reinveste current nonexecutive director share professor sir roy anderson sir crispin davis sir christopher gent sir ian prosser dr r schmitz mr de swaan sir robert wilson ads dr burns mr l culp sir deryck maughan dr podolsky gsk annual report report director remuneration report continue director interest follow interest director company connected person show accordance list rule share ad th february st december st january th february st december st january footnote executive director mr witty ac mr j heslop c dr slaoui b nonexecutive director professor sir roy anderson dr burns mr l culp sir crispin davis sir christopher gent sir deryck maughan dr podolsky sir ian prosser dr r schmitz mr de swaan sir robert wilson glaxosmithkline ad represent glaxosmithkline share interest abovementione director th february reflect change year end date r witty joined board st january holding disclose date b nclude ad purchase glaxosmithkline stock fund retirement saving plan executive supplemental saving plan c nclude share purchase glaxosmithkline sharereward plan mr heslop totalling st december st december share th february mr witty totalling st december share th february nclude share ad receive fee describe nonexecutive director share allocation plan dividend receive share ad convert share ad st december share option option share grant footnote date grant exercise period grant price number exercise lapse mr witty ac mr j heslop c dr slaoui b mr c viehbacher option ad grant date grant exercise period grant price number exercise lapse dr slaoui bc dr jp garnier e mr c viehbacher r witty joined board st january option disclose date b detail include interest dr slaouis connect person employee gsk c main option grant occur th february dr slaoui connect person award ad option grant price option grant dr slaoui vest part award vest february remain vest february line new remuneration policy mr witty mr heslop receive share option forseeable future r viehbacher join board st january option disclose date th september resign board unvested option lapse st december leave company e dr garnier retired board st close balance option disclose dategsk annual report report director remuneration report continue option outstanding st december early late vesting lapse date option market price glaxosmithkline share yearend give table weight average vest date lapse date mr witty grant price number early latest early late option market price yearend vest unvested option market price yearend vest unvested total share option st december weight average vest date lapse date mr j heslop grant price number early latest early late option market price yearend vest unvested option market price yearend vest unvested total share option st december weight average vest date lapse date dr slaoui grant price number early latest early late option market price yearend vest unvested option market price yearend vest total share option st december option market price yearend unvested total ad option st december include share option hold dr slaouis connect person employee gsk weight average vest date lapse date dr jp garnier grant price number early latest early late option market price yearend vest unvested option market price yearend vest total ad option st gsk annual report report director remuneration report continue gsk grant share option executive director senior manager annual basis director hold option share option plan refer note financial statement employee share scheme nonexecutive director interest option company share table set share option grant respect performance period option vest st december performance target performance target vest status annualise growth percentage grant footnote performance period ep award vest february unvested rpi february unveste rpi february unveste rpi rpi rpi performance target share option partially meet result option grant vest anniversary date grant table set share option grant respect performance period targets performance target vest status annualise growth percentage grant performance period ep award vest february award unvested rpi february award unvested rpi rpi rpi rpi option exercise grant market date number price price gain gain dr jp garnier aggregate gain option exercise highest low closing price year end st december glaxosmithkline share respectively high low price glaxosmithkline ad year end st december respectively market price glaxosmithkline share st december st december glaxosmithkline ad st december price th february glaxosmithkline share glaxosmithkline ad incentive plan performance share plan psp award market additional mr witty share number price vest share unveste grant date market dividend unvested performance period grant number price gain lapse reinveste gsk annual report report director remuneration report continue market additional mr j heslop share number price vest share unveste grant date market dividend unvested performance period grant number price gain lapse reinveste market additional dr slaoui share number price vest share unveste grant date market dividend unvested performance period grant number price gain lapse reinveste market additional dr slaoui ad number price vest ad number unvested grant date market dividend unvested grant performance period grant number price gain lapse reinveste include performance share hold dr slaouis connect person employee gsk market additional dr jp garni ad vest number price vest ad unvested defer grant date market dividend unvested performance period grant number price gain lapse reinveste deferred defer set dr garniers contract unvested psp award vest subject achievement performance condition end performance period set market additional mr c viehbacher ad number price vest ad unveste grant date market dividend unvested performance period grant number price gain lapse reinveste mr viehbacher join board st january psps disclose date th september resign board unvested psp lapse mr viehbacher leave company st december term psp number share actually vest determined follow end relevant measurement period dependent gsk performance period describe page gsk annual report report director remuneration report continue dividend reinveste performance share award executive performance period date final award dividend reinvestment calculate exdividend date term psp participant defer receipt vested award total gain vest psp award executive director psp award grant executive director february exclude dr slaoui performance period start st january end st december lapse gsk relative tsr performance median comparator group award senior executive include dr slaoui member cet time award dependent tsr performance ep performance tsr portion lapse eps portion vest follow vest schedule apply psp award vest schedule award performance period tsr rank company percentage award vest median median follow vest schedule apply psp award vest schedule award performance period tsr rank company percentage award vest median median tsr measure prorata basis glaxosmithkline performance fall comparator level vest determined actual relative level tsr simple rank dividend treat reinvested performance period award follow approval new psp agm share value plan award market dr slaoui share ad number price vest defer unvested grant date market unvested number ad plan year grant number price gain lapse grant share ad ad ad ad executive director dr slaoui eligible receive award share value plan award show reflect holding dr slaouis connect person employee gsk award subject threeyear vest period vest contingent continue employment gskgsk annual report report director remuneration report continue vested additional ad vest defer dividend defer participation reinveste participation midterm incentive plan ad exercise market price gain dr jp garni midterm incentive plan mtip share award scheme operate smithkline beecham plan close new entrant completion merger participation grant final award ad receipt award defer director dr garnier defer receipt amount vested year defer award additional ad subsequently receive dividend reinvestment include director interest table retain mtip pay th february company conditional award ad mr viehbacher follow mr viehbacher resignation board effect th september conditional award lapse pension benefit accrue annual pension benefit transfer value executive director office st december retirement set company act require disclosure accrue benefit end year change accrue benefit year transfer value beginning end year change transfer value year listing rule require additional disclosure change accrue benefit net inflation transfer value change pension executive director disclose currency pension payable change change personal accrue transfer value accrue accrue accrue contribution transfer transfer change benefit change benefit benefit benefit value value transfer year net accrue executive director e r e r va l u e infla ti ben e fi mr witty mr j heslop dr slaoui dr slaoui executive director dr jp garnier mr c viehbacher show net contribution individual mr witty mr heslop participate glaxo wellcome define benefit plan accrual rate th final pensionable salary annum benefit accrue glaxo wellcome uk pension arrangement augment trustee plan reflect distribution surplus augmentation apply element mr witty mr heslops pension earning st march mr wittys mr heslops transfer value calculate basis actuarial advice accordance pension regulation transfer value represent present value future payment pension plan mr wittys annual accrue benefit increase exclude effect inflation transfer value personal contribution increase year increase mr wittys pensionable salary reflect appointment ceo primary reason increase transfer value mr heslops annual accrue benefit increase exclude effect inflation transfer value personal contribution increase year gsk annual report report director remuneration report continue pension benefit director senior management dr slaoui mr viehbacher member executive information provide compensation cash balance pension plan plan provide executive interest director senior management group pension credit gsk make annual contribution group purpose group define executive calculate percentage executive base salary nonexecutive director member cet gsk make contribution base pay fund financial year total compensation pay member increase interest rate set annually advance base group period serve year treasury bond rate provide cash sum capacity aggregate increase accrue retirement plan entitlement spouse pension pension benefit net inflation pension increase aggregate payment define contribution scheme mr viehbacher resign board th september leave company st december member group grant share option ad option transfer value cash sum increase share option plan award share dr slaoui mr viehbacher year ad performance share plan award result accumulation interest contribution pay share ad share value plan company award notional share defer investment dr slaoui active participant belgium fortis plan award plan member group award st plan define benefit plan reinvestment dividend share ad lump sum payable normal retirement age performance share plan notional share plan transfer value cash sum dr slaouis plan notional ad defer investment award plan increase year result th february group comprise person accumulation interest own share ad constitute dr garni retire company st issue share capital company group member cash balance pension plan hold date option purchase share gsk annual contribution calculate ad share ad award percentage base salary bonus gsk annual performance share plan include share contribution dr garniers annual salary bonus ad vest defer vested defer detailed contract fund increase interest ad legacy smithkline beecham midterm incentive rate set annually base year treasury bond rate plan share ad award share provide cash sum retirement plan entitlement value plan notional share award spouse pension pension increase dr garni defer investment award plan holding issue select receive pension payment annual basis executive share option plan describe pay year commence january transfer note financial statement employee share scheme value cash sum increase year dr garnier plan result accumulation director interest contract interest contribution pay company describe note financial statement relate party transaction end financial year dr slaoui dr garnier mr viehbacher member director connected person material interest retirement saving plan k saving scheme open contract significance relation group business employee executive supplemental saving plan group company saving scheme open executive accrue benefit government limit impose retirement saving plan director remuneration report approve contribution plan invest range fund board director sign behalf value accumulate fund pay retirement contribution sir christopher gent pay scheme gsk respect dr slaoui chairman respect dr garni rd march respect mr viehbachergsk annual report financial statement financial statement financial statement set belowoverleaf provide director statement responsibility summary group financial performance independent auditor report position st december financial financial statement statement prepare accordance ifrs consolidated income statement adopt european union ifrs issue consolidated balance sheet international accounting standard board financial consolidated cash flow statement statement comprise follow audit primary statement consolidate statement recognise income expense relate note note financial statement presentation financial statement consolidated income statement accounting principle policy consolidate balance sheet key accounting judgement estimate new accounting requirement consolidate cash flow statement exchange rate consolidate statement recognise income expense segment information major restructuring programme operate income operating profit employee cost finance income finance cost associate joint venture taxation earning share dividend property plant equipment goodwill intangible asset investment associate joint venture investment noncurrent asset inventory trade receivables cash cash equivalent asset hold sale trade payable pension postemployment benefit provision noncurrent liability contingent liability net debt share capital share premium account movement equity relate party transaction adjustment reconcile profit tax operating cash flow reconciliation net cash flow movement net debt acquisition disposal commitment post balance sheet event financial instrument relate disclosure employee share scheme principal group company legal proceeding financial statement glaxosmithkline plc prepare uk gaap gsk annual report financial statement director statement responsibility director statement responsibility relation group financial statement prepare group financial statement accordance ifrs adopt eu ifrs issue iasb true fair view asset liabilitie director responsible prepare annual report financial position profit group remuneration report group financial statement accordance applicable law regulation business review section contain annual report include fair review development performance company law require director prepare financial statement business position group financial year law director prepare description principal risk uncertainty face group financial statement accordance international financial reporting standard ifrs adopt european union disclosure information auditor prepare group financial statement director elect director office date report comply ifrs issue international accounting standard confirm board iasb group financial statement require law far aware relevant audit true fair view state affair group end information company auditor unaware financial period profit loss group period take step ought prepare financial statement director require take director aware select suitable accounting policy apply relevant audit information establish company consistently auditor aware information judgement estimate reasonable confirmation give interpret accordance prudent provision section za company act state group financial statement comply ifrs go concern basis adopt european union ifrs issue iasb make enquiry director reasonable expectation subject material departure disclose explain group adequate resource continue operational existence financial statement foreseeable future reason continue adopt director responsible keep proper accounting record go concern basis prepare financial statement disclose reasonable accuracy time financial internal control position group enable ensure group financial statement director remuneration report comply board audit committee review company act article ias assessment risk internal control framework operate regulation responsible take reasonable step gsk consider effectiveness system internal safeguard asset group ensure operation control operation group year cover report system internal control take reasonable step date approval board directors prevention detection fraud irregularity combine code group financial statement year end st december board consider glaxosmithkline plc apply principle comprise principal statement support note combine code corporate governance financial set financial statement page report council describe corporate governance report page comply provision describe responsibility auditor relation group financial statement set independent auditor require listing rule financial service report authority auditor consider director statement compliance relation point combine code group financial statement year end st december specify review include annual report publish hardcopy print form available company annual report website director responsible maintenance annual report year end st december integrity annual report website accordance comprise report director remuneration report uk legislation govern preparation dissemination financial statement additional information investor financial statement access website available approve board director sign behalf outside uk comparable legislation different current director name function sir christopher gent list corporate governance section annual report chairman confirm good knowledge rd march gsk annual report financial statement independent auditor report members glaxosmithkline plc audit group financial statement glaxosmithkline consider implication report aware plc year end st december comprise apparent misstatement material inconsistency group consolidate income statement consolidate balance sheet financial statement consolidate cash flow statement consolidate statement responsibility extend information recognise income expense relate note group financial statement prepare accounting basis audit opinion policy set conduct audit accordance international standard audit uk ireland issue auditing practice board report separately parent company financial audit include examination test basis evidence relevant statement glaxosmithkline plc year end amount disclosure group financial statement st december information remuneration include assessment significant estimate report describe audit judgment director preparation group respective responsibility director auditor financial statement accounting policy director responsibility prepare annual report appropriate group circumstance consistently apply group financial statement accordance applicable law adequately disclose international financial reporting standard ifrs adopt plan perform audit obtain european union set director statement information explanation consider necessary responsibility opposite order provide sufficient evidence reasonable responsibility audit group financial statement assurance group financial statement free material accordance relevant legal regulatory requirement misstatement cause fraud irregularity error international standard audit uk ireland report form opinion evaluate overall adequacy include opinion prepare presentation information group financial statement companys member body accordance section opinion company act purpose give opinion opinion accept assume responsibility purpose person report show hand group financial statement true fair view come save expressly agree prior consent writing accordance ifrss adopt european union state group affairs st december report opinion group financial profit cash flow year end statement true fair view group financial statement properly prepared accordance group financial statement properly prepare company act article ia regulation accordance company act article report opinion information ias regulation give report director consistent group information give report director consistent financial statement group financial statement addition report opinion separate opinion relation ifrs receive information explanation require explain note group financial statement group audit information specify law director addition comply legal obligation comply ifrs remuneration transaction disclose adopt european union comply ifrs review corporate governance statement reflect issue international accounting standard board company compliance provision combine opinion group financial statement true fair code specify review list rule financial view accordance ifrs state group affair service authority report require st december profit cash flow consider board statement internal control cover year end risk control form opinion effectiveness group corporate governance procedure risk control procedure pricewaterhousecooper llp charter accountant register auditor read information contain annual report consider london consistent audit group financial statement rd march information comprise chairman ceo summary strategy report director exclude audit remuneration report director statement responsibility shareholder information gsk annual report financial statement consolidated income statement year end st december result result major major total major major total total note restructure restructuring restructure restructuring turnover cost sale gross profit sell general administration research development operating income operate profit finance income finance cost share tax profit associate joint ventures profit taxation taxation profit taxation year profit attributable minority interest profit attributable shareholder basic earning share penny p p p dilute earning share penny p p p calculation result major restructuring describe note presentation financial statementsgsk annual report financial statement consolidate balance sheet st december note noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax liability pension postemployment benefit provision derivative financial instrument noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity minority interest total equity approve board rd march sir christopher gent chairman gsk annual report financial statement consolidate cash flow statement year end st december note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment share transaction minority shareholder purchase business net cash acquire disposal business interest associate investment associate joint venture decreaseincrease liquid investment interest receive dividend associate joint venture net cash outflow investing activity cash flow financing activity proceed share employee share option share acquire esop trust issue share capital purchase share cancellation purchase treasury share increase longterm loan repayment longterm loan net repayment ofincrease shortterm loan net repayment obligation finance lease interest pay dividend pay shareholder dividend pay minority interest finance cash flow net cash outflow financing activity increasedecrease cash bank overdraft exchange adjustment cash bank overdraft begin year cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft gsk annual report financial statement consolidate statement recognise income expense year end st december exchange movement overseas net asset tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment actuarial lossesgain define benefit plan defer tax actuarial movement define benefit plan fair value movement cash flow hedge defer tax fair value movement cash flow hedge net profitslosse recognise directly equity profit year total recognise income expense year total recognise income expense year attributable shareholder minority interest gsk annual report financial statement note financial statement presentation financial statement estimate total cost approximately billion expand programme expect deliver annual pretax description business saving approximately billion time substantially glaxosmithkline major global healthcare group complete give extent cost operational engaged creation discovery development manufacture excellence programme management believe material marketing pharmaceutical product include vaccine impact gsk operating result manner overthecounter otc medicine healthrelate consumer gsk business conduct gsk present restructuring cost product gsk principal pharmaceutical product include incur solely direct result operational excellence medicine follow therapeutic area respiratory central programme separate column income statement title nervous system antiviral antibacterial metabolic vaccine major restructure cardiovascular urogenital oncology emesis addition restructuring cost operational excellence compliance applicable law ifrs programme major restructuring column income financial statement prepare accordance statement include restructuring cost incur solely direct company act article ias regulation result restructure programme follow relate international accounting standard ias international material acquisition operation acquire financial reporting standard ifrs relate interpretation business overlap extensively gsk exist operation adopt european union restructuring activity follow relate financial statement compliance ifrs issue acquisition nature undertake international accounting standard board operational excellence programme carry composition financial statement follow detailed formal plan management consider appropriate present cost restructuring activity consolidate financial statement draw sterling manner billion million acquisition functional currency glaxosmithkline plc accordance reliant pharmaceutical december acquisition ifrs accounting presentation financial statement comprise october meet criterion set consolidated income statement acquisition cost incur direct result consolidated balance sheet relate restructuring programme include consolidated cash flow statement major restructuring column consolidate statement recognise income expense group result cost operational excellence note financial statement programme acquisitionrelate restructuring programme meeting criterion describe present accounting convention separate column income statement describe financial statement prepare historical result major restructure presentation cost convention modify revaluation certain item gsk intend apply consistently future major restructuring state accounting policy programme material impact gsk operate financial period result manner gsk business conduct financial statement cover financial year st adopt clearly group result january st december comparative figure cost restructure programme financial year st january st december management believe presentation assist investor appropriate st january st december gain clear understanding group financial performance make projection future financial composition group performance result include cost virtue list subsidiary associate undertaking opinion size nature limited comparative value presentation director principally affect profit net consistent way management assess group asset group give note principal group company financial performance presentation restructuring cost restructuring cost arise solely direct result october board approve implementation operational excellence programme restructure detailed formal plan gsk announce significant programme follow relate acquisition meet new operational excellence restructure programme criterion describe continue report operate second formal plan represent significant expansion expense result major restructure operational excellence programme approve board announce february restructure programme comprise detailed formal plan cover area gsk business include manufacturing sell rd infrastructuregsk annual report financial statement note financial statement continue accounting principle policy entity group power govern preparation financial statement conformity financial operating policy account subsidiary generally accept accounting principle require management group ability exercise joint control estimate assumption affect report amount entity account joint venture group asset liability disclosure contingent asset ability exercise significant influence account liability date financial statement report associate result asset liability associate amount revenue expense report period joint venture incorporate consolidated financial actual result differ estimate statement equity method account financial statement prepare accordance interest acquire entity consolidated date group accounting policy approve board group acquire control interest sell deconsolidate describe note accounting principle policy date control cease information application accounting policy transaction balance subsidiary eliminate include area estimation judgement give note profit tax take sale subsidiary key accounting judgement estimate appropriate sale joint venture associate product sell comparative figure reclassify ensure consistent customer outside group defer tax relief unrealise presentation current year information intragroup profit account extent restate comparative information consider recoverable result review strategic direction group goodwill arise acquisition interest subsidiary joint regional reporting structure pharmaceutical ventures associate represent excess acquisition business realign russia number develop cost group share fair value identifiable eastern european market previously report europe asset liability contingent liability acquire capitalise include emerge market sector rest separate item case subsidiarie world change reporting structure cost investment case joint venture associate consumer healthcare business market goodwill denominate currency operation report europe acquire cost acquisition fair value group take opportunity review allocation net asset acquire difference recognise directly entity expense pharmaceutical income statement consumer healthcare business result entity foreign currency translation china reclassify pharmaceutical consumer foreign currency transaction book functional healthcare comparative information restate currency group company exchange rate rule consistent basis date transaction foreign currency monetary asset liability reallocation impact group turnover group retranslate functional currency rate exchange operate profit rule balance sheet date exchange difference include income statement parent company financial statement financial statement parent company glaxosmithkline consolidation asset liability include related goodwill plc prepare accordance uk gaap uk overseas subsidiary associate joint venture accounting presentation company balance sheet present translate sterling rate exchange rule balance accounting policy give sheet date result cash flow overseas subsidiary associate joint venture translate sterling accounting principle policy average rate exchange consolidation exchange adjustment arise open net asset consolidated financial statement include profit year retain overseas subsidiary associate joint venture translate sterling exchange asset liability result cash flow difference arise related foreign currency borrowing company subsidiary include esop trust hedge group net investment operation take group share result net asset associate separate component equity joint venture financial statement entity consolidate st december year gsk annual report financial statement note financial statement continue accounting principle policy continue research development research development expenditure charge income translate sterling asset liability result statement period incur development cash flow overseas subsidiary associate joint venture expenditure capitalise criterion recognise asset report currency hyperinflationary economy meet usually regulatory filing major adjustment reflect current price level loss market approval consider highly probable property plant net monetary asset charge consolidated equipment research development depreciate income statement accordance group policy revenue environmental expenditure revenue recognise income statement good environmental expenditure relate exist condition result service supply available external customer past current operation current order receive title risk loss pass future benefit discernible charge income statement customer reliable estimate relevant group recognise liability sitebysite basis deduction turnover represent net invoice value reliably estimate liability include group portion deduction discount allowance give accrual total cost portion potentially responsible estimate future rebate return methodology party cost probable able assumption estimate rebate return monitor satisfy respective share cleanup obligation recovery adjust regularly light contractual legal reimbursement record asset virtually certain obligation historical trend past experience project market condition market condition evaluate wholesaler legal dispute thirdparty analysis market research datum internally provision anticipate settlement cost legal generate information turnover include copromotion dispute group outflow resources income group record share revenue consider probable reasonable estimate related cost sale value add tax sale taxis likely outcome addition provision legal exclude revenue expense arise claim receive dispute respect product liability claim relate product royalty income recognise operate income sufficient history claim settlement incur accrual basis accordance term relevant report ibnr actuarial technique determine licensing agreement reasonable estimate group exposure unasserted claim expenditure product provision basis expenditure recognise respect good service provision unasserted claim receive supply accordance contractual term obligation exist dispute possible provision obligation exist future liability reasonable estimate cost associate claim respect past event obligation group party charge income statement reliably estimate manufacturing startup cost incur validation achievement normal production expense incur advertising promotion expenditure pension postemployment benefit charge income statement incur shipment cost cost provide pension define benefit scheme intercompany transfer charge cost sale distribution calculate project unit credit method spread cost sale customer include sell general period benefit expect derive administrative expenditure employee service consistent advice qualified actuary pension obligation measure present value restructuring cost recognise provide estimate future cash flow discount rate reflect appropriate respect direct expenditure business yield high quality corporate bond reorganisation plan sufficiently detail advanced appropriate communication affect undertakengsk annual report financial statement note financial statement continue accounting principle policy continue lease lease agreement transfer group substantially pension scheme asset measure fair value balance benefit risk ownership asset treat sheet date actuarial gain loss difference finance lease asset purchase outright expect actual return asset effect change asset include ppe computer software capital actuarial assumption recognise statement element leasing commitment show obligation recognise income expense year finance lease asset hold finance lease arise group contribution define contribution plan depreciate basis consistent similar own asset charge income statement incur cost lease term short interest element lease rental postemployment liability calculate similar include income statement lease operate way define benefit pension scheme spread lease rental cost charge income statement period benefit expect derive straightline basis lease term employee service accordance advice qualified actuary goodwill goodwill state cost impairment goodwill deem employee share plan indefinite useful life test impairment annually incentive form share provide employee share option share award scheme fair value interest acquire entitys asset liability contingent liability exceed consideration pay fair value option award calculate excess recognise immediately gain income statement grant date blackschole option pricing model charge income statement relevant vesting period intangible asset intangible asset state cost provision amortisation group provide finance esop trust purchase company impairment share open market meet obligation provide share employee exercise option award cost run licence patent knowhow marketing right separately esop trust charge income statement share hold acquire acquire business combination esop trust deduct reserve transfer amortise estimate useful life exceed year reserve retain earning vest straightline basis time available period relate share option award reflect ultimate use estimate useful life determine amortisation proceed receivable employee exercise charge account patent live applicable value obtain period nonexclusivity asset property plant equipment life review appropriate adjust annually property plant equipment ppe state cost contingent milestone payment recognise point purchase construction provision depreciation contingent event certain development impairment financing cost capitalise cost incur group associate acquire depreciation calculate write cost residual value licence patent knowhow marketing right write ppe exclude freehold land straightline basis income statement incur criterion expect useful life residual value life review recognition internally generate intangible asset meet appropriate adjust annually normal expect usually regulatory filing major market useful live major category ppe approval consider highly probable freehold building year acquire brand value independently fair value leasehold land lease term year business acquire party brand building value substantial longterm brand plant machinery year contractual legal nature sell separately fixture equipment year rest business acquire brand amortise estimate useful life consider disposal ppe cost relate accumulate useful economic life indefinite depreciation impairment remove financial statement net proceed take cost acquire develop computer software income statement internal use internet site external use capitalise intangible fix asset software site support significant business system expenditure lead creation durable asset erp system software amortise seven year computer software year gsk annual report financial statement note financial statement continue accounting principle policy continue trade receivable trade receivables carry original invoice impairment noncurrent asset provision doubtful debt provision carry value noncurrent asset review evidence risk nonpayment take account age impairment indication asset previous experience general economic condition impair additionally goodwill intangible asset indefinite trade receivable determine uncollectable write useful life intangible asset available firstly provision available use test impairment annually provision income statement impairment charge income statement year concern subsequent recovery amount previously provide credit income statement longterm receivables impairment goodwill reverse impairment loss discount effect material noncurrent asset reverse change estimate determine recoverable amount trade payable extent revise recoverable amount trade payable hold amortise cost equate exceed carry value exist nominal value longterm payable discount net depreciation amortisation impairment effect material recognise cash cash equivalent investment associate joint venture cash cash equivalent comprise cash hand current balance investment associate joint venture carry bank similar institution highly liquid investment consolidate balance sheet group share net asset original maturity month readily date acquisition postacquisition retain profit convertible know amount cash insignificant loss goodwill arise acquisition risk change value availableforsale investment taxation liquid investment investment classify current tax provide amount expect pay availableforsale investment initially record fair apply tax rate enact substantively enact value plus transaction cost remeasure subsequent balance sheet date reporting date fair value unrealised gain loss defer tax provide liability method availableforsale investment recognise directly equity temporary difference arise tax basis asset impairment arise significant prolong decline liability carry amount financial statement fair value investment reduce carrying defer tax asset recognise extent probable asset directly charge income statement future taxable profit available disposal impairment investment gain temporary difference utilise defer tax provide loss defer equity recycle temporary difference arise investment subsidiarie income statement dividend equity investment recognise associate joint venture time income statement group right receive reversal temporary difference control payment establish equity investment record non probable temporary difference reverse current asset expect sell year foreseeable future defer tax provide rate tax purchase sale equity investment account enact substantively enact balance sheet trade date purchase sale availableforsale date defer tax liability asset discount investment account settlement date derivative financial instrument hedge inventory derivative financial instrument manage exposure inventory include financial statement low market risk treasury operation principal derivative cost include raw material direct labour direct cost instrument glaxosmithkline foreign currency swap relate production overhead net realisable value cost interest rate swap forward foreign exchange contract generally determine basis prelaunch group hold issue derivative financial instrument inventory hold asset high probability trade speculative purpose regulatory approval product point provision carry value recoverable provision reverse point high probability regulatory approval determinedgsk annual report financial statement note financial statement continue accounting principle policy continue level accrual review adjust regularly light contractual legal obligation historical trend past derivative financial instrument classify heldfortrading experience project market condition market condition carry balance sheet fair value derivative evaluate wholesaler thirdparty analysis market designate hedge instrument classify inception research datum internally generate information future event cash flow hedge net investment hedge fair value hedge cause assumption accrual base change fair value derivative designate cash flow change affect future result group hedge recognise equity extent hedge group copromote product party effective ineffective portion recognise profit loss record sale group record share revenue co immediately amount defer equity recycle promotion income turnover nature copromotion income statement hedge item affect profit loss activity group record cost sale net investment hedge account similar way cash pharmaceutical turnover include copromotion revenue flow hedge million million million change fair value derivative designate fair value taxation hedge record income statement current tax provide amount expect pay change fair value hedge asset liability defer tax provide temporary difference tax basis asset liability carry amount change fair value derivative instrument rate enact substantively enact qualify hedge accounting recognise immediately balance sheet date income statement group open tax issue number revenue discount authority gsk continue believe adequate time effect money material balance discount provision liability likely arise open assessment current value appropriate rate interest unwind open issue exist ultimate liability matter discount record finance incomecost vary amount provide dependent outcome negotiation relevant tax authority key accounting judgement estimate necessary litigation proceeding prepare financial statement management require legal dispute estimate assumption affect amount gsk provide anticipate settlement cost outflow asset liability revenue expense report financial resource consider probable reasonable estimate statement actual amount result differ likely outcome dispute legal estimate follow consider key accounting expense arise claim group judgement estimate company director take legal advice turnover establish provision take account relevant revenue recognise title risk loss pass fact circumstance matter accordance customer reliable estimate relevant accounting requirement provision product liability claim deduction gross turnover reduce rebate discount certain product incur report allowance product return give expect give basis sufficient history claim settlement vary product arrangement buy group available provision unasserted arrangement purchase organisation dependent claim claim reasonable estimate likely submission claim time initial recognition outcome sale accrual time sale estimate rebate discount allowance payable return ultimate liability pende unasserted claim vary base available market information historical experience amount provide dependent outcome litigation proceeding investigation possible amount estimate fully reflect settlement negotiation final outcome amount subject change dependent thing type buy group product sale mix gsk annual report financial statement note financial statement continue key accounting judgement estimate pension postemployment benefit continue cost provide pension postemployment benefit charge income statement accordance property plant equipment ias period benefit derive carry value property plant equipment review employee service cost assess basis impairment indication value assumption select management assumption include asset impaired impairment determine reference future earning pension increase discount rate expect high fair value cost sell value use long term rate return asset mortality rate measure assess riskadjuste future cash flow discount disclose note pension postemployment appropriate interest rate future cash flow base benefit business forecast inherently judgemental future event cause assumption expect long term rate return bond determine impairment review change consequent adverse effect base portfolio mix indexlinke government future result group corporate bond equity risk premium add equity goodwill discount rate base appropriate longterm index include goodwill arise business combination capitalise iboxx year aa index uk moodys aa index allocate appropriate cash generating unit deem usa sensitivity analysis provide note pension indefinite life amortise annual postemployment benefit reduction impairment test relevant cash generating unit discount rate lead increase net pension perform impairment test base establish market deficit approximately million increase annual multiple riskadjuste future cash flow discount pension cost approximately million selection different appropriate interest rate future cash flow base assumption affect future result group business forecast inherently judgemental future event cause assumption new accounting requirement impairment review change consequent adverse follow ifrs ifric interpretation issue effect future result group iasb likely affect future annual report intangible asset expect material impact result intangible asset acquire gsk party financial position group cost acquisition capitalise licence compound ifrs operating segment issue november development amortise point require implement gsk st january available use estimate useful life standard replace ia align segmental include period nonexclusivity estimate useful life report requirement equivalent review annually impairment test undertake event standard segmental information disclose occur question carry value asset basis internal reporting purpose brand acquire business capitalise independently gsk assess impact standard presentation separable expect life segmental information year brand amortise straightline basis estimate useful life exceed year ias revise borrowing cost issue march end useful economic life foresee brand implement prospectively st january amortise subject annual impairment test require borrow cost attributable acquisition impairment test base established market multiple risk construction certain asset capitalise option adjust future cash flow discount appropriate interest currently take gsk expensing cost incur rate future cash flow base business forecast long available inherently judgemental future event cause assumption impairment review change consequent adverse effect future result groupgsk annual report financial statement note financial statement continue ia revise presentation financial statement issue exchange rate september effective st january group use average exchange rate prevail amendment standard mandate presentation period translate result cash flow overseas format disclosure adopt subsidiary joint venture associate undertaking gsk movement equity present statement sterling period end rate translate net asset change equity note financial statement undertaking currency influence ifrs revise sharebased payment issue january translation relevant exchange rate revise standard apply retrospectively st january specifies cancellation share average rate base payment arrangement include employee counterparty receive accounting treatment euro require immediate recognition income statement yen charge recognise remainder service period period end rate iasbs annual improvement project publish euro effective st january project yen make minor amendment number standard topic include investment associate intangible asset borrowing cost impairment asset ifrs revise business combination issue january apply business combination arise st january change new standard require recognition subsequent change fair value contingent consideration income statement goodwill transaction cost recognise immediately income statement fair value gain loss exist investment acquire company recognise income statement date acquisition ias revise consolidated separate financial statement issue january implement time ifrs revise respect transaction noncontrolle interest group entity result change control revise standard require difference consideration pay receive record noncontrolle interest recognise equity case divestment subsidiary retain interest remeasure fair value difference fair value previous carrying value recognise immediately income statement ifrs revise ia revise apply prospectively transaction occur implementation date possible assess advance impact financial statement group gsk annual report financial statement note financial statement continue segment information group primary segment report business sector geographical report secondary format business sector consist pharmaceutical consumer healthcare geographical sectors usa europe rest world reflect group significant regional market consistent group regional market management reporting structure business sector datum include allocation corporate cost sector appropriate basis sale business sector group activity organise global basis geographical sector figure influence location group operate resource particular manufacturing research variation time intragroup trading funding arrangement turnover show business sector location customer location subsidiary operating profit show business sector location subsidiary geographic information give location subsidiary follow review strategic direction group year entity reclassify europe rest world addition entity china reclassify pharmaceutical consumer healthcare comparative information restate consistent basis restate restate turnover business sector pharmaceutical consumer healthcare turnover profit business sector pharmaceutical consumer healthcare operate profit finance income finance cost share tax profit associate joint ventures pharmaceutical consumer healthcare profit taxation taxation profit taxation year property plant equipment intangible asset business sector addition pharmaceutical consumer healthcare total addition depreciationamortisation pharmaceutical consumer healthcare total depreciationamortisation impairment pharmaceutical consumer healthcare total impairment impairment reversal pharmaceutical consumer healthcare total impairment reversal gsk annual report financial statement note financial statement continue segment information continue restate investment associate joint venture business sector pharmaceutical consumer healthcare investment associate joint venture total asset business sector pharmaceutical consumer healthcare total operating asset investment associate joint venture liquid investment derivative financial instrument cash cash equivalent current defer taxation asset hold sale total asset total liability business sector pharmaceutical consumer healthcare total operating liability shortterm borrowing longterm borrowing derivative financial instrument current defer taxation total liability net asset business sector pharmaceutical consumer healthcare net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation asset hold sale net asset gsk annual report financial statement note financial statement continue segment information continue restate restate turnover location customer usa europe rest world turnover turnover location subsidiary undertaking usa europe rest world turnover include intersegment turnover usa europe rest world intersegment turnover usa europe rest world external turnover operate profit location subsidiary undertaking usa europe rest world operate profit property plant equipment intangible asset addition location usa europe rest world total addition total asset location usa europe rest world intersegment trading balances total operating asset gsk annual report financial statement note financial statement continue segment information continue net operating asset location usa europe rest world net operating asset uk segment uk include group europe market region turnover location customer turnover include intersegment turnover intersegment turnover turnover location subsidiary noncurrent asset major restructuring programme october gsk announce significant new operational excellence programme improve effectiveness productivity operation significant expansion operational excellence programme approve board announce february total cost implementation expand programme expect approximately billion incur period approximately cost incur st december approximately expect incur balance total approximately cost expect cash expenditure expect accounting writedown uncertainty exist exact time cash outflow result potential future exchange rate fluctuation element restructure programme subject employee consultation procedure make difficult predict precision procedure complete majority remain cash payment expect programme expect deliver total annual pretax saving billion saving realise business cost million incur operational excellence programme arise follow area commencement closure number manufacture site include dartford crawley uk cidra puerto rico give rise asset writedown staff reduction foreign exchange loss liquidation subsidiary adoption customise sale approach lead staff reduction number sale force principally usa cost saving project rd focus primarily simplification streamline support infrastructure project eliminate unnecessary process simplify continue process lead staff reduction administrative support function addition cost million incur year restructure programme relate integration reliant pharmaceuticals inc business usa follow acquisition december gsk annual report financial statement note financial statement continue major restructuring programme continue analysis cost incur programme follow asset staff impairment reduction cost total cost sale sell general administration research development effect operate profit net finance expense effect profit taxation effect taxation effect earning asset staff impairment reduction total cost sale sell general administration research development effect profit taxation effect taxation effect earning asset impairment million million cost total million nil noncash item charge settle cash restructuring cost report major restructuring column income statement cost relate major restructuring programme cost relate minor restructure activity initiate prior october amount million million report result major restructuring cost major restructuring programme arise follow increase provision major restructuring programme note provision reverse unused note impairment property plant equipment note foreign exchange loss recognise liquidation subsidiary noncash charge cash cost net finance expense effect profit taxation noncash charge principally accelerate depreciation arise asset life shorten result major restructuring programme cash cost include consultancy project management fee termination lease site closure costsgsk annual report financial statement note financial statement continue operate income royalty milestone income impairment equity investment disposal equity investment disposal asset legal settlement fair value adjustment derivative financial instrument income royalty milestone income principally core recur income outlicense intellectual property fair value adjustment derivative financial instrument include movement expire quest collar theravance option operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment amortisation intangible asset net foreign exchange gainslosse inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor audit parent company consolidated financial statement fee payable company auditor associate service reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration fee payable company auditor associate service audit account group uk overseas subsidiary relate pension scheme company pursuant legislation assurance service pursuant legislation tax service service include regulatory compliance treasury relate service st december pricewaterhousecooper llp associate fee invoice million comprise statutory audit million taxation service million service million fee payable pricewaterhousecooper llp associates increase cer term fee respect glaxosmithkline pension scheme include audit service gsk annual report financial statement note financial statement continue employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity wage salary decline cer term group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff number group employee end financial year give financial record average number person employ glaxosmithkline plc nil nil compensation director senior management member cet aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan finance income interest income arise cash cash equivalent availableforsale investment derivative fair value profit loss loan receivables realise gain liquid investment fair value adjustment derivative fair value profit loss net investment hedge ineffectiveness unwind discount asset derivative fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ia interest income arise derivative fair value profit loss relate swap interest incomegsk annual report financial statement note financial statement continue finance cost interest expense arise financial liability amortise cost derivative fair value profit loss fair value hedge fair value adjustment derivative designate hedge instrument fair value adjustment hedge item fair value adjustment derivative fair value profit loss unwind discount provision derivative fair value profit loss designate effective hedging instrument classify heldfortrade financial instrument ia associates joint ventures associate share tax profit quest diagnostic inc share tax loss associate share tax profitslosse joint venture share turnover joint venture sale joint ventures associate summarise income statement information respect group associate set total turnover quest diagnostic inc total profit quest diagnostic inc gsk annual report financial statement note financial statement continue taxation taxation charge base profit year uk corporation tax uk statutory rate double taxation relief overseas taxation current taxation defer taxation reconciliation taxation rate group profit uk statutory rate taxation overseas taxis benefit special tax status rd credit intercompany stock profit impact share base payment tax profit associate difference prior year item restructure tax rate additional uk corporation tax double taxation relief arise dividend receive overseas subsidiary group operate country tax rate differ uk tax rate impact overseas taxis overall rate tax show profit arise certain operation singapore puerto rico ireland accord special status tax reduce rate compare normal rate tax territory effect reduction taxation charge increase earning share p p p group require ifrs create defer tax asset respect unrealise intercompany profit arise inventory hold group yearend apply tax rate country inventory hold tax rate country profit originally tax pay practice uk gaap result difference accounting treatment group tax rate ifrs increase decrease decrease arise change workinprogress finished good integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax resolution issue continue fact life gsk group main open tax issue usa canada japan july follow discussion hmrc group settle substantially outstanding uk tax issue period include st december follow audit period irs issue statutory notice deficiency gsk assert income withholding tax deficiency associate penalty arise reclassification intercompany financing arrangement year debt equity consequent recharacterisation amount pay dividend subject withholding tax uk treaty amount financing arrangement pay timely basis final payment april irs commence audit period june examine issue year gsk disagree irs position august initiate action united states tax court contest statutory notice deficiency gsk estimate irs claim tax penalty interest st december net federal tax relief million gsk believe claim merit adjustment warrant contrary gsk view irs prevail argument court respect year gsk expect additional liability year period million tax penalty interest st december net federal tax relief year event company able resolve issue irs court decision expect gsk annual report financial statement note financial statement continue taxation continue low court japan uphold claim tax authority yen billion million relate japanese cfc legislation company pay fully provide tax pursuing claim refund japanese supreme court canada court decision respect transfer pricing early complete gsk file appeal june court date await gsk continue believe adequate provision liability likely arise open assessment ultimate liability matter vary amount provide dependent outcome litigation proceeding negotiation relevant tax authority provision taxation arise distribution profit retain overseas subsidiary associate undertaking ground remittance profit retain st december require way incremental tax arise aggregate unremitte profit balance sheet date approximately billion billion payable recoverable net movement current tax account st january exchange adjustment charge year cash pay transfer tofrom defer tax movement st december movement defer tax asset liability pension manu share accelerate intra post legal facture stock option net offset defer taxation capital group retirement tax restruct valuation award temporary allowance intangible profit benefit loss dispute ure adjustment scheme difference country total assetliability defer tax asset st january defer tax liability st january st january exchange adjustments chargecredit income statement creditcharge equity transfer tofrom current tax acquisition st december defer tax asset st december defer tax liability st december defer tax charge income relate change tax rate million defer tax movement arise origination reversal temporary difference net temporary difference include accrue expense provision gsk annual report financial statement note financial statement continue taxation continue st december group recognise defer tax asset million million respect income tax loss approximately million million loss million million expire million million expire million million available indefinitely st december group recognise defer tax asset respect income tax loss approximately million million million million expire million million expire million million available indefinitely group capital loss st december approximately billion respect defer tax asset recognise defer tax asset recognise probable future taxable profit available utilise loss earning share pence pence pence basic earning share adjustment major restructuring result major restructure earning share basic diluted earning share adjustment major restructuring result major restructure earning share dilute basic adjust earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share adjust earning share calculate result major restructure earning calculation result major restructuring describe note presentation financial statement dilute earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option dilute share hold esop trust exclude trustee waive right dividend share hold esop trustsgsk annual report financial statement note financial statement continue dividend interim second interim interim fourth interim total total dividend dividend share penny paidpayable th july th october th january th april total dividend dividend share penny pay th july th october th january th april total dividend dividend share penny pay th july th october th january th april ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder property plant equipment plant land equipment asset building vehicle construction total cost st january exchange adjustment addition addition business combination disposals writeoff reclassification transfer asset hold sale cost st december exchange adjustment addition addition business combination disposals writeoff reclassification transfer asset hold sale cost st december gsk annual report financial statement note financial statement continue property plant equipment continue plant land equipment asset building vehicle construction total depreciation st january exchange adjustment provision year disposal writeoff transfer asset hold sale depreciation st december exchange adjustment provision year disposal writeoff transfer asset hold sale depreciation st december impairment st january exchange adjustment disposal writeoff impairment loss reversal impairment impairment st december exchange adjustment disposal writeoff impairment loss reclassification reversal impairment impairment st december total depreciation impairment st december total depreciation impairment st december net book value st january net book value st december net book value st december net book value st december group land building comprise freehold property million million property lease year million million property lease year million million include land building st december lease asset cost million million accumulate depreciation million million impairment million nil net book value million million include plant equipment vehicle st december lease asset cost million million accumulate depreciation million million net book value million st january million lease agreement include renewal purchase option escalation clausesgsk annual report financial statement note financial statement continue property plant equipment continue impairment loss principally arise decision rationalise facility calculate base fair value cost sell value use value use calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate country specific risk impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately impairment loss charge cost sale million rd million sga million include million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale goodwill cost st january exchange adjustment addition business combination impairment cost st december net book value st january net book value st december addition year translate acquisition exchange rate comprise million acquisition sirtris pharmaceuticals inc million acquisition bms egypt business note acquisition disposal detail carry value goodwill translate yearend exchange rate balance arise acquisition follow company cash generating unit reliant pharmaceuticals inc pharmaceuticals d biomedical corporation vaccine sirtris pharmaceuticals inc worldwide pharmaceuticals glaxosmithkline kk japan pharmaceuticals domantis limit worldwide pharmaceuticals cns inc consumer healthcare polfa poznan sa poland pharmaceuticals bms egypt emerge market pharmaceutical corixa corporation vaccine gsk annual report financial statement note financial statement continue goodwill continue goodwill allocate cash generating unit test impairment annually valuation worldwide pharmaceutical cash generating unit sirtris pharmaceutical domantis pharmaceutical cash generating unit reliant pharmaceutical prepare fair value cost sell basis turnover earning multiple derive observed market datum case value goodwill inherent cash generating unit considerably excess book value acquire goodwill recoverable amount cash generating unit assess value use fair value cost sell model value use calculate net present value project riskadjuste posttax cash flow plus terminal value cash generating unit goodwill allocate initially posttax discount rate apply calculate net present value posttax cash flow posttax discount rate base group wacc cash generating unit integrate operation large part group discount rate increase specific country risk sufficiently significant material impact outcome impairment test group wacc equivalent pretax discount rate approximately impairment test indicate recoverable value unit close carrying value reperforme pretax discount rate pretax cash flow order determine impairment exist establish magnitude fair value calculate similar discount cash flow approach base group acquisition valuation model posttax discount rate apply project riskadjuste posttax cash flow terminal value detail relate discount cash flow model impairment test significant goodwill balance follow vaccines cgu japan pharmaceuticals cgu consumer healthcare cgu poland pharmaceuticals cgu d biomedical glaxosmithkline kk cns polfa poznan valuation basis fair value cost sell fair value cost sell fair value cost sell value use key assumption sale growth rate sale growth rate sale growth rate sale growth rate profit margin profit margin advertising profit margin discount rate discount rate promotion investment discount rate terminal growth rate determination growth rate internal growth rate internal growth rate internal growth rate internal assumption forecast base forecast base forecast base forecast base internal external internal external internal external internal external market information market information market information market information margin reflect past margin reflect past advertising promotion margin reflect past experience adjust experience adjust investment base experience adjust expect change expect change historical level adjust expect change discount rate base discount rate base management view discount rate base group wacc group wacc support need group wacc innovation expansion terminal growth rate base management estimate future long term average growth rate period specific year year year year project cashflow discount rate terminal growth rate pa pa pa pa decline terminal growth rate exceed longterm project growth rate relevant market terminal growth rate value use calculation poland pharmaceutical cgu reflect impact future generic competition take account new product launch consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value million million detailed note intangible asset case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwillgsk annual report financial statement note financial statement continue intangible asset computer licence amortise indefinite life software patent etc brand brand total cost st january exchange adjustment capitalise internal development cost addition business combination addition disposal asset writeoff transfer asset hold sale cost st december exchange adjustment capitalise internal development cost addition business combination addition disposal asset writeoff reclassification cost st december amortisation st january exchange adjustment provision year disposal asset writeoff transfer asset hold sale amortisation st december exchange adjustment provision year disposal asset writeoff amortisation st december impairment st january exchange adjustment impairment loss disposal asset writeoff impairment st december exchange adjustment impairment loss impairment reversal impairment st december total amortisation impairment st december total amortisation impairment st december net book value st january net book value st december net book value st december gsk annual report financial statement note financial statement continue intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development addition business combination year million comprise million acquire acquisition sirtris pharmaceuticals million acquire acquisition bms egypt note acquisition disposal st december net book value include million arise acquisition reliant pharmaceuticals inc million arise acquisition d biomedical corporation include million million internally generate cost million million relate computer software million million relate compound development amortise brand include otc right relate alli book value st december million million indefinite life brand comprise portfolio consumer healthcare product acquire acquisition sterling winthrop inc block drug company inc cns inc book value major brand follow panadol sensodyne breathe right polident corega biotene poligrip solpadeine brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment apply fair value cost sell methodology generally year posttax cash flow forecast terminal value calculation discount rate equal group posttax weight average cost capital adjust appropriate countryspecific risk main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply management estimate future longterm average growth rate relevant market case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment brandsgsk annual report financial statement note financial statement continue investment associate joint venture joint associate joint associated venture undertaking total venture undertaking total st january exchange adjustment addition transfer investment fair value adjustment retain profitloss year st december principal associate undertaking quest diagnostic inc clinical laboratory business list new york stock exchange investment book value st december million million market value million million st december group own quest group hold ownership interest voting control quest group ability exercise significant influence significant shareholding nominate director active participation quest board director board subcommittee transfer investment relate group hold chemocentryx previously classify investment increase year summarise balance sheet information respect group associate set total asset quest diagnostic inc total liability quest diagnostic inc net asset group share associate net asset gsk hedge equity value hold quest diagnostic inc series variable sale forward contract contract equity collar renew structure series million quest share mature second series hedge contract additional million share enter th february contract structure series million quest share mature year contract hold lehman brothers finance sa respect total million quest share terminate material financial impact gsk investment joint venture comprise million share gross asset million million share gross liability million principally arise interest joint venture shionogiglaxosmithkline holding lp develop specify chemical compound glaxosmithkline shire canada primarily comarket combivir trizivir epivir certain territory interest joint venture pharmaceutical insurance limit mutual insurance company cover pharmaceutical property risk gsk annual report financial statement note financial statement continue investment st january exchange adjustment addition net fair value movement impairment transfer associate disposal st december investment comprise noncurrent equity investment availableforsale investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate reference current market value similar instrument reference discount cash flow underlie net asset equity investment record noncurrent asset expect sell year case record current asset group hold number equity investment entity group enter research collaboration investment include list investment million million offer group opportunity return dividend income fair value gain disposal investment fair value movement reclassify reserve income statement base average cost share acquire different time impairment loss record table recognise income statement year operate income amount recycle fair value reserve recognition impairment impairment initially result prolonged significant decline fair value equity investment acquisition cost subsequent decline fair value immediately take income statement st december impair assets fair value million million include investment transfer associate relate group hold chemocentryx increase year noncurrent asset amount recoverable insurance contract pension scheme surplus receivables inventory raw material consumable work progress finish good gsk annual report financial statement note financial statement continue trade receivable trade receivables prepay pension contribution prepayment accrue income interest receivable employee loan advance receivables trade receivable include million million associate joint venture bad doubtful debt provision st january exchange adjustment charge year subsequent recovery amount provide utilise st december cash cash equivalent cash bank hand shortterm deposit commercial paper asset hold sale land building plant equipment vehicle gsk annual report financial statement note financial statement continue trade payable trade payable wage salary social security payable defer income customer return rebate accrual accrual customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer principally usa provision time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome amount subject change dependent thing type buy group product sale mix level provision review adjust quarterly light historical experience actual rebate discount allowance give return change arrangement future event cause assumption provision base change affect future result group pension postemployment benefit pension postemployment cost uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme postemployment cost cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service hybrid define benefit scheme include define contribution sectionsgsk annual report financial statement note financial statement continue pension postemployment benefit continue pension cost define benefit scheme accounting purpose calculate project unit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year actuarial movement year recognise statement recognise income expense uk discount rate derive aa rate corporate bond yield intend reflect term expect benefit payment expect rate return bond reflect portfolio mix indexlinke government corporate bond equity risk premium add long term government bond yield expect rate return equity project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt uk mortality rate determine adjust pa standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line medium cohort ie improvement recently observe high level assume continue minimum improvement year male females usa mortality rate calculate rp fully generational table project scale aa white collar adjustment mortality assumption uk scheme review update gsk expect review average life expectancy assume individual age project apply individual age follow uk usa male female male female year year year year current project asset fund scheme generally hold separately administer trust insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment follow asset liability study group decide adopt strategy reduce gradually allocation investment equity uk propose strategy link funding level scheme consider trustee uk scheme target allocation equity property scheme reduce total uk define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent uk employee entitle join define contribution scheme usa glaxo wellcome smithkline beecham define benefit scheme merge addition group operate number postretirement healthcare scheme principal usa group apply follow financial assumption assess define benefit liability uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earning discount rate expect pension increase na na na cash balance creditconversion rate na na na inflation rate gsk annual report financial statement note financial statement continue pension postemployment benefit continue amount record income statement statement recognise income expense year end st december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit uk usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial lossesgain record statement recognise income expense amount include settlement curtailment include million augmentation cost arise major restructuring programme note provision postretirement pension benefit uk usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial gain record statement recognise income expense postretirement pension benefit uk usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial gain record statement recognise income expense total actuarial loss record statement recognise income expense st january milliongsk annual report financial statement note financial statement continue pension postemployment benefit continue fair value asset liability uk define benefit pension scheme aggregate datum define benefit pension scheme group follow uk usa rest world group average expect rate fair expect rate fair expect rate fair fair st december return value return value return value value equitie property bond asset fair value asset present value scheme obligation unrecognise past service cost restriction surplus recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset uk usa rest world group average expect rate fair expect rate fair expect rate fair fair st december return value return value return value value equitie property bond asset fair value asset present value scheme obligation include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report financial statement note financial statement continue pension postemployment benefit continue uk usa rest world group average expect rate fair expect rate fair expect rate fair fair st december return value return value return value value equitie property bond asset fair value asset present value scheme obligation include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report financial statement note financial statement continue pension postemployment benefit continue postretirement pension benefit movement define benefit obligation uk usa rest world group group obligation st january exchange adjustment service cost interest cost settlement curtailment actuarial lossesgain scheme participant contribution benefit pay obligation st december exchange adjustment service cost interest cost settlement curtailment actuarial gain scheme participant contribution benefit pay transfer provision recognise balance sheet st december unrecognise past service cost obligation st december exchange adjustment service cost interest cost settlement curtailment actuarial gain scheme participant contribution benefit pay transfer obligation st december unrecognise past service cost recognise balance sheet st december uk define benefit scheme include define contribution section obligation total million st december million million liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation reduce year postretirement healthcare scheme amend main change increase cap company cost st december plan obligation million million million accordance ias unvested benefit improvement recognise immediately balance sheet recognise gradually income statement st december unrecognised million primarily relate effect change postretirement scheme st december past service cost recognise scheme amount million gsk annual report financial statement note financial statement continue pension postemployment benefit continue define benefit pension obligation analyse follow fund unfunded postretirement benefit unfunded postretirement pension benefit movement fair value asset uk usa rest world group group assets st january exchange adjustment expect return asset settlement curtailment actuarial gain employer contribution scheme participant contribution benefit pay asset st december exchange adjustment expect return asset settlement curtailment actuarial gain employer contribution scheme participant contribution benefit pay asset st december exchange adjustment expect return asset settlement curtailment actuarial loss employer contribution scheme participant contribution benefit pay asset st december uk define benefit scheme include define contribution section account balance total million st december million million group special funding contribution uk pension scheme total million million uk pension scheme million relate prepayment contribution gsk formalise agreement trustee uk define benefit pension scheme additional contribution year addition normal contribution fouryear period end st december order eliminate pension deficit fund scheme ias basis gsk commit eliminate future deficit arise rolling fiveyear period agreement review employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefitsgsk annual report financial statement note financial statement continue pension postemployment benefit continue postretirement pension benefit history experience gain loss uk usa rest world group group experience loss scheme asset percentage scheme asset st december experience lossesgain scheme liability percentage scheme obligation st december fair value asset present value scheme obligation deficit scheme experience gainslosse scheme asset percentage scheme asset st december experience gainslosse scheme liability percentage scheme obligation st december fair value asset present value scheme obligation deficitssurpluse scheme experience gain scheme asset percentage scheme asset st december experience lossesgain scheme liability percentage scheme obligation st december fair value asset present value scheme obligation deficitssurpluse scheme experience gain scheme asset percentage scheme asset st december experience loss scheme liability percentage scheme obligation st december fair value asset present value scheme obligation deficit scheme experience gain scheme asset percentage scheme asset st december experience lossesgain scheme liability percentage scheme obligation st december fair value asset present value scheme obligation deficit scheme gsk annual report financial statement note financial statement continue pension postemployment benefit continue sensitivity analysis effect change assumption annual define benefit pension postretirement cost benefit obligation decrease discount rate follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation year increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation decrease expect rate return asset follow approximate effect increase annual pension cost increase rate future healthcare inflation follow approximate effect increase annual postretirement benefit cost increase postretirement benefit obligation increase inflation follow approximate effect increase annual pension cost increase pension obligation provision integration legal major employee restructuring relate manufacturing dispute programme provision reorganisation provision total st january exchange adjustment charge year reverse unused unwind discount utilise transfer pension obligation reclassification movement st december settle year settle year st december gsk annual report financial statement note financial statement continue provision continue provision staff severance payment management formal decision eliminate certain legal dispute position communicate group gsk involve number legal dispute include employee affect provision staff severance notification possible claim set note legal payment immediately proceeding provision legal dispute include amount relate antitrust product liability contract approximately cost incur st december termination selfinsurance environmental cleanup property approximately expect incur rental company director take legal balance total specialist advice establish provision take approximately cost expect cash account insurance agreement regard expenditure expect accounting write relevant fact circumstance matter down uncertainty exist exact time accordance accounting requirement cash outflow result potential future exchange rate fluctuation element restructure charge year include charge million programme subject employee consultation procedure announce january relate investigation make difficult predict precision gsk market promotional practice originate procedure complete majority colorado discount provision decrease million remain cash payment expect million decrease calculate riskadjuste project cash flow riskfree rate return movement include decrease million arise addition cost million incur year change discount rate year number product restructuring programme relate integration history claim settlement make possible reliant pharmaceuticals inc business usa follow use ibnr incur report actuarial technique acquisition december determine reasonable estimate group exposure pension augmentation arise staff redundancie unasserted claim relation product apart million charge year ibnr provision provision unasserted transfer pension obligation provision show claim ultimate liability matter vary note pension postemployment benefit asset amount provide dependent outcome litigation writedown recognise impairment property proceeding investigation possible settlement negotiation plant equipment note property plant equipment nature group business number employee relate provision matter include provide ibnr actuarial technique employee relate provision include exchange offer incentive subject negotiation litigation year programme operate time merger encourage large individual amount provide expect settle staff convert glaxo wellcome smithkline beecham share year option glaxosmithkline share option incentive pay st december expect million employee exercise relevant option million provision legal option lapse impact discount dispute reimburse party insurer provision increase million include current noncurrent asset discussion calculate riskfree rate return group provide legal issue refer note legal proceeding certain medical benefit disabled employee spouse usa st december provision benefit major restructuring programme amount million employee benefit reflect variety october gsk announce significant new operational provision severance cost jubilee awards long excellence programme improve effectiveness service benefit productivity operation note major restructuring programme significant expansion operational integration manufacturing reorganisation excellence programme approve board group recognise cost previous year respect announce february total cost implementation plan integration glaxo wellcome smithkline expand programme expect beecham business implementation integration follow approximately billion incur period merger substantially complete cost recognise remain merger integration provision respect identify severance expect settle small costsaving initiative merger include category gsk annual report financial statement note financial statement continue noncurrent liability accrual defer income payable contingent liability st december contingent liability comprise guarantee discount bill item arise normal course business amount million million st december million million financial asset pledge collateral contingent liability discussion tax legal issue refer note taxation note legal proceeding net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange commercial paper bank loan overdraft loan obligation finance lease longterm borrowing european medium term note london stock exchange float rate note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange loan stock bank loan loan private financing obligation finance lease net debt gsk annual report financial statement note financial statement continue net debt continue current asset liquid investment classify availableforsale investment st december include government bond treasury note effective interest rate liquid investment st december approximately approximately liquid investment balance st december earn interest float fix rate million million respectively million million effective interest rate cash cash equivalent st december approximately approximately cash cash equivalent balance st december earn interest float fix rate million million respectively million million gsk tighten criterion hold cash equivalent liquid investment response credit crisis gsk policy credit quality cash cash equivalent refer note financial instrument relate disclosure shortterm borrowing commercial paper comprise billion programme nil nil issue st december billion billion back commit facility day duration billion billion billion billion renewable annually liquid investment cash cash equivalent show table weight average interest rate current bank loan overdraft st december longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year longterm borrowing repayable year carry interest effective rate repayment date range average effective interest rate note st december approximately approximately secure liability gsk loan secure charge noncurrent current asset year nil group pledge investment treasury note par value million million security irrevocable letter credit issue group behalf respect group selfinsurance activity provision respect selfinsurance include provision legal dispute discuss note provision finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation finance lease obligation st december bear interest float fix rate million million respectively million million gsk annual report financial statement note financial statement continue share capital share premium account share ordinary share p premium number share capital authorise st december st december st december share capital issue fully pay st december issue share option scheme st december issue share option scheme share capital purchase cancel st december issue share option scheme share capital purchase cancel st december st december st december number share issuable outstanding option note number unissue share option st december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme share capital purchase cancel include cancellation million previously acquire treasury share total billion spend company st january st december buying share cancellation hold treasury share billion spend repurchase total billion repurchase current billion share buy programme purchase st december programme gsk expect significant share repurchase table set monthly purchase share buyback programme average share price exclude number share commission stamp duty month january february march april june july august september october november december total share purchase cancel detail substantial shareholding refer substantial shareholding gsk annual report financial statement note financial statement continue movement equity shareholder equity share share retain minority total total capital premium earning reserve interest equity st january recognise income expense year change minority shareholding distribution minority shareholder dividend shareholder ordinary share issue ordinary share purchase held treasury share ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax share base incentive plan st december recognise income expense year distribution minority shareholder dividend shareholder ordinary share issue ordinary share purchase cancel ordinary share purchase held treasury share ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan st december recognise income expense year distribution minority shareholder dividend shareholder ordinary share issue ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan st december gsk annual report financial statement note financial statement continue movement equity continue retain earning reserve amount million st december million million million million million relate joint venture associate undertaking cumulative translation exchange equity show follow table net translation exchange include total fair value retain minority translation reserve earning interest exchange st january exchange movement overseas net asset st december exchange movement overseas net asset st december exchange movement overseas net asset recycle exchange liquidation overseas subsidiary st december analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserve total st january transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share transfer esop trust writedown share hold esop trust st december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust st december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust st december reserve consist nondistributable merger premerger reserve amount million st december million million reserve include capital redemption reserve create result share buyback programme amount million st december million milliongsk annual report financial statement note financial statement continue related party transaction gsk hold interest quest diagnostics inc st december group quest diagnostic party longterm contractual relationship quest diagnostic primary provider clinical laboratory testing support group clinical trial testing requirement worldwide quest diagnostic provide service million million group st december balance payable gsk quest diagnostic nil million group shionogi co ltd enter transaction joint venture company support research development activity conduct joint venture company gsk provide service joint venture million million st december balance gsk joint venture million million dr shapiro nonexecutive director glaxosmithkline plc receive fee form ad subsidiary company membership group scientific advisory board fee include annual remuneration remuneration report aggregate compensation director cet company secretary give note employee cost adjustment reconcile profit tax operating cash flow profit tax tax profit share tax profit associate joint venture finance incomecost depreciation amortisation intangible asset impairment asset write profit sale intangible asset profit sale equity investment change work capital increase inventory decreaseincrease trade receivables decreaseincrease receivables decreaseincrease trade payable decreaseincrease payable increasedecrease pension provision sharebase incentive plan cash generate operation result reclassification cash generate operation million million low give gsk unaudite preliminary result announcement issue th february addition decrease liquid investment year reclassify financing activity invest activity comparative amount reclassify gsk annual report financial statement note financial statement continue reconciliation net cash flow movement net debt net debt begin year increasedecrease cash bank overdraft cash inflowoutflow liquid investment net increase longterm loan net repayment ofincrease shortterm loan net repayment obligation finance lease exchange adjustment noncash movement movement net debt net debt end year analysis change net debt exchange acquisition cash flow liquid investment cash cash equivalent overdraft debt year commercial paper eurobond mediumterm note debt year eurobond mediumterm note private financing net debt information significant change net debt note net debt acquisition disposal detail acquisition disposal subsidiary associate undertaking joint venture business give acquisition sirtris pharmaceuticals inc th june group acquire issue share capital sirtris pharmaceuticals inc biopharmaceutical company base massachusetts usa cash consideration million company focus discover develop proprietary orally available small molecule drug potential treat disease associate ageing include metabolic disease type diabete sirtris drug candidate design mimic certain beneficial health effect calorie restriction activation sirtuin recently discover class enzyme sirtris believe control ageing process transaction account purchase method accounting goodwill arise acquisition reflect potential enable gsk enhance metabolic neurology immunoinflammation research effort establish worldleading presence sirtuin field aid existence company highly experienced development team encompass aspect sirtuin biology sirtris pharmaceuticals inc turnover nil loss tax million year nil turnover million loss tax relate period acquisition include group accountsgsk annual report financial statement note financial statement continue acquisition disposal continue book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration bristol myers squibb egypt th october group acquire egyptian mature product business bristol myers squibb bms cash consideration million million defer payment alternative supply arrangement establish group acquire brand product occupy lead market position therapeutic disease area egypt include duricef antibiotic capozide capoten ace inhibitor theragranh iron supplement kenacomb topical steroid total sale combine mature product pharmaceutical business million group ownership bmss high quality manufacturing facility giza great cairo continue supply acquire product group ability export generic version acquire product market outside egypt create opportunity drive sale growth middle east north africa region fact reflect goodwill arise acquisition business turnover million profit tax million year million turnover million profit tax relate period acquisition include group account fair value set base provisional valuation subject change future book fair value fair value adjustment value net asset acquire intangible asset property plant equipment inventory goodwill total consideration sirtris bms egypt acquire beginning year combine group turnover year million combine group profit year million shionogi euclid sr glaxosmithkline cash flow sirtris bms egypt partner lp holdings ltd total cash consideration cash cash equivalent acquire net cash payment acquisition euclid sr partner lp additional million invest euclid sr partner lp associate group share shionogiglaxosmithkline holdings ltd additional million invest shionogiglaxosmithkline holdings ltd joint venture group share gsk annual report financial statement note financial statement continue acquisition disposal continue acquisition reliant pharmaceuticals inc th december group acquire issue share capital reliant pharmaceuticals inc pharmaceutical company base usa cash consideration million company specialise development marketing speciality medicine combat heart disease include right lovaza treatment adult patient high level triglyceride transaction account purchase method accounting goodwill arise acquisition reflect potential product growth usa puerto rico expect synergies group reliant pharmaceuticals inc turnover million profit tax million year million turnover million profit tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration domantis limit th january group acquire issue share capital domantis limited drug discovery company base uk cash consideration million company develop generation antibody therapy transaction account purchase method accounting goodwill arise acquisition reflect potential combine worldleading technology domantis development programme place gsk group forefront biotechnology domantis limited turnover nil loss tax million year nil turnover million loss tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration gsk annual report financial statement note financial statement continue acquisition disposal continue praecis pharmaceuticals inc th february group acquire issue share capital praecis pharmaceuticals inc biopharmaceutical company base usa cash consideration million company develop efficient method identify drug lead target human disease proprietary technology transaction account purchase method accounting praecis pharmaceuticals inc turnover nil loss tax million year nil turnover million loss tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax asset liability goodwill total consideration reliant domantis praecis total cash flow cash consideration cash cash equivalent acquire net cash payment acquisition reliant domantis praecis acquire beginning year combine group turnover year million combine group profit year million acquisition cns inc th december group acquire issue share capital cns inc consumer healthcare company base usa cash consideration million company market breathe right nasal dilator strip fiberchoice dietary fibre supplement key intangible asset acquire value discount cash flow calculation transaction account purchase method accounting goodwill arise acquisition reflect potential expansion brand overseas market expect synergies group cns inc turnover million million profit million profit million million turnover nil profit relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration gsk annual report financial statement note financial statement continue acquisition disposal continue euclid sr partner lp additional million invest euclid sr partner lp associate group share shionogiglaxosmithkline holdings ltd additional million invest shionogi glaxosmithkline holdings ltd joint venture group share pliva research institute ltd group purchase entire share capital pliva research institute ltd cash consideration million million defer payment phase clinical trial initiate glaxosmithkline kk august japanese subsidiary group cash payment million complete purchase remain share capital hold minority shareholder payment precede year dividend minority shareholder million represent additional consideration shionogi pliva euclid sr glaxosmithkline research glaxosmith cns partner lp holdings ltd institute kline kk total cash flow cash consideration cash cash equivalent acquire net cash payment acquisition net cash proceed disposal commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment business combination pension commitment interest loan finance lease charge commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount majority intangible commitment denominate dollar significant strengthen foreign currency year lead increase commitment report number commitment licensing agreement include arrangement actelion pharmaceutical limited archemix corporation dynavax technologies corporation mpex pharmaceuticals inc commitment relate business combination reflect agreement acquire issue share capital genelabs technologies inc bristol myers squibb pakistan private limited az tika snc subject clearance swedish competition authority gsk formalise agreement trustee uk pension scheme additional contribution addition normal contribution fouryear period end st december order eliminate fund pension deficit ias basis point table show commitment net million additional contribution exclude normal ongoing annual funding requirement approximately million gsk commit eliminate future deficit arise rolling fiveyear periodgsk annual report financial statement note financial statement continue commitment continue group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap commitment noncancellable operating lease rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total commitment noncancellable operating lease post balance sheet event rd january gsk acquire ucbs market product portfolio certain territory africa middle east asia pacific latin america million th february synta pharmaceuticals corp announce follow identification safety concern stop phase iii study elesclomol compound develop jointly gsk gsk intangible asset include million relate milestone pay synta pharmaceutical relation compound likely impair possible determine final impairment pende completion analyse datum subsequent yearend gsk complete business product acquisition genelabs bms pakistan collaboration agreement archemix idenix gsk annual report financial statement nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss continued financial instrument relate disclosure sell margin sufficient cover normal operating cost operation cash generative glaxosmithkline plc report sterling pay dividend sterling profit role corporate treasury manage operate cash flow fund investment research monitor external internal funding requirement development new product financial risk support corporate objective routine outflow capital expenditure tax dividend treasury activity govern policy procedure repayment mature debt extent determine approve board director recently th board share repurchase september policy borrow centrally variety capital treasury management group tmg chair chief financial market issue borrow facility meet anticipate officer meet monthly basis review treasury activity funding requirement member receive management information relate treasury borrowing cash generate activity internal auditor review treasury internal control operation onlent fund ongoing environment regularly operation acquisition strategy gsk use variety financial instrument include total capital group increase derivative finance operation manage market million million result risk operation derivative principally comprise primarily increase net debt partially set forward foreign currency contract interest rate currency decrease total equity decrease total equity principally swap swap borrowing liquid asset arise actuarial loss define benefit pension plan currency require group purpose manage year share repurchase partially offset exposure funding risk change foreign exchange retain earning net debt primarily increase rate interest rate issuance billion debt shelf registration gsk hold issue derivative financial instrument statement million emtn programme speculative purpose treasury policy specifically primarily long term debt proceed prohibit activity transaction financial instrument repay mature shortterm debt result overall increase undertaken manage risk arise underlie cash position st december business activity speculation liquidity risk capital management manage net borrowing requirement manage capital ensure entity group portfolio longterm borrowing include bond able operate go concern optimise return shortterm finance billion commercial shareholder appropriate balance debt paper programme equity board review group dividend policy year commit undrawn bank facility funding requirement annually reduce billion billion consequence capital structure group consist net debt acquisition abn amro collapse lehman brothers note net debt shareholder equity note facility renew october consider movement equity level commit facility adequate give current cash holding recent change financial market expect investment opportunity arise allow group european medium term note programme invest support strategic priority ensure billion st december billion sufficient flexibility advantage opportunity note issue programme shelf currently expect significant share repurchase registration statement st december investment opportunity continue assess billion billion note issue programme strict financial criterion tmg monitor cash flow forecast monthly basis operation global primarily subsidiary longterm borrowing mature date company establish market trade longterm debt rating remain stable significant level patent protection pharmaceutical february currently rate stable outlook product compete largely product efficacy standard poor negative outlook moodys pricegsk annual report financial statement note financial statement continue financial instrument relate disclosure gsk great concentration credit risk billion continue billion invest treasury treasuryrepo money market fund bear credit exposure shortterm debt rating p standard government detail group total poor moodys respectively commit financial asset facility substantial cash liquid investment treasuryrelate credit risk amount billion st december benefit strong positive cash flow operating unit credit risk increase global credit crisis report relationship bank credit rating present market risk annually tmg approval interest rate risk management policy interest rate risk management require aggregate credit risk respect financial instrument minimum net borrowing fix rate increase group counterparty limited reference ratio forecast interest payable trading profit longterm credit rating assign counterparty fix float ratio review monthly tmg moodys standard poor table set credit rating counterpartie liquid investment cash use interest rate swap redenominate cash equivalent derivative external borrowing interest rate coupon require gsk duration swap match duration ccreredditi tr raatitningg fc coouunnteterprpaartryty principal instrument interest rate derivative instrument aaaaaa aaaa aaaa aaaa aa aa total account fair value cash flow hedge relevant bank balance asset liability deposit foreign exchange risk management treasury foreign currency transaction exposure arise internal treasury repo external trade flow hedge exposure overseas money operating subsidiary transaction risk minimise market fund match local currency income local currency cost corporate debt purpose internal trading transaction match instrument centrally manage intercompany payment term government security reduce risk exceptional foreign currency cash flow hedge rd party financial selectively management corporate treasury derivative manage shortterm cash surplus borrow total requirement subsidiary company centrally forward contract hedge future repayment ccrreeddiitt rraattiinngg ooff ccoouunntteerrppaarrttyy originate currency aaaaaaaaaa aaaa aaaa aa aa total seek denominate borrowing currency bank balance principal asset cash flow primarily deposit denominate dollar euro sterle certain treasury borrowing swap currency require treasury repo money borrowing denominate swap foreign market fund currency match investment overseas group assets corporate debt treat hedge relevant asset forward instrument contract major currency reduce government exposure investment overseas group asset net security investment hedge section note detail rd party financial tmg review ratio borrowing asset major derivative currency monthly total credit risk credit rating table assign group consider maximum credit risk moodys investor service standard poor respectively million million total global associate opinion group financial asset exception rating agency differ gsk assign low rating investment bear credit risk counterparty gsk annual report financial statement nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd financial instrument relate disclosure cash cash equivalent approximate continued carry liquid investment base quote market price centrally manage cash reserve amount billion case marketable security base principal amount st december available month case nonmarketable security short group invest centrally manage liquid asset bank deposit reprice period treasuryonly money market fund credit rating aaa aaa standard poorsmoodys investor service short investment investment trade active market term corporate debt instrument minimum shortterm determine reference relevant stock exchange quote credit rating ap bank deposit bid price investment determine reference current market value similar instrument reference global counterparty limit assign gsk discount cash flow underlie net asset banking investment counterpartie base longterm shortterm loan overdraft approximate credit rating moodys standard poor corporate carrying short maturity treasury usage limit monitor daily instrument corporate compliance officer cco independent corporate treasury breach limit report longterm loan base quote market price cfo immediately cco monitor credit rating case eurobond fix rate borrowing counterpartie change rating occur approximate carry case float notifie corporate treasury appropriate amendment rate bank loan loan limit forward exchange contract base market datum wholesale retail credit risk exchange rate balance sheet date usa line pharmaceutical company currency swap base market datum balance group sell product small number wholesaler sheet date addition hospital pharmacie physician interest rate swap base net present value group sale large wholesaler discount cash flow approximately group pharmaceutical sale receivables payable approximate st december group trade receivable carrying wholesaler total million lease obligation approximate carry million group expose concentration credit risk respect wholesaler fair value investment gsk share encounter financial difficulty materially st december esop trust held gsk share adversely affect group financial result carry value million million group credit risk monitoring activity relate fair value million million base wholesaler include review quarterly financial quote market price share represent purchase information standard poor credit rating development esop trust satisfy future exercise option award gsk internal risk rating establishment periodic employee incentive scheme carry value review credit limit group believe low cost expect proceed share credit risk provision require excess normal recognise deduction reserve provision bad doubtful debt note trade st december gsk hold treasury share cost receivable outside usa customer account million million trade receivable balance deduct retain earning fair value financial asset liability commit facility table present carry amount group commit facility commercial fair value group financial asset liability paper programme billion billion billion st december st december billion day duration renewable annually st december undrawn commit facility total fair value financial asset liability include billion billion billion billion instrument exchange current transaction willing party force liquidation sale follow method assumption estimate fair valuesgsk annual report financial statement note financial statement continue financial instrument relate disclosure continue carry fair carry fair value value value value cash cash equivalent availableforsale investment liquid investment redeemable share government bond total liquid investment investment loan receivables trade receivables noncurrent asset scope ias heldfortrade financial asset derivative designate accounting hedge derivative total financial asset financial liability measure amortise cost borrowing bond designate hedge relationship bond commercial paper bank loan overdraft loan private financing obligation finance lease total borrowing trade payable noncurrent liability scope ias heldfortrade financial liability derivative designate accounting hedge derivative total financial liability net financial asset financial liability gsk annual report financial statement nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd financial instrument relate disclosure continue trade receivables noncurrent asset scope ias follow table reconcile trade receivables noncurrent asset fall scope ia relevant balance sheet amount asset include tax receivables pension surplus balance prepayment outside scope ias financial asset predominantly noninterest earn trade receivables note noncurrent asset note analyse financial asset scope ia asset follow table show age financial asset past provision bad doubtful debt raise past day past day past day past day past day amount past great day total million million balance million million relate receivable state hospital authority certain european country give profile customer include large wholesaler government back agency credit risk identify trade receivable past balance allowance trade payable noncurrent liability scope ias follow table reconcile trade payable noncurrent liability fall scope ia relevant balance sheet amount liability include payment account tax social security payable outside scope ia financial liability predominantly noninterest bear trade payable note noncurrent liability note analyse financial liability scope ias liabilities gsk annual report financial statement note financial statement continue financial instrument relate disclosure continue debt interest rate repricing table follow table set exposure group interest rate debt effect interest rate swap maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing obligation finance lease effect effect interest interest debt rate swap total debt rate swap total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest total interest bear noninterest bearing sensitivity analysis sensitivity analysis prepare assumption net debt ratio fix float interest rate debt derivative portfolio proportion financial instrument foreign currency constant basis hedge designation place st december financial instrument affect market risk include borrowing deposit derivative financial instrument follow analysis intend illustrate sensitivity financial instrument change relevant foreign exchange interest rate foreign exchange sensitivity table show group sensitivity foreign exchange rate dollar euro yen financial instrument exclude obligation finance lease certain nonderivative financial instrument net debt present material exposure currency major currency gsk financial instrument denominate gsk consider movement currency year conclude movement rate reasonable benchmark table financial instrument consider sensitive foreign exchange rate functional currency entity hold intercompany loan fully hedge maturity currency swap exclude analysis increasedecrease reduction increasedecrease reduction income equity income equity appreciation appreciation dollar appreciation appreciation euro appreciation appreciation yen depreciation state currency equal opposite effect movement income statement relate primarily hedge instrument dollar legal provision trade payable trade receivables whilst economic hedge provision financial instrument include table sensitivity hedge instrument insignificant provision include movement equity relate foreign exchange position hedge group asset denominate dollar euro yen depreciation currency swap rise correspond appreciation group asset foreign exchange sensitivity group asset financial instrument include gsk annual report financial statement nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd financial instrument relate disclosure continue interest rate sensitivity table show group sensitivity interest rate float rate sterling dollar euro financial instrument currency gsk historically issue debt hold investment gsk consider movement interest rate year conclude increase reasonable benchmark debt maturity year float rate calculation movement interest rate deem material effect equity increasedecrease increasedecrease income income increase increase sterling interest rate increase increase dollar interest rate increase increase euro interest rate decrease interest rate equal opposite effect exception dollar interest rate decrease currently maximum decrease income limit million interest rate movement obligation finance lease foreign currency interest rate derivative trade payable trade receivables financial instrument net debt present material exposure group balance sheet base increase decrease interest rate contractual cash flow nonderivative financial liability derivative instrument follow analysis anticipate contractual cash flow include interest payable group nonderivative financial liability undiscounte basis purpose table debt define class borrowing obligation finance lease interest calculate base debt hold st december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate st december finance charge trade obligation obligation interest finance finance payable st december debt debt lease lease net debt total year year year year year year great year gross contractual cash flow finance charge trade obligation obligation interest finance finance payable st december debt debt lease lease net debt total year year year year year year great year gross contractual cash flow gsk annual report financial statement note financial statement continue financial instrument relate disclosure continue follow table provide analysis anticipate contractual cash flow group derivative instrument exclude embed derivative equity option undiscounted cash flow cash flow foreign currency translate spot rate st december receivables payable receivables payable year year year year year great year gross contractual cash flow derivative financial instrument hedge programme follow table set principal amount fair value derivative hold gsk fair value fair value principal principal asset liability asset liabilitie cash flow hedge cross currency swap fair value hedge interest rate swap net investment hedge foreign exchange contract cross currency swap derivative designate accounting hedge foreign exchange contract equity relate instrument option warrant equity collar embed derivative derivative total derivative instrument analyse current noncurrent total gsk annual report financial statement nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd financial instrument relate disclosure employee share scheme continue group operate share option scheme derivative financial instrument option grant employee acquire share ad principal foreign exchange contract calculate glaxosmithkline plc grant price savingsrelate base outstanding position balance sheet date share option scheme share award scheme calculate net currency buysell position majority award grant employee acquire share ad contract period month glaxosmithkline plc cost subject achievement group specify performance target st december group hold outstanding foreign exchange contract consist primarily currency swap group operate share award scheme share value total fair value million million plan award grant employee acquire share represent hedge intercompany loan deposit ad glaxosmithkline plc cost year vest designate accounting hedge change fair value period grant restrict share award replace take profit loss period offset exchange gain grant option certain employee cost scheme loss relate intercompany lending borrowing readily equate potential gain cash flow hedge employee group enter cross currency swap designate grant share option scheme normally exercisable cash flow hedge convert fix euro interest euro debt year date grant grant group japanese subsidiary payable annually fix restricted share share award normally exercisable yen payment bond mature risk hedge end year vestingperformance period grant variability cash flow arise currency fluctuation savingsrelate share option scheme normally exercisable ineffectiveness assume hedge cash flow year save option share option scheme relate hedge expect occur year grant market price ruling date grant amount recognise equity recycle income accordance uk practice majority option statement offset exchange gain loss savingsrelate share option scheme grant price period underlie bond result revaluation market price ruling date grant share option balance sheet date award director effect grant cet subject performance criterion recognise equity cross currency interest rate swap million debit million credit recycle equity income statement cross currency interest rate swap offset exchange gain underlying bond recognise income statement million million net fair value movement cash flow hedge disclose consolidated statement recognise income expense fair value hedge group designate interest rate swap fair value hedge risk hedge variability fair value bond arise interest rate fluctuation gain loss fair value hedge disclose note finance cost net investment hedge foreign exchange contract designate net investment hedge respect foreign currency translation risk principally arise consolidation group net investment dollar euro yen foreign operation addition euro loan capital issue billion million previous year designate nonmonetary net investment hedge respect foreign currency translation risk principally arise consolidation group net investment euro operation net investment hedge ineffectiveness disclose note finance incomegsk annual report financial statement note financial statement continue employee share scheme continue option pricing purpose value option arrive stockbase compensation charge blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life option grant share option scheme year year year savingsrelate share option share award scheme year year year weight average share price grant year ordinary share ad volatility determine base year share price history appropriate fair value performance share plan grant account market condition expect life option determine base weighted average historic exercise option option outstanding share option share option savingsrelate scheme share scheme ad share option scheme weight weight weight weight weight weight number exercise fair number exercise fair number exercise fair price value price value price value st january option grant option exercise option lapse st december option grant option exercise option lapse st december option grant option exercise option lapse st december range exercise price weight average remain contractual life year year year gsk annual report financial statement nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd employee share scheme continue order encourage employee convert option exclude savingsrelate share option hold glaxo wellcome smithkline beecham share ad glaxosmithkline share ad programme establish additional cash benefit exercise price original option provide employee voluntarily leave group year date merger exercise option early month expiry date original option year date merger cash benefit pay option expire unexercised market price exercise price date expiry share option share option savingsrelate option outstanding scheme share scheme ad share option scheme st december weight late weight late weight late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option normally exercisable year date grant certain circumstance vest early set scheme rule change effective exercise price outstanding option year share option share option savingsrelate option exercisable scheme share scheme ad share option scheme st december weight weight weight number exercise number exercise number exercise price price price st december st december st december gsk annual report financial statement note financial statement continue employee share scheme continue glaxosmithkline share award scheme performance share plan group operate performance share plan award grant director senior executive cost percentage award vest base performance group year measurement period performance condition consist part apply award condition compare gsk tsr period tsr pharmaceutical company comparator group period second performance condition compare gsk earning share growth increase uk retail price index year performance period award grant director member cet subject single performance condition compare gsk tsr period tsr company comparator group period share weight ad weight number share ad issuable number fair value number fair value st january award grant award exercise award cancel st december award grant award exercise award cancel st december award grant award exercise award cancel st december share value plan group operate share value plan award grant form share certain employee cost award vest year performance criterion attach share weight ad weight number share ad issuable number fair value number fair value st january award grant award exercise award cancel st december award grant award exercise award cancel st december award grant award exercise award cancel st december gsk annual report financial statement nnootteess ttoo tthhee fifinnaanncciiaall ssttaatteemmeennttss ccoonnttiinnuueedd employee share scheme continue defer investment award plan group operate defer investment award plan award grant form notional share certain senior executive cost award typically vest threeyear period commence fourth anniversary date grant award initially vest subsequent year performance criterion attach share weight ad weight number share ad issuable number fair value number fair value st january award grant award exercise award cancel st december award grant award exercise award cancel st december award grant award exercise award cancel st december employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share open market finance provide group way loan contribution cost run esop trust charge income statement share hold esop trust deduct reserve hold value proceed receivable employee exercise deem permanent diminution value reflect transfer retain earning trust acquire hold share meet notional dividend reinveste deferred award smithkline beecham midterm incentive plan trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value gsk annual report financial statement note financial statement continue principal group company follow represent principal subsidiary associated undertakings glaxosmithkline group st december detail give principal country operation location headquarters business segment business activity equity share capital undertaking wholly own group percentage interest show company incorporate principal country operation state europe location subsidiary segment activity england brentford glaxosmithkline holdings limited phch h brentford glaxosmithkline holding limited phch h brentford glaxosmithkline service unlimited phch brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc ph f brentford smithkline beecham plc phch e h p r brentford wellcome limited phch h greenford glaxo group limit ph h greenford glaxo operation uk limit ph p brentford glaxo wellcome international bv phch h brentford glaxo wellcome investment bv phch h brentford glaxosmithkline export limit ph e brentford glaxosmithkline research development limit ph r brentford glaxosmithkline uk limit ph p brentford smithkline beecham investments limited phch f brentford setfirst limited phch h brentford setfirst limited phch h greenford wellcome foundation limit ph p cambridge domantis limit ph r brentford smithkline beecham overseas limit ph h brentford smithkline beecham holdings uk limit ph h brentford glaxosmithkline netherlands bv ph h austria vienna glaxosmithkline pharma gmbh ph belgium genval glaxosmithkline sa ph rixensart glaxosmithkline biological sa ph e p r czech republic prague glaxosmithkline sro phch denmark orestadt glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharma ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph r marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch st amand les eaux glaxosmithkline biological sas ph p germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h p r munich glaxosmithkline gmbh co kg ph h p r greece athens glaxosmithkline aebe phch hungary budapest glaxosmithkline medicine healthcare product limited phch e italy verona glaxosmithkline spa ph h r milan glaxosmithkline consumer healthcare spa ch h verona glaxosmithkline manufacturing spa ph p gsk annual report financial statement note financial statement continue principal group company continue europe location subsidiary segment activity luxembourg mamer glaxosmithkline international luxembourg sa phch f h netherlands zeist glaxosmithkline bv ph utrecht glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p poznan gsk service spz oo ph warsaw glaxosmithkline consumer healthcare spz oo ch e portugal alge glaxosmithklineprodutos farmaceuticos limitada ph republic carrigaline smithkline beecham cork limited ii ph p r ireland cork glaxosmithkline trading services limited ii ph e dublin glaxosmithkline consumer healthcare ireland limited ii ch dublin glaxosmithkline ireland limit ph russian moscow glaxosmithkline trading zao ph federation moscow glaxosmithkline healthcare zao ch spain madrid glaxosmithkline sa ph madrid glaxosmithkline consumer healthcare sa ch aranda de duero glaxo wellcome sa ph p sweden solna glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline ag ph usa usa hamilton corixa corporation ph p philadelphia smithkline beecham corporation phch e h p r pittsburgh cns inc ch pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch h liberty corner reliant pharmaceuticals inc ph r wilmington glaxosmithkline holdings americas inc phch h wilmington glaxosmithkline capital inc ph f wilmington sirtris pharmaceuticals inc ph r americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc ph p r oakville glaxosmithkline consumer healthcare inc ch laval d biomedical corporation ph h laval d biomedical corporation quebec ph p r asia pacific australia boronia glaxosmithkline australia pty ltd phch e p r china beijing glaxosmithkline china investment co ltd phch h hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd phch p r gsk annual report financial statement note financial statement continue principal group company continue asia pacific location subsidiary segment activity india mumbai glaxosmithkline pharmaceutical limit ph p nabha glaxosmithkline consumer healthcare limited iii ch p malaysia petale jaya glaxosmithkline pharmaceutical sdn bhd ph selangor glaxosmithkline consumer healthcare sdn bhd ch new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch p e philippines makati glaxosmithkline philippines inc phch singapore singapore glaxochem pte ltd ph h singapore glaxo wellcome manufacturing pte ltd ph h p r singapore glaxosmithkline pte ltd phch south korea seoul glaxosmithkline korea limited ph ch p thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline kk phch p latin america argentina buenos aires glaxosmithkline argentina sa phch e p brazil rio de janeiro glaxosmithkline brasil limitada phch e p colombia bogota glaxosmithkline colombia sa phch mexico delegacion tlalpan glaxosmithkline mexico sa de cv phch e p puerto rico guaynabo glaxosmithkline puerto rico inc ph venezuela caracas glaxosmithkline venezuela phch middle east africa egypt cairo glaxosmithkline sae ph p south africa bryanston glaxosmithkline south africa pty limited phch p turkey istanbul glaxosmithkline ilaclari sanayi ticaret ph p usa usa madison quest diagnostic incorporate iv clinical testing incorporate netherlands ii exempt provision section company amendment act ireland iii c onsolidate subsidiary undertaking accordance section company act ground dominant influence iv equity account ground significant influence directly hold wholly own subsidiary glaxosmithkline plc key business segment ph pharmaceutical ch consumer healthcare business activity development e export f finance h hold company insurance marketing p production r research service detail group subsidiary associate undertaking attach company annual return file registrar company glaxosmithkline capital inc glaxosmithkline capital plc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report financial statement note financial statement continue legal proceeding october group file complaint patent dispute chamber regional court dsseldorf germany group involve significant legal administrative neolab uk infringement german patent proceeding principally product liability intellectual property claim composition contain combination salmeterol tax antitrust governmental investigation related fluticasone propionate seretide know viani private litigation group make provision proceeding germany complaint base neolab state intention regular basis summarise note accounting principle letter market salmeterolfluticasone combination product policy note provision group germany event occur trial take place additional significant provision legal proceeding patent dispute chamber regional court dsseldorf require event development january neolab argue letter state matter consistent generally accept accounting principle propose intent sell future constitute basis litigation particularly usa inherently unpredictable infringement decision decision expect march excessive award occur justify january neolab file action invalidate evidence group future incur judgement combination patent federal court germany revocation enter settlement claim result payment action combination patent germany exceed current provision file mylan dura gmbh march hexal ag material adverse effect group financial condition result december trial date set action operation andor cash flow intellectual property claim basic patent cover combination product seretide expire include challenge validity enforceability group september subject supplementary protection patent product process assertion certificate extend protection september noninfringement patent loss case result loss patent protection product issue march group initiate infringement action consequence loss significant decrease federal court hague number internet sale product materially affect future result pharmacy organisation cipla limited operation group infringement group dutch combination patent relate seretide action hear th october legal expense incur provision relate legal claim decision date th november court find charge sell general administration cost provision infringement indicate see evidence bring take appropriate legal specialist advice patent validity question particular court note reasonable estimate likely outcome prior uk revocation decision correspond dispute group establish actuarially determined uk patent outdate reach provision product liability claim incur report interpretation law relate inventive step describe note provision st december long follow group aggregate provision legal dispute include tax matter describe note taxation revocation action basic patent cover seretide billion ultimate liability legal claim vary combination ireland file high court dublin amount provide depend outcome litigation behalf ivax july trial schedule begin proceeding investigation possible settlement negotiation march significant matter describe argatroban december encysive pharmaceuticals inc mitsubishi kasei intellectual property corporation group file action district court advairseretide southern district new york barr laboratories september group apply patent inc infringement mitsubishis pharmaceutical composition trademark office uspto reissue combination patent patent cover argatroban pursuant license mitsubishi advair inhale combination salmeterol fluticasone encysive develop argatroban treatment heparin propionate expire september uspto reissue induce thrombocytopenia hold new drug application patent february reissue patent approve fda encysive license marketing september expiration date original combination right argatroban group mitsubishi patent patent list register pharmaceutical patent expire june barr file abbreviate new drug maintain fda orange book application anda fda certification invalidity unenforceability noninfringement mitsubishi patent fda approval anda stay early resolution patent infringement action case discovery phasegsk annual report financial statement note financial statement continue legal proceeding continue august group file suit lupin district court district delaware infringement avodart combination patent group file suit lupin january group receive notice barr laboratories crystal form patent fda approval lupins anda file anda fda allegation invalidity stay early january resolution patent patent list orange book cover infringement action favourable lupin teva lupin active ingredient avodart use treat benign prostatic challenge compound patent claim lamivudine hyperplasia bph february smithkline beecham file active ingredient combivir patent expire action district court district delaware barr infringement patent basic compound coreg cr patent expire patent expire december group receive notice united research fda approval barrs anda stay early july laboratory incmutual pharmaceutical company inc file resolution patent infringement action case anda fda certification invalidity unenforceability discovery phase noninfringement patent cover crystalline salt form delay release technology manufacturing boniva product expire respectively february group participate marketing boniva pursuant group file suit crystal form patent copromotion agreement roche september roche alternative request court dismiss mutual certification laboratory commence action district court ineffective anda accept filing district new jersey generic drug manufacturer fda send certification april court case roche allege infringement roche patent relate dismiss case summary judgement mutual appeal boniva tablet defendant file anda court appeal federal circuit appeal fda certification invalidity unenforceability dismiss november noninfringement roche patent manufacturer challenge basic compound patent march fda accept mutual anda mutual expire final fda approval andas stay file second certification coreg cr allege group early november resolution relevant patent patent coreg cr invalid unenforceable infringe infringement action august roche obtain new group file suit april district court patent monthly dose regimen boniva bring suit eastern district pennsylvania crystal form patent anda filer challenge patent new patent covering use coreg cr treat congestive heart patent expire case ongoing failure october group file motion dismiss action give mutual covenant nottosue patent combivir mutual oppose dismissal case party await patent list orange book combivir include composition decision motion dismiss coreg cr grant matter tclamivudine combination lamivudine azt data exclusivity fda preclude approval generic lamivudine crystal form patent expire april respectively september group receive notice teva file anda fda allege paxilseroxat combination patent invalid usa number manufacturer distributor generic paxil file application fda market generic november group file action district court version prior expiration group patent district delaware teva pharmaceuticals paroxetine hyrdrochloride hemihydrate action infringement combination patent fda approval tevas remains pende action apotex anda stay early march resolution district court eastern district pennsylvania patents patent infringement action favourable teva case composition matter process manufacture claim discovery phase october teva file certification case discovery phase antitrust counterclaim group patent cover crystal form lamivudine invalid assert apotex discuss europe infringe group file suit patent generic product contain paroxetine hydrochloride july receive notice lupin pharmaceutical market european country litigation synthon file certification fda allege combination bv recently settle litigation fal ongoing patent invalid infringe product lupin file counterclaim unfair competition assert certification group patent cover crystal form group follow litigation canada apotex lamivudine invalid infringe patent relate paroxetine apotex launch generic product canada october gsk annual report financial statement note financial statement continue legal proceeding continue wellbutrin xl december biovail commence action district apotex allege result litigation court central district california anchen enjoin launch product receipt pharmaceutical district court southern regulatory approval action apotex recover damage district florida abrika pharmaceutical case relate delay occasion injunction ongoing allege infringement biovail formulation patent wellbutrin paxil cr xl april biovail file action district court patent covering delay control release formulation eastern district pennsylvania impax laboratory paroxetine hydrochloride paxil cr issue group infringement patent patent expire june list fda orange book anchen abrika impax file anda group file action district court district fda certification invalidity noninfringement new jersey mylan infringement newly issue biovail patent group licensee patent patent subsequently party reach settlement mylan august judge grant anchen motion rule enter market term anchen anda product infringe biovail patent biovail settlement agreement appeal decision cafc case remain appeal group party action requip xl september biovail commence action district january group receive letter impax court southern district new york watson laboratories inc actavis south atlantic llc indicate laboratory allege infringement biovail formulation andas requip xl accept fda patent watsons party counterclaim group letter include allegation patent license group base listing activity associate fda orange book skyepharma cover extend release formulation dismiss october mg generic product infringe product group bring suit launch usa december company march biovail announce comprehensive settlement treximet anchen impax watson teva follow voluntary october group receive letter par review federal trade commission certain aspect pharmaceutical fda accept anda treximet settlement remain confidential party disclose include certification patent own pozen define exception generic company inc relate treximet invalid unenforceable andor market mg strength wellbutrin xl infringe pozen patent license group november generic version mg tablet launch usa pozen file suit par patent district court eastern district texas november group receive letter alphapharm designate uspto action agent mylan pharmaceutical fda accept october group file action patent anda treximet include certification pozen trademark office district court eastern patent relate treximet invalid unenforceable andor district virginia enjoin permanently final regulation infringe pozen file suit alphapharm mylan january publish patent trademark office infringement patent district court limit number continuation patent application patent eastern district texas delaware treximet data claim patent applicant prosecute office exclusivity preclude approval generic product regulation effective april group party lawsuit st november bring pozen october court issue order preliminarily enjoin valtrex implementation rule hearing decision group commence action district party crossmotion summary judgement follow court district new jersey ranbaxy laboratory hear february court issue permanent injunction allege infringement group compound patent implementation uspto propose rule april valacyclovir active ingredient valtrex patent expire uspto appeal rule court appeal december ranbaxy file anda fda federal circuit cafc appeal hear cafc certification group compound patent invalid december party await decision unenforceable infringe case settle term permit ranbaxy enter market late take account expect paediatric exclusivity respect group compound patentgsk annual report financial statement note financial statement continue legal proceeding continue claim person take baycol injure risk future injury suffer economic product liability damage purchase baycol plaintiff seek preclinical clinical trial conduct remedy include compensatory punitive statutory damage development potential product determine safety creation fund medical monitoring efficacy product use human follow approval group bayer corporation principal subsidiary regulatory body notwithstanding effort drug bayer ag sign allocation agreement vaccine introduce marketplace unanticipated safety bayer corporation agree pay settlement issue evident group currently defendant compensatory damage judgement party retain number product liability lawsuit relate group responsibility attorney fee punitive damage pharmaceutical product significant matter federal case consolidate mdl proceeding describe district court district minnesota date avandia statewide class action certify medical monitoring new england journal medicine nejm case pennsylvania consumer fraud deceptive publish article avandia author base business practice act case illinois medical monitoring metaanalysis clinical trial raise concern use action dismiss court summary judgement drug rosiglitazone avandia associate increase certification consumer fraud case currently appeal risk heart attack cardiovascular death comparison illinois appellate court use placebo antidiabetic therapy follow nationwide class thirdparty payer certify publication nejm article group name pennsylvania state court case settle trial product liability lawsuit behalf individual purport class action gsk name defendant class action case assert consumer fraud andor personal injury certify oklahoma case decertifie claim behalf purchaser user avandia federal deadline appeal decertification order pass case multidistrict litigation mdl proceeding claim death injury pende district court eastern district settle thousand allege muscle ache pain pennsylvania case file state court case file voluntarily involuntarily dismiss philadelphia coordinate mass tort program matter discovery phase additionally purport paxil paxil cr nationwide class action suit file february group receive lawsuit claim allege use district court eastern district pennsylvania behalf paxil paroxetine pregnancy result birth party payer seek economic damage child birth defect health issue separately group state unfair trade practice consumer protection law receive lawsuit claim patient take paxil group process evaluate complaint commit attempt commit suicide andor act violence group receive lawsuit claim file behalf finally purport class action file israel patient allege suffer symptom discontinue briefing certify class action underway seven treatment paxil case file philadelphia class action pende canada early stage coordinate mass tort program september baycol label paxil update reflect new information august bayer ag withdraw baycol cerivastatin sodium suggest increase risk congenital malformation worldwide light report adverse event include death particularly cardiovascular malformation infant bear involve rhabdomyolysis group participate mother take paxil trimester pregnancy marketing baycol usa pursuant copromotion december paxil label update agreement bayer licence holder include new datum strengthen pregnancy warning manufacturer product follow withdrawal bayer category c category category indicate evidence group name defendant thousand lawsuit risk foetus potential benefit use file state federal court usa behalf drug pregnant woman outweigh risk individual putative class baycol user number suit allege plaintiff suffer personal injury include rhabdomyolsis use baycol gsk annual report financial statement note financial statement continue legal proceeding continue case purport class action determination case paxil label update include permit proceed class action number purport class warning concern persistent pulmonary hypertension class action jurisdiction withdraw newborn arise mother take selective serotonin reuptake dismiss plaintiff seek remedy include compensatory inhibitor ssri antidepressant th week pregnancy punitive statutory damage cost fund group receive purport class action litigation medical monitoring research canada date report limited number case group receive numerous claim lawsuit allege approach trial date vaccine manufacturer treatment paxil cause homicidal suicidal behaviour manufacturer thimerosal contain medicinal product exhibit user product class certification deny successful exclude testimony plaintiff expert january purport personal injury class action lawsuit witness causation specifically ground plaintiff case remain pende federal state court case file fail establish hypothesize link thimerosal philadelphia coordinate mass tort program neurodevelopmental disorder generally accept reliable january fda approve box warning relevant scientific community additionally february antidepressant increase risk suicidal thought behaviour office special masters united states court paediatric patient strengthen warning ssri federal claim reject approximately product include paxil class paxil label autism claim file national vaccine injury compensation update warn young adult especially program nvcip ground claimants fail produce major depressive disorder increase risk suicidal reliable scientific evidence link vaccination medical behaviour treatment paroxetine condition include autism august fda require update label antidepressant group party proceeding finding class state box warning antidepressant evidence pende lawsuit increase risk suicidal think behaviour child group nvicp claimant option adolescent young adult increase show appeal decision reject instead pursue age reduction risk adult age old personal injury lawsuit manufacturer vaccine depression psychiatric disorder administer remain approximately nvcip associate increase risk claimant ultimately option pursue personal group receive lawsuit file state federal court injury lawsuit vaccine manufacturer include usa canada behalf thousand plaintiff group early determine announcement include purport class action allege paroxetine nvcip decision likely lead increase number active ingredient paxil addictive cause dependency civil case file group date report withdrawal reaction federal case consolidate case schedule trial group mdl proceeding january conditional settlement defendant agreement effective group admit liability respect allegation lawsuit virtually sale marketing regulation action resolve california court appeal marketing promotion reverse dismissal class claim purport class action february group receive subpoena consumer fraud lawsuit focus discontinuation symptom attorney office colorado group sale case proceeding decision class certification promotional practice relate large selling product purport class action litigation canada group period january particular defend litigation commence uk government inquire allege promotion drug behalf hundred plaintiff allege paroxetine offlabel use groupsponsore continue medical cause suffer withdrawal reaction dependency education programme speaker event special issue board thimerosal advisory board speaker training programme clinical study group number pharmaceutical relate grant fee travel entertainment original company name defendant numerous subpoena issue attorney office colorado individual personal injury lawsuit state federal district scope inquiry nationwide court usa allege thimerosal preservative manufacture vaccine cause neurodevelopmental disorder injury include autismgsk annual report financial statement note financial statement continue legal proceeding continue number state respective attorney general county new york state file civil lawsuit government inquire group response state federal court gsk drug company october letter fdas division drug marketing claim damage restitution awp andor wac price advertising communication request information report pharmaceutical product cover states medicaid group allege promotion wellbutrin sr offlabel use programme state seek recovery behalf state payer group cooperate investigation provide case behalf instate patient consumer request information group separately resolve awp claim state medicaid february verona public prosecutor commence programme twothird state criminal investigation group sale marketing doj settlement separate negotiation litigation concern practice italy specific area investigation include medical awp issue continue state new education programme clinical study congresse york county july alabama state court jury return interaction group representative physician million verdict group case file public prosecutor propose number physicians state alabama group seek decision representative group face criminal charge reverse appeal alabama supreme court hear january public prosecutor nominal pricing agreement verona court dismiss charge group respond letter request remain defendant close case securities senate committee finance date april february exchange commission sec staff initiate investigation document information relate nominal allegation group cooperate investigation price exception good price reporting requirement receive request information sec medicaid drug rebate programme january committee release finding pharmaceutical follow united nations report allege bribe manufacturer inappropriately nominal price exception pay iraqi government official connection un oil contrary committee interpretation congressional intent food programme group receive subpoena group advise department sec february respect group participation justice investigate certain group nominal programme department justice initiate price bundle sale arrangement determine investigation december uk fraud office arrangement qualify exception good price issue formal notice group require production reporting requirement violate civil statute law march document relate group participation programme group receive broad letter request group cooperate investigation department justice seek range document relate provide document responsive subpoena notice group nominal pricing arrangement respond follow question request possible bundle sale group continue cooperate average wholesale price investigation produce document group united states department justice number state receive subpoenas request document information putative class private payer year delaware michigan relate group nominal price investigate andor bring civil litigation allegation arrangement group cooperate investigation numerous pharmaceutical company include gsk violate produce responsive document addition federal state fraud abuse law result way average governmental investigation allegation concern nominal wholesale price awp wholesale acquisition cost wac pricing certain government payer determine report drug reimburse awp litigation group enter nominal medicare medicaid insurance programme price arrangement december group reach million civil settlement federal government resolve allegation relate pricing marketing zofran kytril group amend exist corporate integrity agreement requirement settlement group receive final approval million nationwide private payer class action settlement relate group price report mdl proceed district court district massachusetts gsk annual report financial statement note financial statement continue legal proceeding continue october group announce plan cease operation b programme cidra site gsk expect continue production paxil cr site production transfer facility group defend action file federal court group currently expect place production district court northern district california product site discontinue end county santa clara county seek represent putative class hospital clinic entity california eligible receive discount ceiling price april fda complete general gmp inspection pharmaceutical federal programme know b result inspectional observation group programme plaintiff allege group numerous respond observation complete corrective pharmaceutical manufacturer set ceiling price action commitment higher allow law contract govern april group advise fda site complete programme overcharge entity corrective action plan group submit fda california eligible participate b programme september group continue provide fda lawsuit dismiss reinstate august quarterly report activity associate closure follow appeal actively litigate facility july group successfully complete final trial court level annual inspection site independent party paxilseroxat expert require consent decree follow group settlement lawsuit file new october federal government execute search york state attorney general office allege failure disclose warrant cidra facility seize record relate datum use paxil child adolescent similar case manufacture operation site purport class action file private plaintiff seek recover amount pay paxil purchase april group receive subpoena attorney use patient age minnesota court office boston request production record approve million class settlement ensue lawsuit manufacture cidra site cover information similar seeking recovery behalf insurance company seize government puerto rico subsequently thirdparty payer payment prescription paxil group receive additional subpoena government relate child adolescent group deny liability january cidra facility group cooperate attorney similar purport class action file canada seek office produce record responsive subpoena economic damage behalf individual party payer addition july group learn district court governmental entity purchase paxil use patient district massachusetts unseal complaint bring age group likewise deny liability employee federal false claim act claim monetary damage result allege failure cidra facility comply uk medicine healthcare product regulatory agency gmp manufacture product mhra complete investigation group pharmacovigilance report obligation relate clinical datum group name purport consumer fraud class seroxatpaxil child action take action lawsuit file california state court matter conclude district court district puerto rico allege paxil product manufacture accord gmp plaintiff seek cidra puerto rico manufacturing site economic statutory punitive damage request follow fda inspection october november injunctive relief summer group reach result observation possible deficiency tentative agreement settle matter subject court approval manufacturing practice group manufacture facility settlement cover nationwide class paxil cr consumer cidra puerto rico march fda seize certain lot purchaser party payer provide claim procedure paxil cr avandamet manufacturing issue fda class member receive payment splitdefective observation relate certain aspect production control paxil cr tablet process validation laboratory investigation april group reach agreement fda consent decree january group learn writ summon file consent decree provide independent expert review philadelphia court common plea group party manufacturing process site compliance fda good payer information belief action relate allege manufacturing practice gmp requirement provide paxil cr manufacturing issue cidra group currently consent decree september group provide report gain information filing relation fda deficiency identify review set class litigation corrective plan timetable completiongsk annual report financial statement note financial statement continue legal proceeding continue wellbutrin sr december january february lawsuit antitrust purport class action file paxilseroxat district court eastern district pennsylvania paroxetine patent infringement action bring group behalf direct indirect purchaser group describe intellectual property apotex wellbutrin sr complaint allege violation antitrust certain company file antitrust unfair competition law sham litigation fraud patent office counterclaim group district court group obtain enforce patent cover eastern district pennsylvania wellbutrin sr complaint follow introduction generic competition wellbutrin sr april district base allegation group monopolise appellate court ruling generic manufacturer market paxil bring allegedly sham patent litigation infringe group patent party involve discovery allegedly abuse regulatory procedure list group file motion summary judgement patent fda orange book whilst apotex matter remain pende remain discovery stage matter company resolve secondary wholesaler july rxusa wholesale inc secondary wholesaler november ftc staff advise group file suit group pharmaceutical conduct nonpublic investigation determine manufacturer wholesaler district court group violate section federal trade commission eastern district new york complaint allege act monopolise attempt monopolise defendant engage conspiracy refuse supply market paroxetine hydrochloride prevent generic pharmaceutical product rxusa violation federal competition paxil request group submit certain state antitrust law group motion dismiss complaint information connection investigation october remain pende ftc closed investigation basis finding action warrant follow public wellbutrin xl reference ftc investigation paxil number outgrowth intellectual property matter discuss governmental private civil action claim initiate respect wellbutrin xl action file usa matter exception biovail gsk purport class direct indirect reference apotex matter resolve purchaser allege unlawful monopolization anti trust violation relate enforcement biovail wellbutrin october competition directorate european xl patent file biovail citizen petition group commission initiate inspection concern allegation file motion dismiss remain pende group abuse dominant position marketplace concern enforcement intellectual property right litigation flonase surround regulatory approval marketing seroxat purport direct indirect purchaser class action europe october commission formal request file district court eastern district pennsylvania information group respond request allege group illegally maintain monopoly power end market flonase charge plaintiff supracompetitive price predicate allegation file january european commission announce inquiry group allegedly sham citizen petition subsequent certain aspect competition pharmaceutical sector litigation group file motion dismiss complaint initiate inspection premise number innovator purport class direct indirect purchaser generic pharmaceutical company include group discovery underway commission publish preliminary report november base information provide innovator generic pharmaceutical company report suggest defensive patenting strategy lead obstacle innovation innovator company employ measure hinder generic come market anticipate final report issue second quarter group continue cooperate commission investigation gsk annual report financial statement note financial statement continue legal proceeding continue plaintiff subsequently amend complaint assert class action limit solely pharmaceutical sale commercial corporate representative work california assert claim security class action california wage hour law september attorney represent purport class suit seek variety compensatory punitive statutory purchaser glaxosmithkline share american depositary damage group move summary judgement dismiss share ad file second amend security class action claim putative class representative ground complaint group district court exempt employee court hold southern district new york allege group violate appeal pende united states court appeal security law failure disclose unfavourable clinical ninth circuit case involve manufacturer virtually datum study paxil misrepresentation remain factual legal argument defer rule patent protection paxil augmentin violation summary judgement motion stay activity federal false claim act basis group recent awp case appellate court rule settlement government october judge company pende case enter order dismissing complaint uphold court appeal second circuit march case file district court district matter conclude arizona november seek establish nationwide collective action behalf entire group pharmaceutical november attorney purport represent class sale representative ground representative purchaser glaxosmithkline share ad file exempt employee fair labor standard amend consolidated complaint group senior act plaintiff seek double damage overtime allegedly officer district court southern district new work group pharmaceutical sale representatives york allege group individual defendant year period violate security law artificially inflate price glaxosmithkline stock mislead investor safety environmental matter avandia amend consolidated complaint allege gsk notify potential responsibility relate past current senior officer member operation past waste disposal practice certain site group engage insider trading motion dismiss primarily usa matter subject complaint file behalf group individual litigation include proceeding initiate federal state defendant district court enter order government waste disposal site remediation cost tort dismissing case defendant plaintiff file appeal action bring private party court appeal second circuit appeal gsk advise responsible party remains pende approximately site appear national priority relenza list create comprehensive environmental response biota holding limit file complaint compensation liability act superfund proceedings victorian supreme court australia allege group seek require operator hazardous waste facility fail fulfil development promotion production transporter waste site generator hazardous obligation zanamivir relenza term licence waste dispose site clean site reimburse agreement group biota biota seek substantial government cleanup cost instance gsk damage mediation order court july involve allege generator hazardous waste dispute settle admission liability gsk site gsk involve current continue sell relenza pursuant licence agreement operator facility superfund provide defendant jointly severally liable cleanup cost wage hour claim proceeding frequently resolve basis nature december purport class action file quantity waste dispose generator site gsk group behalf entire group pharmaceutical sale proportionate liability cleanup cost substantially representative action file transfer determine site refer district court central district california initially allege representative exempt employee gsk potential liability vary greatly site site california law andor fair labor standard act cost investigation study remediation site consequently entitle overtime pay thing time substantial gsk routinely accrue amount relate share liability mattersgsk annual report financial statement glaxosmithkline plc director statement responsibility director statement responsibility relation disclosure information auditor company financial statement director office date report confirm director responsible prepare parent company financial statement remuneration report accordance far aware relevant audit applicable law regulation information company auditor unaware company law require director prepare financial take step ought statement financial year law director take director aware prepared parent company financial statement relevant audit information establish company accordance applicable law united kingdom accounting auditor aware information standard united kingdom generally accept accounting confirmation give interpret accordance practice parent company financial statement require provision section za company act law true fair view state affair company end financial period go concern basis prepare financial statement director make enquiry director reasonable require expectation company adequate resource continue select suitable accounting policy apply operational existence foreseeable future reason consistently continue adopt go concern basis prepare financial statement judgement estimate reasonable prudent combine code state regard parent company financial board consider glaxosmithkline plc apply principle statement applicable uk accounting standard combine code corporate governance financial follow subject material departure disclose reporting council describe corporate governance explain financial statement page comply provision describe director responsible keep proper accounting record disclose reasonable accuracy time require listing rule financial service financial position company enable ensure authority auditor consider director statement parent company financial statement comply compliance relation point combine code company act responsible specified review take reasonable step safeguard asset company ensure operation system internal control take reasonable step prevention detection fraud irregularity parent company financial statement year end st december comprise balance sheet year sir christopher gent end st december support note set chairman page report rd march responsibility auditor relation parent company financial statement set independent auditor report financial statement year end st december include annual report publish hard copy print form available website director responsible maintenance integrity annual report company website accordance uk legislation govern preparation dissemination financial statement access website available outside uk comparable legislation different gsk annual report financial statement glaxosmithkline plc independent auditor report members glaxosmithkline plc audit parent company financial statement basis audit opinion glaxosmithkline plc year end st december conduct audit accordance international standard comprise company balance sheet uk gaap audit uk ireland issue auditing practice board relate note parent company financial statement audit include examination test basis evidence relevant prepared accounting policy set amount disclosure parent company financial audit information remuneration report statement remuneration report audit describe audit include assessment significant estimate report separately group financial statement judgment director preparation parent glaxosmithkline plc year end st december company financial statement accounting policy appropriate company circumstance consistently respective responsibility director auditor apply adequately disclose director responsibility prepare annual report plan perform audit obtain director remuneration report parent company financial information explanation consider necessary statement accordance applicable law united kingdom order provide sufficient evidence reasonable accounting standard united kingdom generally accept assurance parent company financial statement accounting practice set director statement remuneration report audit free responsibility material misstatement cause fraud irregularity error form opinion evaluate responsibility audit parent company financial overall adequacy presentation information statement remuneration report audit parent company financial statement director accordance relevant legal regulatory requirement remuneration report audit international standard audit uk ireland report include opinion prepare opinion company member body accordance section company act purpose opinion give opinion accept assume responsibility parent company financial statement true fair purpose person report show view accordance united kingdom generally accept hand come save expressly agree accounting practice state company affair prior consent write st december report opinion parent company parent company financial statement financial statement true fair view parent director remuneration report audit properly company financial statement remuneration prepare accordance company act report audit properly prepare accordance company act report information give report director consistent opinion information give report director parent company financial statement consistent parent company financial statement pricewaterhousecooper llp addition report opinion company charter accountant register auditor keep proper accounting record receive london information explanation require audit rd march information specify law director remuneration transaction disclose read information contain annual report consider consistent audit parent company financial statement information comprise chairman ceo summary strategy report director include unaudited remuneration report director statement responsibility shareholder information consider implication report aware apparent misstatement material inconsistency parent company financial statement responsibility extend informationgsk annual report financial statement glaxosmithkline plc company balance sheet uk gaap st december note fix asset investment debtor e cash bank current asset creditor amount year f net current liability net asset capital reserve call share capital g share premium account g reserve h profit loss account h equity shareholder fund approve board rd march sir christopher gent chairman gsk annual report financial statement glaxosmithkline plc note company balance sheet uk gaap presentation financial statement expenditure description business expenditure recognise respect good service receive glaxosmithkline plc parent company gsk major global supply accordance contractual term provision healthcare group engage creation discovery obligation exist future liability respect development manufacture marketing pharmaceutical past event obligation product include vaccine overthecounter otc medicine reliably estimate healthrelated consumer product investment subsidiary company preparation financial statement investment subsidiary company hold cost financial statement prepare go concern provision impairment basis draw accordance uk generally accept impairment investment accounting principle uk gaap uk accounting carrying value investment review impairment presentation st december comparative figure indication investment impaired st december appropriate comparative provision result impairment review charge figure reclassify ensure consistent presentation income statement year concern current year information share base payment permit company act profit issuance company subsidiary grant loss account company present annual report company option represent additional capital contribution accounting convention standard company subsidiarie additional investment balance sheet prepare historical cost subsidiary result correspond increase shareholder convention complie applicable uk accounting standard equity additional capital contribution base fair value grant issue allocate underlying grant accounting principle policy vest period preparation balance sheet conformity generally taxation accept accounting principle require management estimate assumption affect report current tax provide amount expect pay amount asset liability disclosure contingent apply tax rate enact substantially enact asset liability date balance sheet actual balance sheet date amount differ estimate company account taxation defer balance sheet prepare accordance accelerate reason timing difference originate company accounting policy approve board reverse balance sheet date defer tax asset describe note b recognise extent consider recoverable future taxable profit b accounting policy defer tax measure average tax rate foreign currency transaction expect apply period time difference foreign currency transaction record exchange rate expect reverse defer tax liability asset rule date transaction forward rate hedge discount forward exchange contract foreign currency asset financial guarantee liability translate rate exchange rule balance liability relate guarantee issue company behalf sheet date forward rate subsidiary hold fair value amortise life dividend pay receive guarantee dividend pay receive include account period relate dividend actually pay receive c operate profit fee relate audit company charge operate profitgsk annual report financial statement glaxosmithkline plc note company balance sheet uk gaap continue fix asset share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited capital contribution relate share base payment e debtor amount year uk corporation tax recoverable amount owe group undertaking amount year amount owe group undertaking f creditor amount year bank overdraft amount owe group undertaking creditor company guarantee debt issue certain subsidiary company receive annual fee subsidiary year company guarantee billion debt issue shelf registration statement subsidiary gsk capital inc aggregate company issue guarantee billion debt instrument subsidiary company relation guarantee fee recover life bond disclose debtor note e gsk annual report financial statement glaxosmithkline plc note company balance sheet uk gaap continue g share capital share premium account share ordinary share p premium number share capital authorise st december st december share capital issue fully pay st january issue share option scheme purchase cancel st december issue share option scheme purchase cancel st december st december st december number share issuable outstanding option number unissue share option st december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme share capital purchase cancel include cancellation million previously acquire treasury share h reserve profit reserve loss account total st january profit attributable shareholder dividend shareholder ordinary share purchase cancel ordinary share purchase hold treasury share capital contribution relate share base payment st december profit attributable shareholder dividend shareholder ordinary share purchase cancel capital contribution relate share base payment st december profit glaxosmithkline plc year million million dividend million million gave retain profit million profit million cost share purchase cancel million million cost share purchase hold treasury share nil million million profit loss account reserve st december stand million million million unrealised milliongsk annual report shareholder information shareholder information section include financial record financial record present historical information prepare accordance quarterly trend ifrs adopt european union ifrs year record issue iasb product development pipeline product development pipeline section discuss shareholder return form dividend shareholder information share price movement provide information share price dividend shareholder nature trading market annual general meeting share price movement dividend show investor relation registrar graph detail price movement dividend taxation information shareholder page glossary term index share price dividend share pence u ukk hsahraer ep rpicreic e u su asd ard prr ipceri cue sus u ukk idviivdiednednsd ps epre srh sahrea u dsiv didievinddesn pde rp aedr asds analysis shareholding st december number total total number account account share share hold share total hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline total bank new york mellon hold hold bny nominees limited represent company adr programme ad represent ordinary share p nominal value th february bny nominees limit hold ordinary share represent issue share capital date th february number holders shares usa holdings share number register holder adr holdings adr certain share adr hold broker nominee result number holder record register holder usa representative number beneficial holder residence beneficial holder gsk annual report shareholder information financial record quarterly trend unaudite analysis group result pharmaceutical sale therapeutic area provide quarter sterle financial year income statement total month q q q q cer cer cer cer cer turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder basic earning share penny p p p p p dilute earning share penny p p p p p income statement result major restructuring turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder adjust earning share penny p p p p p dilute earning share penny p p p p p calculation result major restructuring describe note financial statement presentation financial statementsgsk annual report shareholder information financial record continue quarterly trend unaudite analysis group result pharmaceutical sale therapeutic area provide quarter sterle financial year income statement total month q q q q cer cer cer cer cer turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder basic earning share penny p p p p p dilute earning share penny p p p p p income statement result major restructuring turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder adjust earning share penny p p p p p dilute earning share penny p p p p p calculation result major restructuring describe note financial statement presentation financial statement gsk annual report shareholder information financial record continue quarterly trend pharmaceutical turnover total group q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antiviral hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin altabax oncology emesis hycamtin zofran tykerb vaccine hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix pharmaceutical turnover include copromotion incomegsk annual report shareholder information financial record continue quarterly trend pharmaceutical turnover usa q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antiviral hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin altabax oncology emesis hycamtin zofran tykerb vaccine hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix pharmaceutical turnover include copromotion income gsk annual report shareholder information financial record continue quarterly trend pharmaceutical turnover europe q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antiviral hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin altabax oncology emesis hycamtin zofran tykerb vaccine hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix pharmaceutical turnover include copromotion incomegsk annual report shareholder information financial record continue quarterly trend pharmaceutical turnover rest world q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antiviral hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin altabax oncology emesis hycamtin zofran tykerb vaccine hepatitis infanrixpediarix fluarix flulaval fluprepandemic cervarix rotarix boostrix pharmaceutical turnover include copromotion income gsk annual report shareholder information financial record continue quarterly trend consumer healthcare turnover total group q q q q cer cer cer cer overthecounter medicines panadol franchise smoke cessation tum cold sore franchise breathe right alli oral healthcare aquafresh franchise sensodyne franchise dental care nutritional healthcare lucozade horlick ribena consumer healthcare turnover usa q q q q cer cer cer cer overthecounter medicines panadol franchise smoke cessation tum cold sore franchise breathe right alli oral healthcare aquafresh franchise sensodyne franchise dental care nutritional healthcare lucozade horlick ribena gsk annual report shareholder information financial record continue quarterly trend consumer healthcare turnover europe q q q q cer cer cer cer overthecounter medicines panadol franchise smoke cessation tum cold sore franchise breathe right alli oral healthcare aquafresh franchise sensodyne franchise dental care nutritional healthcare lucozade horlick ribena consumer healthcare turnover rest world q q q q cer cer cer cer overthecounter medicines panadol franchise smoke cessation tum cold sore franchise breathe right alli oral healthcare aquafresh franchise sensodyne franchise dental care nutritional healthcare lucozade horlick ribena gsk annual report shareholder information financial record continue year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board restate restate restate restate turnover business segment pharmaceutical consumer healthcare restate restate restate restate pharmaceutical turnover therapeutic area respiratory antiviral central nervous system cardiovascular urogenital metabolic antibacterial oncology emesis vaccine restate restate restate restate pharmaceutical turnover geographic area usa europe rest world emerge market japan asia pacific canada rest world pharmaceutical turnover include copromotion income restate restate restate restate consumer healthcare turnover otc medicine oral healthcare nutritional healthcare gsk annual report shareholder information financial record continue financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share p p p p p dilute earning share p p p p p financial result major restructuring turnover operate profit profit taxation profit taxation pence pence adjust earning share p p adjust diluted earning share p p million million million million million weight average number share issue basic diluted return capital employ return capital employ calculated total profit taxation percentage average capital employ year balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity minority interest total equity gsk annual report shareholder information financial record continue number employee usa europe rest world asia pacific japan middle east africa latin america canada rest world manufacturing selling administration research development number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report federal reserve bank new york noon buying rate average average rate year calculate average noon buying rate day year feb jan dec nov oct sept high low st december federal reserve bank new york cease publish noon buying rate bank england pm buy rate subsequent calculation pm buy rate th february usgsk annual report shareholder information product development pipeline key inlicense alliance relationship party bla biological license application month submission maa marketing authorisation application europe month regulatory approval maa eu nda new drug application usa approval letter phase evaluation clinical pharmacology usually conduct volunteer al month approvable complete response letter receive indicate phase ii determination dose initial evaluation efficacy conduct ultimately approval give subject resolution small number patient outstanding query phase iii large comparative study compound versus placebo andor establish po month eu positive opinion treatment patient establish clinical benefit safety estimate submission date disclose month date chart date represent likely year submission consider reasonably high probability successfully meeting date assume clinical datum meet expect endpoint clinical trial estimate submission date compound type indication phase maa ndabla biopharmaceutical monoclonal antibody stroke monoclonal antibody alzheimer disease iboctadekin doxil il immunomodulator topoisomerase ii ovarian cancer inhibitor iboctadekin rituximab il immunomodulator anticd nonhodgkin lymphoma monoclonal antibody monoclonal antibody rheumatoid arthritis ii monoclonal antibody severe asthma ii belimumab antib lymphocyte stimulator monoclonal systemic lupus erythematosus ii antibody sc mepolizumab antiil monoclonal antibody severe asthma nasal polyposis ii ofatumumab anticd human monoclonal antibody diffuse large b cell lymphoma ii ofatumumab anticd human monoclonal antibody multiple sclerosis ii belimumab antib lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody iv ofatumumab anticd human monoclonal antibody follicular lymphoma iii ofatumumab anticd human monoclonal antibody rheumatoid arthritis iii otelixizumab anticd monoclonal antibody type diabete iii syncria glucagonlike peptide agonist type diabete iii bosatria mepolizumab antiil monoclonal antibody hypereosinophilic syndrome submit ssep ofatumumab anticd human monoclonal antibody refractory chronic lymphocytic leukaemia submit sfeb sjan cardiovascular metabolic high affinity nicotinic acid receptor hma dyslipidaemia agonist prolyl hydroxylase inhibitor anaemia gastrinrelease peptide grp receptor agonist type diabete muopioid receptor inverse agonist obesity sodium dependent glucose transport sglt type diabetes inhibitor sirt activator type diabete chronic obstructive pulmonary disease copd oxytocin antagonist threaten preterm labour ii bile acid receptor agonist type diabetes ii sirt activator type diabete oncology indication ii losmapimod p kinase inhibitor cardiovascular disease copd depression ii pazopanib multikinase angiogenesis inhibitor eye drop agerelate macular degeneration cancer indication ii remogliflozin etabonate sglt inhibitor type diabetes ii remogliflozin etabonate sglt inhibitor type diabetes ii rilapladib lppla inhibitor atherosclerosis ii ronacaleret calcium antagonist osteoporosis fracture healing ii avandamet xr ppar gamma agonist metformin type diabete extend release iii na avandia simvastatin ppar gamma agonist statin type diabete iii na darapladib lppla inhibitor atherosclerosis iii arixtra synthetic factor xa inhibitor treatment acute coronary syndrome approve aaug alfeb sep avandia ppar gamma agonist prevention disease progression approve snov ajul volibris endothelin antagonist pulmonary arterial hypertension approve aapr na gsk annual report shareholder information product development pipeline continue estimate submission date compound type indication phase maa nda infectious disease plasmodium electron transport chain inhibitor malaria topoisomerase ii inhibitor treatment bacterial infection hiv integrase inhibitor hiv infection novel class antibacterial agent treatment bacterial infection hiv integrase inhibitor hiv infections ii idx nonnucleotide reverse transcriptase inhibitor hiv infections ii sitamaquine aminoquinoline treatment visceral leishmaniasis ii na tafenoquine aminoquinoline plasmodium vivax malaria ii neuroscience ht antagonist depression anxiety nk antagonistssri depression anxiety crf antagonist depression anxiety dopamine antagonist drug dependency dopamine antagonist drug dependency ampa receptor modulator schizophrenia sodium channel blocker bipolar disorder type glycine transport inhibitor schizophrenia muscarinic acetylcholine agonist dementia nknk antagonist schizophrenia purinergic atp receptor antagonist pain orvepitant nk antagonist depression anxiety histamine h antagonist dementia ii glycine antagonist smoking cessation ii crf antagonist depression anxiety ii orexin antagonist sleep disorder ii p kinase inhibitor neuropathic pain ii ht antagonist dementia ii firategrast dual alpha integrin antagonist vla multiple sclerosis ii losmapimod p kinase inhibitor depression cardiovascular disease copd ii solzira voltagegate calcium channel modulator migraine prophylaxis ii solzira voltagegate calcium channel modulator neuropathic pain ii almorexant orexin antagonist insomnia iii lamictal xr sodium channel inhibitor epilepsy partial generalise tonicclonic seizure oncedaily iii na retigabine neuronal potassium channel opener epilepsy partial seizures iii rosiglitazone xr ppar gamma agonist alzheimer disease iii lunivia nonbenzodiazepine gaba agonist insomnia submit pooct na solzira voltagegated calcium channel modulator restless leg syndrome submit ssep jan lamictal xr sodium channel inhibitor epilepsy partial seizure oncedaily approvable na al sep requip modutabxl nonergot dopamine agonist parkinson disease oncedaily control release formulation approve amar ajun treximet ht agonist naproxen migraine fix dose combination approve na aaprgsk annual report shareholder information product development pipeline continue estimate submission date compound type indication phase maa nda oncology pololike kinase inhibitor cancer centromereassociate protein e cenpe cancer inhibitor mitogenactivate protein kinase inhibitor cancer mek totrombopag thrombopoietin receptor agonist thrombocytopaenia sirt activator colon haematologic cancer type diabete ii mesenchymalepithelial transition factor papillary renal cell carcinoma gastric cancer ii cmet kinase inhibitor head neck squamous cell carcinoma pazopanib multikinase angiogenesis inhibitor nonsmall cell lung cancer ii pazopanib multikinase angiogenesis inhibitor ovarian cancer ii pazopanib multikinase angiogenesis inhibitor metastatic breast cancer ii tyverbtykerb epidermal growth factor receptor egfr dual kinase inhibitor revoladepromacta thrombopoietin receptor agonist oncologyrelate thrombocytopaenia ii tyverbtykerb egfr dual kinase inhibitor head neck squamous cell carcinoma unresectable disease ii tyverbtykerb egfr dual kinase inhibitor refractory inflammatory breast cancer ii avodart alpha reductase inhibitor reduction risk prostate cancer iii elesclomol oxidative stress inducer metastatic melanoma iii pazopanib multikinase angiogenesis inhibitor sarcoma iii pazopanib multikinase angiogenesis inhibitor inflammatory breast cancer iii tyverbtykerb egfr dual kinase inhibitor revoladepromacta thrombopoietin receptor agonist chronic liver disease induce thrombocytopaenia iii revoladepromacta thrombopoietin receptor agonist hepatitis c induce thrombocytopaenia iii tyverbtykerb egfr dual kinase inhibitor breast cancer adjuvant therapy iii tyverbtykerb egfr dual kinase inhibitor breast cancer line therapy iii tyverbtykerb egfr dual kinase inhibitor gastric cancer iii tyverbtykerb egfr dual kinase inhibitor head neck squamous cell carcinoma resectable disease iii duodart avodart alpha reductase inhibitor alpha blocker benign prostatic hyperplasia fix dose combination submit sdec alpha blocker pazopanib multikinase angiogenesis inhibitor renal cell cancer agerelate macular degeneration submit sfeb sdec zunrisarezonic nk antagonist chemotherapyinduce postoperative nausea vomiting submit sjul smay hycamtin topoisomerase inhibitor oral small cell lung cancer secondline therapy approve amar aoct revoladepromacta thrombopoietin receptor agonist idiopathic thrombocytopaenic purpura approve sdec anov tyverbtykerb egfr dual kinase inhibitor refractory breast cancer approve ajun amar respiratory immunoinflammation p kinase inhibitor inhale copd chemokine receptor cxcr antagonist cystic fibrosis copd transient receptor potential vanilloid trpv nonallergic rhinitis antagonist intranasal motilin receptor agonist delay gastric empty antiinflammatory macrolide conjugate oral inflammatory bowel disease sirt activator copd type diabete longacte beta agonist copd copd asthma combination ii glucocorticoid agonist longacting beta agonist copd copd asthma combination ii glucocorticoid agonist pde iv inhibitor inhale asthma copd ii muscarinic acetylcholine antagonist copd ii glucocorticoid agonist asthma copd asthma combination ii longacting beta agonist histamine hh dual antagonist oral allergic rhinitis ii novel glucocorticoid agonist inhale asthma ii longacte beta agonist copd copd asthma combination ii glucocorticoid agonist muscarinic antagonist beta agonist copd ii histamine hh dual antagonist intranasal allergic rhinitis ii lipoxygenaseactivate protein flap asthma ii inhibitor darotropium muscarinic acetylcholine antagonist copd ii darotropium muscarinic acetylcholine antagonist copd ii longacte beta agonist losmapimod p kinase inhibitor oral copd cardiovascular disease depression ii entereg peripheral muopioid antagonist post operative ileus approve na amay note financial statement post balance sheet event gsk annual report shareholder information product development pipeline continue estimate submission date compound type indication phase maa bla paediatric vaccine mosquirix recombinant malaria prophylaxis ii hibmencytt conjugate neisseria meningitis group c disease haemophilus iii influenzae type b disease prophylaxis menacwytt conjugate neisseria meningitis groups c w disease prophylaxis iii synflorix conjugate streptococcus pneumoniae disease prophylaxis infant submit pojan child kinrix subunit inactivated diphtheria tetanus pertussis poliomyelitis prophylaxis approve ajun booster th dose rotarix live attenuate oral rotavirusinduce gastroenteritis prophylaxis approve afeb aapr vaccines cytomegalovirus recombinant cytomegalovirus infection prophylaxis hiv recombinant hiv infection prophylaxis nthipneumo recombinant streptococcus pneumoniae haemophilus influenzae disease prophylaxis adult pneumoniae adult recombinant conjugate streptococcus pneumoniae disease prophylaxis tuberculosis recombinant tuberculosis prophylaxis ii zoster recombinant herpe zoster prevention ii flu pandemic hn inactivated split monovalent pandemic influenza prophylaxis iii prepandemic quebec new generation flu vaccine inactivate split trivalent seasonal influenza prophylaxis elderly iii simplirix recombinant genital herpe prophylaxis iii boostrix subunit adult booster diphtheria tetanus pertussis approve ajun adec pandemrix flu pandemic hn inactivated split monovalent pandemic influenza prophylaxis approve amay dresden prepandrix hn inactivate split monovalent prepandemic influenza prophylaxis approve amay flu prepandemic dresden cervarix recombinant human papilloma virus infection prophylaxis approve asep aldec antigen specific cancer immunotherapeutic asci wt recombinant treatment acute myelogenous leukaemia magea asci recombinant treatment melanoma iii magea asci recombinant treatment nonsmall cell lung cancer iiigsk annual report shareholder information shareholder information ordinary share company list london dividend ad stock exchange new york stock exchange nyse table set dividend ad dollar form american depositary share ad detail year translate dollar applicable list debt list refer note net debt exchange rate share price year st january high year low year st december increasedecrease dividend calendar table set middle market closing price quarter exdividend date record date payment date company share price increase compare q th february th february th april decrease ftse index year q th april st th july share price th february q th july st july th october market capitalisation q th november th november th january market capitalisation base share issue exclude treasury share glaxosmithkline st december financial reporting calendar billion date gsk fifth large company publication date market capitalisation ftse index result announcement smithkline beecham plc float rate unsecured quarter april loan stock quarter july loan stock list exchange holder require quarter october smithkline beecham plc redeem loan stock par ie preliminaryquarter january loan stock hold business day march june annual reportsummary februarymarch september december holder wish redeem loan stock complete notice result announcement loan stock certificate return registrar arrive result announcement issue london stock exchange day relevant redemption date available news service shortly issue medium available website send taxation securities exchange commission nyse general information concern uk tax effect share financial report ownership set taxation information shareholder gsk publish annual report shareholder need dividend detail report summary document glaxosmithkline pay dividend quarterly continue increase available date publication website summary cash return shareholder dividend policy dividend send shareholder shareholder elect receive remain essential component total shareholder return annual report writing registrar alternatively shareholder gsk commit increase dividend longterm elect receive notification email publication detail dividend declare payment financial report register wwwshareviewcouk date give note financial statement dividend copy previous financial report available gsk website dividend share print copy obtain registrar uk table set dividend share year gsk response center usa corporate responsibility report year penny late march gsk publish website corporate responsibility report cover performance area include community investment ethic integrity access medicine rd environment health safety gsk annual report shareholder information shareholder information continue nature trading market annual general meeting follow table set period indicate high queen elizabeth ii conference centre th low middle market closing quotation pence share broad sanctuary westminster london stock exchange high low report london swp ee sale price dollar ad nyse agm company principal forum communication penny share private shareholder addition formal business high low presentation chief executive officer quarter end st march performance group future development february opportunity question board chairman january board committee question matter relate december committees november october investor hold share nominee service september arrange nominee service appoint corporate quarter end st december representative proxy respect shareholding order quarter end th september attend vote meeting quarter end th june quarter end st march adr holder wish attend meeting obtain proxy quarter end st december bank new york mellon enable quarter end th september attend vote business transact adr holder quarter end th june instruct bank new york mellon way quarter end st march share represent adr vote year end st december completing return voting card provide bank year end st december accordance instruction give year end st december document display memorandum articles association company dollar ad document refer annual report high low available inspection register office company quarter end st march february exchange control limitation january affect security holder december currently uk law decree regulation november restrict import export capital affect october remittance dividend payment holder september company share nonresident uk quarter end st december limitation relate nonresident uk quarter end th september english law company memorandum article quarter end th june association right holder vote quarter end st march quarter end st december respect company share quarter end th september quarter end th june quarter end st march year end st december year end st december year end st december th february internet information company include detail share price available gsk website wwwgskcom information available website constitute annual reportgsk annual report shareholder information shareholder information continue duplicate publication adr programme administrator query relate receipt duplicate copy gsk adr programme administer publication address registrar bny mellon shareowner services po box investor relation pittsburgh pa investor relation contact follow wwwbnymelloncomshareowner tel toll free uk great west road brentford middlesex tw gs tel outside usa tel email shrrelationsbnymelloncom usa administrators provide global buydirect direct ad franklin plaza po box philadelphia pa purchasesale dividend reinvestment plan adr holder tel toll free gsk response center tel outside usa tel toll free registrar provision detail intend company registrar invitation inducement engage investment activity equiniti advice share dealing obtain stockbroker aspect house spencer road lance west sussex bn da independent financial adviser wwwshareviewcouk tel inside uk tel outside uk equiniti provide follow service nominee deal account individual saving account isa glaxosmithkline corporate sponsor nominee shareview service share deal service dividend reinvestment plan share deal service shareholder trade share hold certificate corporate sponsor nominee internet telephone shareview deal share deal service provide equiniti internet deal log wwwshareviewcoukdeale telephone deal inside uk nominee isa service wwwshareviewcouk deal telephone service available monday friday market trading hour glaxo wellcome smithkline beecham corporate pep share centre limited oxford house oxford road aylesbury buck hp sz tel gsk annual report shareholder information taxation information shareholder statement base uk tax law practice shareholder date report intend general guide follow summary certain uk taxation usa federal holder advise consult adviser respect tax income tax consideration relevant holder consequence purchase ownership share share adr summary apply shareholder adr consequence state local tax law hold share adr capital asset citizen resident usa implications current ukus income usa domestic corporation subject tax convention united states federal income taxation net income basis holder adr generally treat owner respect share adr resident uk underlie share purpose current usauk double uk tax purpose hold share purpose taxation convention relate income gain income tax trade profession vocation carry uk convention estate gift taxis estate gift tax convention branch agency purpose internal revenue code taxation dividend amend code gross dividend receive reduction uk shareholders uk withholding tax treat foreign source dividend income tax purpose eligible dividend receive taxation dividend deduction allow corporation dividend adr th april rate tax credit reduce payable dollar dividend share payable sterling ninth result compensate reduction rate tax dividend pay pound sterling include income dividend income increase tax bear uk resident dollar calculate reference exchange rate individual shareholder tax credit long repayable day dividend receive holder subject certain shareholder tax liability associate tax credit exception shortterm hedge position individual eligible holder subject taxation maximum rate taxation capital gain respect qualified dividend receive uk shareholder liable uk tax gain disposal shareholder advise consult tax adviser share adr disposal prior th april confirm eligibility entitle indexation relief taper relief sale indexation relief calculate market value share taxation capital gain st march cost subsequent purchase generally holder subject uk capital gain tax date purchase indexation relief individual subject tax capital gain realise sale shareholder cease th april capital gain tax disposal share adr marginal tax rate individual disposal th april estate gift taxis indexation taper relief available capital estate gift tax convention shareholder gain tax flat rate marginal generally subject uk inheritance tax tax rate individual stamp duty inheritance tax uk stamp duty sdrt subject certain exemption individual shareholder liable inheritance tax payable issue transfer share adr custodian transfer share adr tax charge depository rate price issue value shareholder estate reduce result consideration provide transfer sale value transfer way gift disposal transfer consideration market value sdrt payable transfer adr uk gift disposal subject uk inheritance stamp duty payable transfer adr provide tax estate gift tax estate gift tax convention instrument transfer execute remain time generally provide tax pay usa credit outside uk stamp duty transfer adr tax payable uk payable rate consideration transfer stamp duty sale underlie share result liability uk uk stamp duty stamp duty reserve tax sdrt subject stamp duty case sdrt rate certain exemption payable purchase share rate purchase pricegsk annual report glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share calledup share capital ordinary share issue fully pay cer growth growth constant exchange rate combine code guideline require listing rule financial service authority address principal aspect corporate governance company glaxosmithkline plc currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan finance lease capital lease freehold ownership absolute right perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party nonequity minority interest preference share issue subsidiary outside party preference share share issue vary dividend rate treat outside interest profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay shareholder fund shareholder equity share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding exclude treasury share statement recognise income expense statement comprehensive income subsidiary entity glaxosmithkline hold majority shareholding andor exercise control treasury share treasury stock turnover revenue gsk annual report index performance overview intellectual property accounting principle policy interest rate risk management acquisition disposal internal control framework adjustment reconcile profit tax operating cash flow inventory annual general meeting investment associate joint venture annual remuneration investor relation registrar asset hold sale key accounting judgement estimate associate joint venture key performance indicator board legal proceeding business review major restructuring programme cash cash equivalent movement equity chairman ceo summary nature trading market combine code net debt commitment new accounting requirement committee report nonexecutive director term condition fee competition nonexecutive director remuneration consolidated balance sheet note financial statement consolidate cash flow statement operating profit consolidated income statement intangible asset consolidate statement recognise income expense investment consumer healthcare noncurrent asset contingent liability noncurrent liability corporate executive team operate income corporate governance provision critical accounting policy outlook dialogue shareholder pension postemployment benefit director senior management performance overview director senior management remuneration pharmaceutical turnover director interest post balance sheet event director interest contract presentation financial statement director statement responsibility principal group company dividend product development pipeline donation eu political organisation eu product political expenditure property plant equipment earning share quarterly trend economy reconciliation net cash flow movement net debt employee cost regulation employee share scheme relate party transaction employee remuneration policy environment health safety remuneration report exchange rate report director executive director term condition remuneration research development finance cost responsibility finance income risk factor financial instrument relate disclosure segment information financial position resource share capital control financial record share capital share premium account financial review share option financial review share price dividend financial statement glaxosmithkline plc prepare shareholder information uk gaap strategy financial trend ratio taxation year record taxation information shareholder foreign exchange management total equity global manufacturing supply trade payable glossary term trade receivables goodwill trademark governance policy treasury operation improve access medicine law regulation incentive plan world economy independent auditor report world market responsibility want work way reflect value head office register office expectation stakeholder ethical glaxosmithkline plc great west road social environmental consideration integral brentford middlesex tw gs business decision making central united kingdom achieve challenge inspire mission tel improve life people worldwide register number find approach corporate print uk paper responsibility production document post consumer waste wwwgskcomresponsibility pulp bleach totally chlorine free process